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EXECUTIVE SUMMARY
Background
As part of the co-coordinated strategy for health research under the Office for Strategic Coordination
of Health Research (OSCHR), the Medical Research Council (MRC) is the lead organisation for
methodological research in the UK. The National Institute for Health and Clinical Excellence (NICE) is
an important public stakeholder in this research area, and it has faced a range of challenges in the
selection and specification of research methods employed in the production of its guidance for the
NHS.
Objectives
The aim of this 6-month project was to undertake a scoping study to provide recommendations for
identifying NICE’s methodological research priorities and to establish an initial set of such priorities.
Specifically the project had three main objectives:
(i) To describe current processes by which methodological research topics are identified and
prioritised at NICE.
(ii) To suggest a range of additional and/or alternative approaches to identifying these priorities.
(iii) To generate an initial short list of methodological research topics.
Methods
A focussed review of recent key policy reports and documents produced by NICE was conducted to
obtain information on the process by which methodological research needs are currently identified
and prioritised at NICE. The review also sought to identify suggestions for methodological research
topics directly related to decision-making at NICE. These documents were supplemented by a
focussed review of the literature for the purpose of identifying suggestions for methodological
research topics.
A series of semi-structured interviews with individuals involved in various ways with NICE was
undertaken by telephone and in face-to-face meetings. Those interviewed included employees of
NICE, members of its advisory committees, individuals from industry and representatives of
organisations closely linked to NICE, such as the Medical and Healthcare products Regulatory
Agency (MHRA). The objectives of the interviews were to obtain information on the current processes
of identifying and prioritising methods research needs at NICE, and elicit opinions on how these
processes could be further developed. Interviewees were also asked about their suggestions for
priority topics for future research. An email survey was administered to a broader range of NICE
employees, the academic groups who conduct reviews of the evidence for NICE and representatives
of a selection of similar organisations outside of the UK.
A list of potential research topics identified from the literature, interviews and the email survey was
collated. A workshop was held to discuss the list of topics, to consider how these might add value to
NICE’s decision-making and whether the questions could be further defined. Participants were also
encouraged to highlight potential priority topics missing from the list and to feedback on topics within
and across areas of methodology. Following the workshop an amended list of topics was made
available via a feedback form on the MRC website. The list was publicly available and people who
had been invited to attend the workshop were specifically encouraged to complete the feedback form.
Individuals were given the opportunity to score each topic on the list (using a categorical scale: very
important, important, somewhat important and not important), to provide comments and to offer other
potential topics. In addition respondents were asked to identify three topics they considered to be the
most important for future research.
iv CHE Research Paper 51
Results
A total of 18 interviews were undertaken and 13 (39%) of a possible 33 responses to the email survey
were received. Seventy-six responses to the web feedback exercise were received.
Process
Little emerged from the review of literature and key policy documents regarding how NICE currently
identifies and prioritises potential methodological research topics. Several formal and informal
processes at NICE were, however, highlighted during interviews and the email survey. Formal
processes include the regular reviews of the NICE methods guides, the activities of the NICE
Research and Development Advisory Committee (RDAC) which advises NICE about its research and
development work and a Technical Forum of NICE’s technical staff. A range of informal processes for
identifying methodological research topics was noted including identification of issues arising during
the course of guidance production. Many interviewees commented on a lack of a formal Institute-wide
process to collate and prioritise methodological research topics.
Specific suggestions for changes in the future included the creation of a ‘Methodology Committee’
with members from both within and outside of NICE, the identification of potential topics as a specific
agenda item in existing (decision-making) committee meetings, greater collaboration between
interested parties both within and outside of NICE and the creation of a formal process for following
up recommendations for topics which have come from the various methods guides. Respondents felt
that an explicit process for prioritisation would be useful. Most of the respondents felt that any criteria
for prioritisation should be on the basis of the issues most important to NICE decision-making. The
need to identify funding for methods work was also raised by many of the respondents, particularly
those external to NICE.
Topic suggestions
Within each stage of the project a slightly different group of individuals, each with varying degrees of
links to NICE, was canvassed for their views on priority topics. Those who were interviewed and
included in the email survey had direct links with NICE, mostly as members of staff, advisory
committees or designated providers of evidence. The workshop included those with direct links to
NICE and a broader group, including methods experts. The web feedback exercise included
responses from some of those who attended the workshop, but also people who stated that they had
no direct involvement with NICE. The topics emerging as priorities from the different exercises are
noted below.
Priorities emerging from the interviews and email survey:
x methodology for indirect and mixed treatment comparisons
x synthesis of qualitative evidence in the NICE decision-making process
x use of quality adjusted life years in decision-making (specifically establishing what benefits of
treatment are not captured by the QALY and/or standardised measures of health-related quality of
life)
x establishing the threshold for cost-effectiveness (including the appropriate methods for estimating
this)
x determining how data on the uncertainty of effectiveness and cost-effectiveness data should be
taken into account in the decision-making process
Priorities emerging from the workshop:
x methods for keeping research synthesis up to date (including developing repositories of
‘approved’ networks of evidence in key diseases)
x methods to assess what types of evidence from patients should be used at different stages of
NICE’s decision-making processes (e.g. when to undertake reviews of qualitative evidence?
When should colloquial evidence be used?)
x extrapolation of the duration of the costs and benefits of interventions beyond those observed in
trials, including the quantification of uncertainty
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x establishing what effects of interventions and programmes are/are not currently captured by the
EQ-5D
x methods for the re-evaluation of the EQ-5D preference set for the UK population with
consideration to (i) the use of patient valuations of health and/or more informed public valuations
and (ii) the appropriate valuation of health states considered to be worse than dead
x methods for valuing health at different time points in a person’s life (e.g. at the end of life)
x methods to determine whether public or patient valuations of health should be used in economic
evaluation
x methods for establishing opportunity cost of NICE guidance (i.e. the threshold) and empirical data
on interventions that are being displaced by NICE guidance
Priorities emerging from the web feedback exercise:
x optimal methods for analysing disease registers and other non-experimental data sources
x methods to adjust for bias in meta-analysis
x methods for conducting systematic reviews of complex interventions
x optimal methods for evaluating diagnostic and screening technologies
x methods for conducting efficient systematic reviews
x methods for the extrapolation of costs and benefits
x research to assess whether the predictions of economic models are borne out in practice
x methods to capture wider benefits not captured in the QALY
x methods to assess whether additional evidence is needed prior to the routine introduction of
interventions (e.g. ‘only in research’ or ‘coverage with evidence’ decisions).
Conclusions
Methodological topics have been discussed with the MRC and, in a few cases, taken forward as
vignettes and, in one case, active commissioning has taken place. This indicates that some form of
process exists through which these topics were selected and progressed. However, there is clearly a
need for a formal Institute-wide process to collate and prioritise topics. A range of ideas emerged on
how this might be progressed. Issues to consider in any changes to the process include:
x How the full range of NICE’s activities are to be covered, recognising the variety of methods
issues that are likely to be seen as important across the centres and teams.
x Which team or as yet unspecified group of individuals within the Institute is to be the repository for
topic suggestions over time? To what extent would this team/group be proactive in identifying
topics or wait to be contacted by others?
x Whether specific discussion forums within NICE are organised at which methodological issues
are discussed with a view to identifying potential research topics and feeding into the prioritisation
process.
x What role would be played by those not formally employed by NICE, but closely related to its
activities, in the identification process?
x What role would be specified for external methodologists in the process of identification and
prioritisation?
x What role could external stakeholders and research funders play in the process of topic
identification and prioritisation (e.g. technology manufacturers)?
Relatively few comments emerged on the process of prioritisation of a long-list of potential research
topics. One feature of a more explicit process that may be of value (and has been part of the web-
based prioritisation reported here) is to ask those individuals and groups forwarding topics to justify
their suggestions by addressing some very key questions for each. These might include: To which
area of NICE’s activities does the research relate? What potential exists for methodological research
to increase the value or efficiency of NICE’s activities?
Little was discussed in the interview and survey about two particular issues. The first is how to
translate an area of methodological uncertainty where it is felt that research might be potentially
helpful into a researchable question. The second relates to the use of methodologists external to
NICE who might contribute to the process of identifying and prioritising research topics, and then
working them up into researchable questions. The advice of such externals is likely to be important in
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the process, but the problem of their potential conflicts of interest are clear if they were subsequently
to bid for research in a topic on which they have advised.
An alternative approach would be to work with the MRC to prepare quite general calls for methods
research applications – that is, to take topics which are not much more specifically defined than those
detailed here as coming out of the scoping project.
In terms of potential topics, a total of 125 topics were presented on the web survey, with a limited
number of additional suggestions coming from that part of the process. Across the five areas into
which topics were arranged, there appears to be a broad relevance across the range of NICE’s
decision-making activities.
The issue of what constitutes methodological research was raised throughout the project. This needs
to be addressed as research topics are considered further and attempts are made to link them with
appropriate potential research funders. A large proportion of suggested topics would probably be
considered clearly methodological in that they relate to the further development and refinement of
evaluative and analytical tools which have relevance beyond a single application. Other topics may
be considered less obviously methodological. It may be that research commissioners other than the
MRC Methodology Research Programme, whose remit is specifically focussed on generalisable
methods development research, should be approached about funding some of the topics suggested
in this document.
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1. Introduction
1.1 Introduction
The National Institute for Health and Clinical Excellence (NICE) has established a national and
international reputation for its use of evidence and rigorous analytical methods to inform decisions
about the effectiveness and the cost-effectiveness of medical and public health interventions and
programmes. Few health care organisations globally have been so ambitious in their use of
evidence-based decision-making. All aspects of NICE’s activities have faced a range of challenges,
in particular regarding the selection and specification of research methods. For example, in reviewing
NICE’s Technology Appraisal Programme, the House of Commons Health Select Committee drew
attention to a number of issues with important methods implications.1
As part of the co-coordinated strategy for health research under the Office for Strategic Coordination
of Health Research (OSCHR), the Medical Research Council (MRC) is the lead organisation for
methodological research. NICE is an important public stakeholder in this research area, and
improving methods for undertaking health technology assessments, appraisals and evidence
synthesis was also highlighted as an area for further research in the Cooksey review.2 Issues of
appropriate research methods have also been raised by the Office of Fair Trading’s report on
pharmaceutical price regulation.3
To help identify priority methodological research topics to support NICE’s decision-making, the MRC
commissioned a group of researchers to undertake a short scoping project to provide
recommendations for identifying NICE’s methodological research priorities and to establish an initial
set of such priorities.
1.2 Aims and objectives
The agreed aim of the project was to undertake a scoping study to provide recommendations for
identifying NICE’s methodological research priorities and to establish an initial set of such priorities.
Specific objectives agreed with the MRC were:
1. To describe current processes by which methodological research topics are identified and
prioritised at NICE.
2. To suggest a range of additional and/or alternative approaches to identifying these priorities.
3. To generate an initial shortlist of methodological research topics by:
(a) Reviewing recent key literature relating to NICE’s activities with a view to identifying issues
with potential implications for methodological research.
(b) Convening a workshop to develop a ‘long list’ of methodological research priorities.
(c) Using a web-based interface, to engage the methodological research community in scoring
topics from the ‘long list’.
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2. Methods
2.1 Literature review
Given the time and funding constraints, it was not possible to undertake an extensive literature
review. A highly focussed literature review was undertaken to identify two types of information:
1. Details of the process by which methodological research needs are currently identified and
prioritised at NICE.
2. Suggestions for methodological research topics.
A broad view of methodological research was taken. The review specifically focussed on recent
publications relating to NICE which may have discussed the process of identifying and/or prioritising
methods topics at NICE and/or raised issues with potential implications for methodological research.
A number of key policy documents and journal articles such as the Cooksey report on health research
funding, the House of Commons Health Select Committee report on NICE and the NICE methods
guidance documents were identified by the project team and its advisors, and included reports
identified in the project specification. A full list of the policy documents considered is provided in
Appendix A7. The documents were reviewed in their entirety and data extracted using a number of
headings. Specifically these were:
1. Does the paper comment on the current process/system that NICE uses to prioritise
methodological research?
2. Does the paper make suggestions for research into methodology that is relevant to decision-
making at NICE?
3. Does the paper work these suggestions into researchable questions?
4. Does the paper comment on the type of research required to address these questions?
5. Does the paper make any other relevant comments?
In addition, focussed searches (see below for search strategies) were conducted by an information
specialist. These included searches of recent conference abstracts (e.g. NICE conference) and
reference lists of important identified articles. This was supplemented by use of recent literature
searches that are routinely conducted by information specialists at NICE for the purpose of identifying
articles of interest for NICE technical staff. In addition, reports from a series of workshops held as part
of the 2008 review of the methods for NICE technology appraisals were reviewed. Suggestions for
key articles were also canvassed from the wider project team.
2.1.1 Search strategies
An initial current awareness search on NHSEED (which searches MEDLINE and EMBASE) and the
Cochrane Methodology register was conducted by colleagues at the Centre for Reviews and
Dissemination (CRD) at the University of York. This focused on identifying methods papers in the
period 2004-2008. Search terms were restricted to methodology, method, methods.
In addition, papers were identified by a NICE information specialist. These searches are restricted to
Medline and Medline-in process. The search terms used are given in Appendix A1.
2.2 Interviews
Discussions with individuals involved with NICE’s activities (hereafter referred to as ‘stakeholders’)
were central to defining options for alternative approaches for identifying research needs. The list of
individuals to interview was guided by the MRC and NICE.
A combination of face-to-face and telephone interviews was used with the various stakeholders.
Stakeholders who were interviewed included: the chair (and other members) of the NICE Research
and Development Committee; directors of the centres of Health Technology Evaluation, Clinical
Practice and Public Health Excellence and the Clinical and Public Health Director; representatives of
the Technology Appraisal Committees, Public Health Interventions Advisory Committee,
Interventional Procedures Advisory Committee and guideline development groups; and
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representatives from the pharmaceutical industry. The full list of interviewees can be found in
Appendix A2 in the appendix, along with the methods employed for the interviews.
The interviews were semi-structured and their content was shaped, in part, by the review of key
documents described above. The interview schedule for face-to-face and telephone interviews is
presented in Appendix A3. The questions in the schedule were used as prompts where necessary
and questions were not necessarily asked to all interviewees if they were not appropriate.
Interviewees were asked about the current processes at NICE for identifying and prioritising
methodological research, and for their opinions regarding potential changes to those processes.
During the interviews stakeholders were also asked to identify priority topics for methodological
research. These were topics that could have a direct impact on the decision-making process at NICE.
2.3 Email survey
In addition to the face-to-face and telephone interviews, an email survey of other stakeholders was
also conducted. This was to allow the views of a wide range of NICE stakeholders to be accounted
for. The recipients of the email survey included:
x NICE employees (associate directors with responsibility for methodology in the clinical
guideline and public health programmes, and technical advisers)
x NICE Technology Assessment Group (TAG)/Evidence Review Group representatives
x National Collaborating Centres (NCCs) Clinical Guideline representatives
x Healthcare Commission
x National Institute for Health Research
x Health Departments (England, Northern Island, Scotland, Wales)
x The Cochrane Collaboration
x The Campbell Collaboration
x The Society for Research Synthesis Methodology
x International Organisations (German Agency for HTA, European Network for HTA, Agency for
Healthcare Research and Quality, International Society for Pharmacoeconomics and
Outcomes Research).
The selected respondents were divided into four groups based on their relationship with NICE, their
role within similar organisations, and their role within a research funding/providing organisation. Using
these groupings, stakeholders were sent one of four versions of the survey (see Table 1 below).
Copies of the four surveys can be found in Appendix A4, along with a list of responders.
Table 1: Content of email survey by respondent group
Group Potential
methodological
research
priority topics
Potential future
processes for
identifying
methodological
research priorities
Current NICE
process for
identifying
methodological
research priorities
Current process [in
their own
organisation] for
identifying
methodological
research priorities
1. NICE secretariat Y Y Y
2. UK Healthcare/
Research
organisations/
International HTA
Y Y Y
3. Evidence
Collaboration
Organisations
Y Y
4. UK HTA
methodologists/
NCC and TAG
representatives
Y
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2.4 Workshop
A 1-day workshop was organised with the objective of clarifying and refining the list of potential
methodology research topics identified via the literature review and interviews.
The workshop involved 38 participants whose selection was agreed with the MRC and NICE. The
participants included the project team, key staff from NICE, members of NICE decision-making
committees, representatives from InterTASC (the collaborative group of academic technology
assessment groups), national collaborating centres, public health assessment groups, industry, other
stakeholders and methodologists. The full list of workshop participants can be seen in Appendix A5.
The agenda for the workshop is presented in Appendix A6. The workshop was structured around the
potential methodological research topics identified from all the preceding stages of the project which
were grouped into five broad methodological areas:
1. Analysis and design of effectiveness studies and their synthesis
2. Synthesis of evidence from patients, the public and stakeholders
3. Economic analysis and uncertainty
4. Measurement and valuation of benefits
5. Decision-making at NICE
Following presentations from key methodologists who gave an overview for each of the topic areas,
delegates engaged in a series of small group discussions about the topics within each area. Each
small group was assisted by a facilitator and a scribe. Participants were asked to review the list of
topics and consider the following questions:
 Do they address challenges?
 How can they add value to NICE’s role?
 Can questions be further defined?
 Are there additional topics?
 What should be the initial prioritisation?
The intended output from the workshop was the suggestion of other topics not identified via the
literature review and interviews, dismissal of particular topics which the workshop attendees felt had
been significantly well researched not to require further prioritisation and general feedback on the
priority of topics within and across areas of methodology.
2.5 Web-based consultation
The list of topics generated from the literature review, interviews and email survey were updated
following feedback from the workshop. This list of topics was then placed on the MRC website to
which those invited to the workshop, and a wider group of individuals, were given access. Individuals
were given the opportunity to score each topic on the list (with options of very important, important,
somewhat important and not important), to provide comments and to offer other potential topics. In
addition, they were asked to provide their top three topics across areas and themes. The aim of this
aspect of the project was to identify topics to feed into NICE’s future determination of methodological
research priorities.
2.6 Analytical methods
2.6.1 Analytical methods relating to processes
Responses to the face-to-face and telephone interviews were collated with responses to the email
survey. A thematic analytical approach was used to summarise the comments. This identifies
themes emerging from the qualitative interviews.4
Comments relating to any current process for identification and prioritisation at NICE were largely
based on responses from NICE staff. These were divided into comments relating to formal and
informal processes employed at NICE. The wider network of respondents was used to summarise
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comments relating to future processes. These distinguished issues relating to identification,
prioritisation and funding of topics.
Comments relating to the process for identifying and prioritising topics at other organisations were
summarised separately from the comments relating to NICE.
2.6.2 Analytical methods relating to topic suggestions
Topics identified in the literature review were added to those obtained from the interviews and email
survey. Duplicate topics were removed and similar topics combined. A reasonably broad definition of
methodological research was taken to ensure all relevant topics were captured, and that these related
to all areas of NICE’s decision-making activities. Topics were excluded that were considered not to
relate to methodological research or that did not relate to decision-making at NICE. Following the
workshop, some topic suggestions were rephrased for clarity and/or merged with other topic
suggestions.
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3. Process of identifying and prioritising topics
3.1 Process of identifying and prioritizing methodological topics at NICE
3.1.1 Literature review
Ten policy documents were reviewed. With respect to journal articles, a total of 759 records were
identified from the Centre for Reviews and Dissemination (CRD) current awareness searches along
with 423 records from the NICE ‘what’s new’ bulletin searches. Forty duplicate records were found
which gave 1142 records in total. In addition six reports were included from workshops held as part of
the 2008 review of the NICE Technology Appraisals Methods Guide.
The wider project team was consulted on the list of included papers. As a result two additional (in
press) papers were identified. In total 1150 papers were screened for inclusion in the review. The
titles and abstracts for all 1150 records were screened by two reviewers. No disagreements were
found between the two reviewers.
After initial screening, only 19 papers were identified as considering methodological issues specific to
NICE decision-making. These papers are listed in Appendix A7 and were reviewed in detail.
As described in the methods section, relevant information from these documents and articles was
extracted using predefined questions. Three policy documents referred to processes used by NICE to
develop or promote methodological research.1, 5, 6 From the journal articles, no comments were made
about the process that NICE uses, or could use, to identify and prioritise methodological research
relevant to NICE’s decision-making. The full extraction from these documents and articles can be
found in Appendix A7, and a summary is provided below.
 The House of Commons Health Select Committee1 praised the open nature of the development of
the NICE methods guides, and comments that NICE’s process and methodology should be
continually developed and debated.
 The NICE Guide to the methods of technology appraisal7 comments on the specific process by
which the methods guide is updated, encouraging further development of methods, and describes
how the Institute looks to regularly review its processes and methodology. It states that the
Institute sponsors future research into HTA, and that it welcomes suggestions for research topics.
 The NICE R&D programme consists of a small team within the Clinical and Public Health
Directorate and a Research and Development Advisory Committee (RDAC). One of their key
objectives is to improve the research methods used by NICE. The programme also takes
responsibility for the Citizens Council, a group of 30 members of the public which advises NICE
on its social value judgements (www.nice.org.uk/aboutnice/howwework/researchanddevelopment/). The
objectives, as stated in the most recent version of the R&D strategy, are detailed in full in Box 1.
This document is in the process of being updated and some elements are no longer applicable
(for example, the National Coordinating Centre for Research Methodology has ceased to
operate). The 2004 R&D strategy document5 highlights that NICE has limited capacity to act
directly on resolving and producing research into methodological issues when they arrive.
However, RDAC will consider topics of methodological uncertainty and, if it is agreed that these
are of importance, relevance and benefit to NICE and other organisations, as well as being
researchable, it will be directed to an external research funding body.
 NICE's 'End of Life' consultation document6 was reviewed and, whilst no direct comments about
the process that NICE uses to prioritise methodological research were made, this supplementary
methods guidance is a formal change to NICE's decision-making criteria, and has not been
developed through one of the formal reviews of NICE's methods, or the R&D process. It should
be noted, however, that research commissioned by NICE and NHS R&D into weighting of QALYs
had suggested that the public did not consider that the current NICE position that all QALYs
should be considered equal was sustainable. The nature of this type of development does
highlight a need for a responsive process of NICE methods research identification and
mechanisms to ensure it can be undertaken within the necessary timeframe.
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Box 1: Improving NICE methods (adapted from 2004 NICE Research and Development Strategy page 10 -
http://www.nice.org.uk/niceMedia/pdf/R&D_strategy_2006.pdf)
NICE 2004 Research and Development Strategy - Objective 2 – Improving NICE methods
Background
The Institute’s work programmes use a wide range of complex methods to develop questions, identify
and critically appraise relevant evidence, involve stakeholders with a range of views, and generate
guidance. NICE and its partners have taken great care to ensure that the methods used are robust and
informed by up to date research and current best practice. Nonetheless, areas of uncertainty exist – for
example, debate continues about the best approach to grading evidence and classifying clinical
recommendations in NICE guidelines. These uncertainties present opportunities for improvement in
the research base so that the methods underpinning the Institute’s guidance continue to be of the
highest quality.
Uncertainties can be uncovered in the process of work on a particular piece of guidance, but are more
often highlighted as the processes and methods used by a programme are formally reviewed (as
happens on a regular basis in all programmes). Some of these uncertainties are relatively intractable,
and are likely to remain. Others can be resolved, or at least reduced, by the application of research
findings. The Research and Development Programme will support the Institute in these areas.
Process
Uncertainties amenable to resolution within NICE
The Institute has access to some research capacity, including that of its own staff (e.g. Technical
Forum) and staff employed in partner organisations (including the Review Body for Interventional
Procedures, the National Collaborating Centres, the Technology Appraisals Review Groups and the
Decision Support Unit). This capacity can be used to resolve some methodological uncertainties, which
may constitute a good use of Institute resources, as well as developing internal capacity.
In such cases the R&D programme will have an important role in scrutinising and commenting on study
protocols, providing support for ethical committee applications and advising on the approach taken.
Additionally, the R&D programme will keep a record of such work. (For more details about the
programme’s approach to research in which it is involved, see section 7).
Larger questions
Some areas of methodological uncertainty are too large to be resolved using ‘in-house’ capacity. In
such cases the following process will be followed.
• The programme proposing the research will submit a methods research recommendation to the
Research and Development Advisory Committee.
• The Research and Development Advisory Committee will discuss the recommendation, reviewing its
importance, clarity, relevance and benefit to NICE, relevance to other organisations and feasibility. The
Advisory Committee will also wish to consider other ongoing methods research of relevance to the
recommendation.
• If the Advisory Committee supports the recommendation it will be promoted to an external research
funder, if it is of general importance to the NHS or others. Alternatively, if it is of particular interest to
NICE, the R&D programme may fund the research, normally in partnership with the National
Coordinating Centre for Research Methodology.
3.1.2 Interviews with stakeholders and email survey
The interviews with stakeholders were conducted by two of the project team members. In total 18
face-to-face and telephone interviews were completed (a list of the stakeholders that were interviewed
is given in Appendix A2).
Response rates for the email survey were disappointing (see Table 2). Of thirty-three invited
respondents, only thirteen (39%) completed surveys. Whilst the response rate is low, there was a
reasonable response rate from NICE employees, UK HTA methodologists and NCC and TAG
representatives. No responses were returned from evidence collaborations (group 3); however, two
of the three invited recipients in this group responded that they did not feel sufficiently informed
regarding NICE to respond.
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Table 2: Response rates for the email survey
Invited recipients Respondents (proportion of invited
recipients)
Group 1: NICE employees 5 3 (60%)
Group 2: UK Healthcare/
Research organisations/ International HTA
13 2 (15%)
Group 3: Evidence collaboration organisations 3 0 (0%)
Group 4: UK HTA methodologists/
NCC and TAG representatives
12 8 (75%)
Total 33 13 (39%)
The results of these interviews and responses to the email survey are summarised below. Current
process for identifying and prioritising topics at NICE have been distinguished from changes to the
process for identifying and prioritising topics.
3.1.2.1 Current processes within NICE
Formal processes. NICE staff described a number of formal processes within NICE, that contribute
towards the identification and prioritisation of methods topics. These processes, however, have
limited visibility to many people outside of NICE and many are unsure how these processes are
connected, in particular to whom methods topics are fed for further consideration, and how they are
taken forward. There was felt to be no overall strategic plan regarding the identification and
prioritisation of methods topics. Areas that require methodological development tend to currently be
identified at a team level rather than an Institute level, and these tend to be ‘needs driven’ rather than
forming part of an overall strategic plan. Specifically NICE staff suggested that methods topics can be
identified via the following avenues:
x We were told that the R&D team is very small and no longer has a formal budget for research
funding. Perhaps because of this, the R&D team is used for what was described as ad hoc
methodological issues. Not all of them are related to research (e.g. to help formulate and
implement equalities plan).
x Within the R&D programme the Research and Development Advisory Committee (RDAC), was
established in 2003, to advise NICE about its research and development work. We were told that
this committee was originally a sub-Committee of the NICE board and, following NICE gaining
responsibility for the confidential enquiries programme, had a specific budget associated with
restructuring enquiries. However, the confidential enquiries programme is no longer part of NICE
and the RDAC is now a strategic committee without a dedicated budget. The RDAC includes
representatives from key partner organisations such the MHRA and MRC, as well as direct lay
representation. NICE staff suggested that the RDAC was originally intended to meet
approximately three times per year, but had met infrequently at the time of writing. Many
respondents felt that the role of this committee was unclear, in particular if research considered by
the committee was clinical or methodological or a combination of both. Previously the RDAC has
provided criteria for prioritising clinical research topics, and has also supported topic-specific
initiatives, such as a joint workshop with AHRQ to discuss recommending interventions only in the
context of research (OIR) initiative, a topic which was subsequently referred to the MRP and is
currently in the process of being commissioned.
x The majority of respondents discussed the NICE’s methods guides which are a highly visible
output of NICE that contributes towards the promotion and development of methods work.
Respondents indicated that each programme has a methods guide for stakeholders which is
regularly updated. As part of the updating process, we were told that methodology areas that
have caused concerns or uncertainties are highlighted. Some respondents considered that the
topics that emerge from this process usually involve a tweak to existing methods rather than
recommendations to commission major new research. It was noted that the methods issues
listed in the guides are just the current recommendations and as such the process is repeated
during each methods update. Despite the general optimistic view of the methods guides from
NICE staff and respondents external to NICE, in terms of generating and promoting methods
research, one respondent external to NICE felt that the methods guide had not impacted on
methodological research.
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x Respondents referred to the use of methods reviews (for all NICE programmes) to actively
highlight areas where methods development is needed. For example, as part of the 2008 review
of the methods guide for the Technology Appraisals programme, a series of workshops of specific
methodological areas were held. A series of briefing papers produced by NICE’s Decision
Support Unit was commissioned to facilitate discussion at those workshops. The main aim of the
workshops was to discuss possible changes to the Technology Appraisals methods guide;
however, we were told that some methodological development needs were also identified as part
of this process (i.e. without a workshop). A few of the respondents stated that the methods guide
and supporting documentation helps to highlight the methods areas that are felt to need further
work, which can be helpful for some researchers obtaining funding for research. It was felt that
the downside of this is that subjects that are not mentioned as areas of uncertainty in the methods
guide, but still actually are, may get overlooked (an example was given of the use of patient or
public preferences for deriving Quality Adjusted Life Year (QALY) weights).
x The technical forum is a monthly meeting of technical staff within the Institute. It is an
environment in which to discuss issues with a mix of internal and external speakers. It has a role
in sharing experience across programmes. As well as the technical forum, we were told that other
workshops organised by NICE provide opportunities to identify methodological development
needs and to exchange views between internal and external people (e.g. the workshop on
economic evaluation of public health interventions).
Informal processes
In addition to the more formal processes to identify methods topics, a number of informal processes
for identifying methodological research needs were described by members of NICE staff. These take
a number of forms:
x Respondents noted that members of NICE staff identify topics via a personal/professional
interest. This is more a consequence of professional observations rather than an explicit process
of identification. NICE staff use methods during the process of producing guidance and
consequently assess whether they are appropriate; and, as such, a portfolio of themes constantly
emerges. We were told that, during discussions amongst technical staff, topics often ‘bubble up’
over time and gradually priorities emerge. It is during these ‘acute moments of learning’ that work
such as the ‘End of Life’6 can be initiated. It was suggested that often a fairly quick solution is
needed to methodological issues and that the NICE programmes often have a clearer view than
the academic world of the issues that are important to the work of NICE in producing guidance on
appropriate patient care for the NHS.
x Respondents indicated that, when a problem is identified, work is often commissioned externally
or, to a more limited extent, conducted internally. For internally conducted work, often no explicit
funding is available for this work and, instead, it is funded by soft resources. An example of this is
the use of student placements. For example, in 2007 the Technology Appraisals directorate
looked at the selection and use of health state utility values in NICE Technology Appraisals.
Explicit funding in these circumstances was seen by some respondents to be beneficial, although
it is not clear where this funding would come from. It was generally agreed by respondents that,
within NICE, it should be everyone’s responsibility to identify topics, whichever area they are in
and to communicate these appropriately.
x One respondent suggested that there were differences in research-culture amongst Institute
teams. The reasons were not probed in-depth but it was suggested that there were different
incentives and support, for example the background of individuals within the teams.
x One respondent felt that public health in particular has been challenged because limited
methodology existed in the same way it did for HTA. It was considered that this programme has
been very proactive in developing methodology.
x It was noted that the Patient and Public Involvement Programme (PPIP) has undertaken their own
evaluation of patient expert experience, including a survey of lay members of appraisal
committees, guidelines development groups (GDGs) and the citizens’ council. We were told that,
during this process, a whole raft of issues around assessing quality of life was identified. As well
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as the team within NICE, the NCCs linked with NICE often identify methodological research and
conduct it independently. However, it was noted that there is no formal route from an NCC to
NICE for identifying methodological research development needs or communicating ongoing
methodological work.
x We were informed that, to encourage discussion including issues of methodology, each of the
analyst teams within NICE has an annual away day. For many of the teams, part of the day is
focussed on identifying methodological questions of relevance.
x Some respondents stated that, although there is no formal process during committee meetings to
feed methods topics forwards and to develop them, methodological issues often arise in these
meetings. These are often context specific, but there are some topics that are over-arching such
as which perspective to take, issues relating to QALYs and what cost-effectiveness threshold to
use. It was noted that concerns are also expressed by stakeholder groups during the course of
guidance development, for example how information from patients is incorporated into evidence
used by NICE. Despite topics often arising during committee meetings, many respondents
expressed the concern that there is no formal mechanism for taking these issues forward.
x Respondents indicated that, more generally, methods gaps are highlighted when applying the
methods guides to the development of individual pieces of guidance. It was noted that a few
pieces of guidance (for example, Public Health Guidance on Behaviour Change) contain methods
research recommendations. In addition, issues arise during consultation with stakeholders or
during the appeal process for technology appraisals. Issues that arise repeatedly during
guidance development tend to be informally collated until they are considered sufficiently
important to warrant further work. It was noted by respondents that issues that affect the process
are often considered particularly important and take precedent.
x Respondents noted a number of other informal systems which can be used to identify methods
gaps, in addition to core NICE activities. Gaps can be highlighted during ad hoc meetings of
chairs, for example PHIAC’s discussions on methodology in public health evaluation led to the
recent workshop on economics in public health. The Centre for Clinical Practice (CCP) technical
team also works closely with technical staff from collaborating centres to identify broad areas of
need. The collaborating centres and NICE conducted a review of methods needs in 2005 to
identify areas of challenging methods across the programme.
x Respondents suggested that the ‘What’s new’ internal bulletin also serves to highlight issues that
may be relevant for NICE decision-making to NICE staff. This is essentially a sift of methods
papers from some key journals by an information specialist and two senior members of staff for
internal circulation. The aim is not specifically to identify methods research needs but these are
often highlighted as part of the searches.
x We were told that NICE also benefits from the relationships it has built with various academic
groups, in particular relationships forged with those who conduct assessments of evidence for the
Institute. There is an expectation that these centres will have the highest awareness of
methodological developments in HTA. Academic groups who have worked with NICE and helped
to produce the technical manuals have taken forward some issues in the past (e.g. value of
information). Some NICE staff did express a concern about competing interests when allowing
external collaborators to lead the focus of methods work. They considered that, for NICE, the
focus should always be on identifying where methods development is needed to support NICE
decision-making rather than pursuing academic interests of external collaborators.
In summary, several current formal processes for identifying topics were highlighted during interviews
with staff at NICE, including the work of RDAC which advises NICE about its research and
development work, the regular updating of the methods guides and the technical forum. In addition to
the more formal processes to identify methods topics, a number of informal processes were described
by members of NICE staff. These included identification of topics by NICE staff motivated by
personal/professional interest, discussions during committee meetings, ad hoc meetings of NICE
chairs, staff away days and the ‘What’s new’ internal bulletins. These processes are intended to help
identify and promote methods work with NICE; however, many respondents outside of NICE felt that
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the mechanisms to identify methods topics had limited visibility and they were unsure how these
various processes were co-ordinated.
All of the formal and informal processes described by the interview respondents and email survey
focus on the identification of topics rather than their prioritisation or their development into specific
researchable questions. There are no defined systems of prioritisation and no current criteria for
prioritisation of methods research.
3.1.2.2 Suggested improvements to the NICE process
Identification of topics. Respondents external to NICE and members of NICE staff had some clear
ideas about how the process for identifying methods topics should be changed. In particular, they
advocated the idea of a more explicit and coherent plan for identifying topics; engaging the individual
teams within NICE more formally, something perhaps along the lines of the existing topic selection
panels. A number of specific suggestions were made. These suggestions were not intended as
mutually exclusive options and could be used in combination, where appropriate. The suggestions
were:
x A ‘Methodology Committee’ with members from both within and outside of NICE, including
methodologists. The committee would meet regularly and be clearly visible within NICE and
externally. Caution would have to be exercised to avoid duplication of effort with other bodies
such as MRP. Suggestions for the types of people who should be involved were: NICE staff –
technical advisors, associate directors, members of the R&D group; representatives from
groups reviewing the evidence for NICE; key people from industry (e.g. access strategy group
within ABPI); and representatives from research funding organisations. Key members of the
appraisal committees, external methodologists and clinicians and other stakeholders such as
NCCHTA might also be involved. In addition it was suggested that there should be an
overarching group of methodologists, such as members of the MRP committee, NICE
methods advisors and wider methods advisors. A more select group could also be used, for
example the MRC or NICE could have quarterly debriefings with committee chairs, where
methodological issues that have arisen/emerged as priority areas during previous period are
discussed.
x RDAC could coordinate a methods identification process by developing a database of
research recommendations generated by guidance-producing centres of the Institute. NICE
currently has such a database for clinical and public health research topics, but this does not
include methods research topics. Information generated by this process could then be fed
back to the relevant guidance producing centres.
x The identification of topics could be included as a specific agenda item in existing committee
meetings. This agenda item would need sufficient time dedicated to it, but would not
necessarily have to be an agenda item at each meeting. Committee chairs and vice chairs
should feed into the process of identifying areas where methodological research is needed. A
mechanism for feeding back any topic suggestions would also have to be established.
x The creation of a formal process for following up recommendations for topics which have
come from the various methods guides, involving a thorough exploration of the basis of the
evidence provided from recommending topics for further research. This would help to provide
a better grounding for the topic recommendations. In addition to the methods guides the
outputs from relevant methods workshops could continue to highlight suggestions for further
research.
x Greater collaboration between interested parties both within and outside of NICE was
suggested (including industry, HTA, James Lind organisation and other international
organisations). Many felt that opportunities for collaboration on methodological topics are not
being fully exploited. Two respondents from industry felt that the need for industry
involvement in generating methods topics is further highlighted during the single technology
appraisal (STA) process. They noted that industry put together the submissions and thus
address the methodological issues associated with specific appraisals. Lots of decisions are
made by the companies themselves and more specific guidance on acceptable methods are
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needed. They considered that collaboration on topic generation would also be good outside of
the assessment process so that any competing objectives/tensions could be put aside.
x Related to the above point, one of the respondents felt that a key issue is capturing the views
of expert advisors that support NICE and getting them to focus on methods rather than
specific appraisals. NICE could set aside time with external advisors away from its day-to-day
process with a focus on methods and identifying the big (top-level) questions. The experts
contributing to this process should be from the NICE advisory committees and from the
groups conducting the evidence reviews for NICE. There could be key methodologists
facilitating the process e.g. statisticians, systematic reviewers. However, it was suggested
that NICE does not want these experts to sway the discussion. It was argued that the topics
that are raised must be things that are understood and valued by people actually using the
methods for decision-making. This said, there were some stakeholders that felt that
identification of topics should be done exclusively by people within NICE, and that there is
sufficient expertise within NICE. They considered there to be a need for generating the
mechanisms to bring this expertise together in some kind of forum.
x An additional way to identify topics would be to take a retrospective look at past appraisals, to
identify areas that have caused problems in the past or where different methods could have
made a difference to the decision. There should be a general process for audit of critical
inputs that most influence cost-effectiveness and what makes a difference to the decision, as
well as of methodological problems that have arisen.
x In relation to the future identification of topics, the role of the R&D programme was mentioned
by a few respondents. A paper on the R&D strategy is planned for 2009, and this will involve
revising the role and function of RDAC. There was a desire for individual centres in the
Institute to contribute to the delivery of future strategy, with R&D as a coordinating and
enabling function; for example, through the quarterly meetings that are held with each centre
to discuss what needs doing and how it could be done. It was noted that there is a need for
the individual centres to inform R&D of the issues that are important to the specific guidance
producing programmes. It was also noted that RDAC could be transformed into a research
forum rather than a committee, possibly with an annual forum plus other seminars.
x Many respondents felt that that NICE should be more proactive and strategic thinking rather
than reactive to individual problems on an ad hoc basis. To operationalise this it was
suggested that NICE needs to develop its expertise in identifying and conducting
methodological work, collaboration on methodology could come in the form of external
placements/interns. This could also be extended to opportunities for NICE staff to undertake
some research, including in collaboration with other institutions. It was felt that the technical
forum currently used at NICE could be more effective if internal staff were more actively
involved in suggesting speakers and presenting themselves.
x Despite a general feeling that a more explicit formal process would be beneficial, one
stakeholder did stress that any changes to the process should not impinge on the ability of
individuals within the Institute to identify areas where methodology needs to be further
developed. As well as formal processes, there is a need for informal discussion and iteration -
letting things emerge as methods are applied. Across the Institute as the teams operationalise
the methodology, different sets of topics and priorities will be emerging and this process
should still be encouraged.
Prioritisation of topics. Again, the general consensus was that there should be an explicit process for
prioritisation or at least a clearer pathway for feeding topics forward within NICE. One respondent felt
that topics can get put on the ‘back burner’ or pushed forward ahead of other worthwhile topics,
because of the political issues associated with them. If there was an explicit process for prioritisation
this would be less likely to happen.
Most of the respondents (both from within and external to NICE) felt that prioritisation of topics should
be on the basis of the issues most important to NICE; specifically, will the research make a difference
to NICE? In determining this, it was proposed that the following questions need to be considered:
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- Is the methods research needed to inform the NICE assessment and decision-making process?
- What are the consequences of not doing the research?
- Will the methods impact on patient care?
- Will the research impact on equity?
- Is the topic researchable and how long will it take to resolve?
- What is the scale of the topic contribution – is it a big issue in the assessment process, and does
it cross themes and will it affect decisions? There is a need to consider things that are currently
issues and things that will be issues in the future.
- Does the topic inform gaps in current methods evidence and/or does it inform issues of
uncertainty and/or a lack of confidence?
- How is the issue perceived by stakeholders?
- Does the research improve the robustness and transparency of NICE’s work?
In consolidating the information on each of these aspects, there were contradictory views on what
mechanisms could be used. A few of the respondents advocated the use of scoring, possibly using
some kind of Likert scale as suggested by one respondent external to NICE. This would have to
include the issue of whether the topic is researchable (in terms of the area but also in terms of
availability of skills). This might enable the generation of a profile of scores (it may not be necessary
have to produce a single score).
Others felt that scoring research topics/questions had little value, especially if conducted in isolation.
Instead priorities should be decided by round table discussion probably by a specific committee with a
similar membership to the topics selection committees.
In terms of who should prioritise topics, many respondents felt this should be handled internally within
NICE. External organisations that have relevant expertise may be able to offer advice and guidance
but may be biased in terms of their research interests and may not fully appreciate NICE’s priorities.
Funding of topics. Aside from the issues of identifying and prioritising methods topics, many of the
respondents, particularly those external to NICE, felt that a clear link with funding sources for methods
research would be useful. The current lack of funding specific to NICE methods research has meant
that a lot of important work has been shelved. Likely funders for this type of work are the MRC and
NHIR. In seeking external funding there is the potential for NICE staff to act as co-applicants for grant
applications along with external researchers. Where there is a lack of capacity, interest or capability
within NICE, external collaborators should lead on the application for funding.
It was suggested that at the very least external funders should be made aware of the priority topics.
Such a system is currently in place for NICE to make the NHS HTA programme aware of clinical
research priorities but these priorities cannot be enforced. In addition some methodological topics are
referred to MRP by NICE e.g. a project was recently commissioned by the MRP entitled ‘Informing a
decision framework for when NICE should recommend the use of health technologies only in the
context of an appropriately designed programme of evidence development (“only in research”)’.
An alternative suggested was that NICE would have its own direct funding for methodological
research. This would require a clear work programme at NICE and some felt this would be a
significant step. NICE would not need to have its own methodologists in house as it could commission
these from other organisations. One respondent suggested that the source for this in house funding
was for the MRC to devolve some budgetary responsibility to NICE for methods work.
In summary the key suggestion for future change was the idea of a more explicit and coherent plan
for identifying and prioritising methods topics. As part of this a number of specific suggestions relating
to the identification of topics were made, including the creation of a ‘Methodology Committee’ with
members from both within and outside of NICE, the identification of potential topics as a specific
agenda item in existing (decision-making) committee meetings, greater collaboration between
interested parties both within and outside of NICE and the creation of a formal process for following
up recommendations for topics which have come from the various methods guides. In terms of
prioritisation, most of the respondents felt that any criteria for prioritisation should be on the basis of
the issues most important to NICE decision-making. The need to identify funding for methods work
was also raised by many of the respondents, particularly those external to NICE.
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3.2 Current processes by which methodological research topics are identified and
prioritised in other organisations
Information on methods to identify and prioritise methodological research topics within other
organisations was not forthcoming from the telephone and face-to-face interviews. However, a
number of respondents to the email survey did provide some detail.
A spokesperson from the European Network for Health Technology Assessment (EUnetHTA)
commented on the process that EUnetHTA uses to identify potential methodological research topics.
It has no systematic process, but identifies topics through an ad hoc review of reports, and their
multidisciplinary Scientific Advisory Board may also point to required methods research. A granting
mechanism for external methodologically oriented projects ended in 2007, and the possibilities of
initiating methods research are currently limited. The EUnetHTA handbook is available at:
http://www.sst.dk/publ/Publ2008/MTV/Metode/HTA_Handbook_net_final.pdf.
A spokesperson from the Agency for Healthcare Research and Quality (AHRQ) stated that it has a
fairly formal method for identifying new needs for methods research. It convenes its researchers and
forms work groups to take a lead on systematically reviewing current methods and recommending
new areas of methods research. It holds expert meetings where invited experts are able to present
work on specific areas of methodology, and the AHRQ sets aside a portion of its budget to fund novel
methods work, led by AHRQ staff.
The AHRQ is currently in the process of documenting their system for identifying methods topics.
Identified areas for research are prioritised by critical review, identified limitations in existing methods
research and their direct impact on the mission of AHRQ. Identified topics are funded by the AHRQ
and competitively assigned after soliciting and peer reviewing proposals. The AHRQ hosts a
symposium (http://effectivehealthcare.ahrq.gov/documents/2008_1209AHRQCallforAbstracts.htm) to
examine new and emerging methods. The AHRQ’s guide for HTA methods can be found at
(http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=60).
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4. Methodological topics
4.1 Results from the literature review
Section 3.1 provides details of the documents reviewed in the project. The documents are listed and
extracted in Appendix 7.
Suggestions for methodological research aimed directly at informing decision-making at NICE were
reported in 11 of the papers. All of these papers referred to areas where methodological development
was considered to be potentially useful, and did not report the suggestions as researchable questions.
4.2 Interviews
Details of the interviews and responses to the email survey are reported in Section 3.1.2. Topics for
future methods development/research were added to those obtained from the literature.
During the interview phase of the project, the definition of what constitutes methodological research
was raised. Some interviewees referred to potential research topics that were not aimed directly at
developing new methods, but rather at reviewing or auditing the use of existing methods or
developing repositories of evidence previously used to develop NICE guidance. The final list of topics
included in the web-based feedback exercise was limited to topics that would develop new or existing
methods, such that if the reviews or audits required methodological development they were included,
but reviews or audits or particular parameter values were not included.
4.3 Topics
4.3.1 Overview
Over one hundred topics for potential methodological research were suggested through the interviews
and email survey, and from the focussed review of the literature. The topics identified from the
different sources were combined. All suggested topics were grouped into the following five areas of
methodology. Each area relates to a different aspect of the assessment and appraisal process. Some
of the topic suggestions related to more than one area of methodology; in which case they were
categorised according to the most closely related area.
x Area 1: Analysis and design of effectiveness studies and their synthesis
x Area 2: Synthesis of evidence from patients, the public and stakeholders
x Area 3: Economic analysis and uncertainty
x Area 4: Measurement and valuation of benefits
x Area 5: Decision-making at NICE
Within each of the five areas, the topics were grouped into related themes. The themes under each of
the five areas are presented in Box 2. Details of specific topic suggestions are detailed in Appendix
A8 as presented at the workshop (see below).
Most of the topics suggested during the interviews and email survey were each raised by a single
respondent. However, some suggestions were raised by several people. Those research topics
raised independently by more than four interviewees included:
x Methodology for indirect and mixed treatment comparisons
x Synthesis of qualitative evidence in the NICE decision-making process
x Use of quality adjusted life years in decision-making (specifically establishing what benefits of
treatment are not captured by the QALY and/or standardised measures of health-related quality of
life)
x Establishing the threshold for cost-effectiveness (including the appropriate methods for estimating
this)
x Determining how data on the uncertainty in estimates of effectiveness and cost-effectiveness
should be taken into account in the decision-making process
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Box 2: Areas and themes under which methodological research questions were grouped
4.3.2 Relationship of topics to NICE activities
Some topic suggestions were specific to the work of a single guidance-producing NICE centre, whilst
others could potentially inform the work of multiple centres or NICE in general. In addition, the topic
suggestions could inform one or more stages of NICE guidance production including formulating the
scope of the guidance, aspects of evidence review and analysis, interaction with NICE stakeholders
and the process of decision-making. Figures 1 to 5 show how each of the areas and specific topic
Area 1: Analysis and design of effectiveness studies and their synthesis
A. Systematic reviews
B. Meta-analysis (including indirect and mixed treatment comparisons)
C. Use of non-experimental data
D. Interpretation and analysis of clinical trial data
E. Clinical heterogeneity
F. Diagnostics and medical devices
G. Behavioural research
Area 2: Synthesis of evidence from patients, the public and stakeholders
A. Evidence from patients
B. Evidence from the general public
C. Evidence from stakeholders
Area 3: Economic analysis and uncertainty
A. Costing
B. Perspective for analysis
C. Time horizon for analysis
D. Economic modelling
E. Uncertainty
F. Other
Area 4: Measurement and valuation of benefits
A. Use of the QALY
B. Standardised measurement tools
C. Valuation of health
D. Use of health state utility data in economic models
Area 5: Decision-making at NICE
A. Threshold for cost-effectiveness
B. Influences on NICE decision-making
C. Handling uncertainty in decision-making
D. Process of decision-making
E. Developing the format/ type of NICE recommendations
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suggestions relate to each of the NICE programmes and specific activities undertaken when
formulating NICE guidance.
The research theme is noted in the central column of each figure. The arrows to the left demonstrate
the programme to which the topics in each research area relate. These include Interventional
Procedures, Technology Appraisals, Public health, Clinical Guidelines. A separate box indicates
topics that could be applicable to all programmes (All) and, given that many of the suggested topics
relate to economic evaluation and that cost-effectiveness is not a consideration in the development of
IP guidance; an additional box represents all the guidance producing programmes except
interventional procedures. The numbers on the arrows relate to the specific topic suggestion within
that theme and area. For example, from Figure 1 all of the topics grouped under Theme E (use of
non-experimental data) could apply to all of the NICE programmes and all relate to the synthesis of
evidence. The arrows to the right indicate the activity in the guidance production process that the
suggested research area is aimed towards.
The majority of topics suggested were relevant to all of NICE’s guidance producing programmes, with
only a few being specific to individual programmes (e.g. methods to evaluate behaviour change in the
context of public health). Most of the methods related to the evidence gathering/analysis
(assessment) phase of producing NICE guidance (areas 1, 3 and 4), although a small number of
topics related to the engagement with different types of stakeholder (area 2) and the decision-making
process (area 5).
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Figure 1: Schematic of topic suggestions for area 1 (analysis and design of effectiveness studies and their synthesis)
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Figure 2 Schematic of topic suggestions for area 2 (Synthesis of evidence from patients, the public and other stakeholders)
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Figure 3: Schematic of topic suggestions for area 3 (Economic analysis and uncertainty)
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Figure 4: Schematic of topic suggestions for area 4 (Measurement and valuation of health benefits)
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Figure 5: Schematic of topic suggestions for area 5 (Decision-making at NICE)
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4.3.3 Workshop
During the workshop, participants discussed the topics identified during the preceding steps of the
project. Topics that were highlighted by delegates within the small-group discussions to be priorities
for methodological research that could benefit NICE decision-making are presented in Appendix A9.
Some topics were highlighted as priorities by more than one group. These included the following:
 Topic 1.A.2: Methods for keeping research synthesis up to date; developing on-going and up to
date repositories of ‘approved’ networks of evidence in key diseases using mixed treatment
comparison
 Topic 2.A.1: Methods to assess what types of evidence from patients should be used at different
stages of NICE’s decision-making processes (e.g. when to undertake reviews of qualitative
evidence? What types of reviews should be conducted? When should colloquial evidence be
used?)
 Topic 3.C.2: Extrapolation of the duration of the costs and benefits of interventions beyond those
observed in trials, including the quantification of uncertainty
 Topic 4.B.3: Establishing what effects of interventions and programmes are/are not currently
captured by the EQ-5D
 Topic 4.C.1: Methods for the re-evaluation of the EQ-5D preference set for the UK population with
consideration to (i) the use of patient valuations of health and/or more informed public valuations
and (ii) the appropriate valuation of health states considered to be worse than dead
 Topic 4.C.3: Methods for valuing health at different time points in a person’s life (e.g. at the end of
life)
 Topic 4.C.4: Methods to determine whether public or patient valuations of health should be used
in economic evaluation
 Topic 5.A.1: What is the current incremental cost-effectiveness ratio (ICER) of things that are
being displaced by NICE guidance (i.e. opportunity cost of NICE guidance)?
 Topic 5.A.2: Methods to estimate the opportunity cost of NICE guidance (i.e. the threshold)
including changes over time
Following feedback during the workshop, some of the topics identified from the interviews, email
survey and literature were rephrased and re-allocated into different areas and/or themes.
4.3.4 Web survey
The web survey can be seen in Appendix A10. Respondents were first given an overview of the
project and link to MRP and were then asked questions on their professional background, whether
they had attended the workshop and their involvement with NICE. The survey is then split into the 5
topic areas as described previously in 4.3.1 (Box 2).
Respondents were asked to rate each topic, within each area and theme, by their level of importance.
At the end of each area respondents were asked to suggest any additional topics. When completing
the questionnaire they were asked to provide their top three topics (across areas and themes) along
with some further detail on why these are important topics for NICE decision-making. Finally,
respondents were asked to suggest any areas and themes they thought had been omitted along with
any feedback on the survey.
The web survey was made publicly available (for a period of four weeks) on the MRC website and
linked to the NICE website. Invitations to complete the survey were sent to all workshop attendees,
people who were invited to the workshop but could not attend, individuals interviewed as part of the
project, people who were invited to be interviewed but could not participate, the wider project team
and others suggested by NICE and the MRC.
The characteristics of respondents can be seen in Table 3. Seventy-six people completed the online
questionnaire, the majority of who were based within academia (65%). A large number of
respondents were health economists or health service researchers (56%). Clinicians and public health
specialists were also well represented in the survey (13% and 9% respectively). The majority of
respondents did not attend the workshop (68%) and were not interviewed as part of the project (89%).
The large majority of respondents had worked with NICE (76%) with 13% directly employed by NICE.
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Table 3: Characteristics of web respondents (n=76)
Organisation
University 50
Private consultancy 1
Pharmaceutical company 7
NHS 5
NICE 10
Patient organisation 0
Other:
Charity
James Lind Initiative
Government
1
1
1
Professional background
Health Economist 20
Public health specialist 7
Clinician 10
Statistician 6
Health services researcher 23
NHS manager 2
Other:
Health Psychologist
HTA manager
Information specialist
Multi-disciplinary team
Research psychologist
Social scientist
Academic research (systematic reviews)
1
1
1
1
1
2
1
Attendance at the workshop
Attended 16
Invited but could not attend 8
Did not attend 52
Interviewed as part of scoping study
Yes 8
No 68
Involvement with NICE
Employed directly by NICE 10
Member of NICE committee/guidelines group 9
Academic reviewer/provider of evidence 21
Provider of submission on behalf of sponsor organisation 7
Other:
Advised of NICE outputs
Advisory committee for NHS evidence
Former member of partner council
Involved in implementation of guidance
Decision support unit
NIHR
Previous NICE employee
Previous committee member
Involved in work co-funded by NICE
1
1
1
3
1
1
1
1
1
No involvement 18
As part of the web survey respondents were given the opportunity to suggest areas and topics
additional to those listed in the survey. Additional topics suggested by respondents are given in
Appendix A11. No additional areas were suggested.
4.4 Prioritisation
The results of prioritisation of topics can be seen below in Tables 4 and 5. In Table 4 the top five
topics in each area are listed. These represent the topics most often rated as ‘very important’ or
‘important’.
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Table 4: Results from web survey prioritisation: top five topics within areas (percentage reporting ‘very
important’ or ‘important’)
Rank Topic %
Area a: analysis and design of effectiveness studies and their synthesis (n=75)*
1 1_C_1: Establishing optimal methods for analysis of disease registers and other
sources of non-experimental evidence (e.g. What methods to use? When should
non-experimental data be used? How are non-experimental data currently used at
NICE?)
77
2 1_B_1: Methods to adjust for potential bias in meta-analysis (for example, issues of
multiple sources of bias and confounding)
76
3 1_A_7: Methods for conducting systematic reviews of complex interventions (e.g. in
public health)
76
4 1_F_3: How best to evaluate diagnostic and screening technologies 75
5 1_A_1: Establishing methods and rules for efficient systematic reviews of
effectiveness, diagnostic test accuracy and prognostic factors (i.e. tackling the trade
off between efficiency and quality)
75
Area b: synthesis of evidence from patients, the public and stakeholders (n=75)
1 2_A_1: Methods to assess what types of patient evidence should be used at different
stages of NICE’s decision-making process (e.g. when to undertake reviews of
qualitative evidence? What types of reviews should be conducted? When should
colloquial evidence be used?)
66
2 2_B_1: Methods to understand how the public view characteristics of conditions and
the technologies used to treat them
47
3 2_C_1: The appraisal and synthesis of ‘colloquial evidence’ (e.g. comments received
from stakeholders during consultation)
44
4 2_C_2: Evaluation of the existing, and development of new methods for participation
of different stakeholder groups at different stages of NICE’s decision-making process
(including representatives of the general public, patients and practitioners)
42
5 2_A_3: Methods for using colloquial evidence to determine the effect of complex
interventions (e.g. in public health)
32
Area c: economic analysis and uncertainty (n=74)
1 3_C_2: Extrapolation of the duration of the costs and benefits of interventions beyond
those observed in trials, including the quantification of uncertainty
82
2 3_D_3: Research to assess whether the predictions of economic models used to
inform NICE guidance are borne out in practice
75
3 3_F_5: Methods to assess the cost- effectiveness of interventions which have costs
and (dis)benefits outside of the health care sector
74
4 3_D_9: Methods for determining the optimal complexity of economic models (i.e. how
complex does a model need to be to be fit for purpose?)
70
5 3_D_4: Methods for the use of surrogate or intermediate measures in models 69
Area d: measurement and valuation of benefits (n=73)
1 4_A_1: Methods to capture a wider set of (dis)benefits that may not be included in
the QALY
78
2 4_B_6: Methods for the measurement of changes in the health of children and
people unable to report the status of their own health
71
3 4_A_2: Consolidating patient reported outcomes with other measures of benefit (e.g.
QALYs)
70
4 4_C_1: Methods for the re-evaluation of the EQ-5D preference set for the UK
population with consideration to (i) the use of patient valuations of health and/or more
informed public valuations and (ii) the appropriate valuation of health states
considered to be worse than dead
68
5 4_C_3: Methods for valuing health at different time points in a person’s life
(especially at the end of life)
68
4_C_4: Methods to determine whether public or patient valuations of health should
be used
Area e: decision-making at NICE (n=74)
1 5_C_3: How should NICE assess whether additional evidence is needed, what type
of evidence is required and the type of evidence for ‘coverage with evidence’
decisions
78
5_E_2: Development of methods to produce guidance to the NHS on the
disinvestment of existing interventions
2 5_A_1: What is the current ICER of things that are being displaced by NICE guidance
(opportunity cost of NICE guidance?)?
74
5_A_2: Methods to estimate the opportunity cost of NICE guidance (i.e. the
threshold) including changes over time
5 5_B_4: Methods for taking factors other than cost-effectiveness (e.g. societal
costs/effects) into account in NICE decision-making (e.g. using multi-criteria decision-
making analysis)
66
*Number of respondents that completed any of this section
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Respondents were asked to list three topics, across all areas and themes, that they considered most
important. The topics most frequently listed are shown in Table 5. Unfortunately, due to a technical
issue with the web survey, only 55 respondents listed three priority topics; others did not complete this
section or listed more than three topics. Therefore, the results of this part of the survey should be
viewed with caution.
Table 5: Results from web survey prioritisation: Most highly rated topics across areas (n= 55)
Rank
overall
Topic Number times ranked in
top 3
1 1_G_1: Methods to evaluate interventions to change behaviour in the
context of public health
13
2 1_A_7: Methods for conducting systematic reviews of complex
interventions (e.g. in public health)
7
3 1_A_1: Establishing methods and rules for efficient systematic reviews of
effectiveness, diagnostic test accuracy and prognostic factors (i.e. tackling
the trade off between efficiency and quality)
6
1_B_5: Establishing the reliability of mixed treatment comparisons and
consistency with direct data
6
4 1_A_2: Methods for keeping research synthesis up to date; developing
on-going and up to date repositories of ‘approved’ networks of evidence in
key diseases using mixed treatment comparison
5
1_D_8: Methods to attribute outcomes to specific components of care
within complex interventions (e.g. public health interventions)
5
5_A_2: Methods to estimate the opportunity cost of NICE guidance (i.e.
the threshold) including changes over time
5
5_B_4: Methods for taking factors other than cost-effectiveness (e.g.
societal costs/effects) into account in NICE decision-making (e.g. using
multi-criteria decision analysis)
5
5_E_2: Development of methods to produce guidance to the NHS on the
disinvestment of existing interventions
5
5 1_B_12: Methods for synthesising both qualitative and quantitative
research
4
1_C_1: Establishing optimal methods for analysis of disease registers and
other sources of non-experimental evidence (e.g. What methods to use?
When should non-experimental data be used? How are non-experimental
data currently used at NICE?)
4
2_A_1: Methods to assess what types of patient evidence should be used
at different stages of NICE’s decision-making process (e.g. when to
undertake reviews of qualitative evidence? What types of reviews should
be conducted? When should colloquial evidence be used?)
4
3_C_2: Extrapolation of the duration of the costs and benefits of
interventions beyond those observed in trials, including the quantification
of uncertainty
4
3_D_1: Methods to develop ‘standardised’ and ‘approved’ models in a
given disease area, including parameter inputs
4
5_B_3: Should NICE decision-making be based on cost-effectiveness
analysis (CEA) modified by social value judgements, or should a range of
social values be used of which CEA is one?
4
5_B_7: How to take inequalities into account at different stages of NICE
guidance production?
4
Topic 1_G_1 on ‘Methods to evaluate interventions to change behaviour in the context of public
health’ was ranked in the top 3 most important topics the greatest number of times. However, it was
not in the list of topics within area A considered to be important or very important by the most
respondents (65% of respondents rated it as very important or important). This may be due to fewer
people completing the top 3 ranking section of the survey. Some of those respondents who prioritised
this topic considered it to be important because of a challenge for NICE to assess the benefits from
these public health interventions in an exchangeable way with the benefits from pharmaceutical
interventions. It was noted that many public health interventions focus on changing behaviours, and
then the change in behaviour must then be linked to changes in health outcomes.
The topic included in the top 3 priorities the second most frequently also related to public health
(Methods for conducting systematic reviews of complex interventions). Information on how it would
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inform NICE guidance was not provided but suggestions for research questions were proposed (see
Appendix A12).
The third most frequently prioritised topic was methods and rules for the efficient systematic review of
effectiveness and diagnostic test accuracy. One respondent stated that they prioritised this topic
because of the importance of the trade-off between time pressures and quality of reviews. Another
respondent stated that it was prioritised because more transparent decisions need to be based on
reliable methods. Two people who prioritised this topic made specific reference to diagnostic tests.
They stated that NICE will increasingly need to evaluate diagnostics and highlighted that research
should include the integration of the evidence from systematic reviews within decision models.
Another noted that diagnostic procedures are being used increasingly within the NHS, yet is unclear
how their effectiveness should be measured and rated against other types of intervention. Comments
provided in support of the most frequently prioritised topics are provided in Appendix A13.
4.5 Summary of suggestions for priority research topics
A long list of potential methods research topics relevant to NICE’s decision-making activities was
identified through a variety of exercises including a focussed review of the literature, interviews with
representatives from NICE and its collaborators, an email survey, a workshop and a publicly available
website. Within each stage of the project a slightly different group of individuals, each with varying
degrees of links to NICE, was canvassed for their views on priority topics. Those who were
interviewed and included in the email survey had direct links with NICE; mostly as members of staff,
advisory committees or designated providers of evidence. The workshop included those with direct
links to NICE and a broader group of people, including methods experts. The web feedback exercise
included responses from some of those who attended the workshop, but also people who stated that
they had no direct involvement with NICE. The topics emerging as priorities from the different
exercises are noted below.
The following topics were noted by several people who were interviewed or responded to the email
survey:
x methodology for indirect and mixed treatment comparisons
x synthesis of qualitative evidence in the NICE decision-making process
x use of quality adjusted life years in decision-making (specifically establishing what benefits of
treatment are not captured by the QALY and/or standardised measures of health-related quality of
life)
x establishing the threshold for cost-effectiveness (including the appropriate methods for estimating
this)
x determining how data on the uncertainty of effectiveness and cost-effectiveness data should be
taken into account in the decision-making process
The following topics emerged as priorities from the workshop:
x methods for keeping research synthesis up to date (including developing repositories of
‘approved’ networks of evidence in key diseases)
x methods to assess what types of evidence from patients should be used at different stages of
NICE’s decision-making processes (e.g. when to undertake reviews of qualitative evidence?
When should colloquial evidence be used?)
x extrapolation of the duration of the costs and benefits of interventions beyond those observed in
trials, including the quantification of uncertainty
x establishing what effects of interventions and programmes are/are not currently captured by the
EQ-5D
x methods for the re-evaluation of the EQ-5D preference set for the UK population with
consideration to (i) the use of patient valuations of health and/or more informed public valuations
and (ii) the appropriate valuation of health states considered to be worse than dead
x methods for valuing health at different time points in a person’s life (e.g. at the end of life)
x methods to determine whether public or patient valuations of health should be used in economic
evaluation
x methods for establishing opportunity costs of NICE guidance (i.e. the threshold) and empirical
data on interventions that are being displaced by NICE guidance
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The following topics were rated as important or very important by 75% or more of respondents to the
web feedback exercise:
x optimal methods for analysing disease registers and other non-experimental data sources
x methods to adjust for bias in meta-analysis
x methods for conducting systematic reviews of complex interventions
x optimal methods for evaluating diagnostic and screening technologies
x methods for conducting efficient systematic reviews
x methods for the extrapolation of costs and benefits
x research to assess whether the predictions of economic models are borne out in practice
x methods to capture wider benefits not captured in the QALY
x methods to assess whether additional evidence is needed prior to the routine introduction of
interventions (e.g. ‘only in research’ or ‘coverage with evidence’ decisions).
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5. Discussion and conclusions
5.1 Project limitations
Given the time and resource constraints of the project, it was necessary for the literature review to be
highly focused. Ideally the review would have extended to literature relating to processes and
methods priorities for organizations similar to NICE internationally. Indeed, it could have been
broader, looking at the extensive methods literature relating to the evaluation of health service and
medical technology evaluations. More extensive reviews such as these would have extended the
project markedly. Moreover, it is unclear whether the methods research topics that might have
emerged from this additional work would have directly applied to NICE’s activities.
The interviews and email survey focused on individuals who are employed by NICE or who have a
close professional association with the Institute. Although methodologists were involved in this
process, and in the February 2008 workshop, more extensive involvement of methodology specialists,
working across the range of NICE’s activities, would have been desirable if time and resources had
permitted. The value of such an extension, however, would depend on whether potential
methodological research topics are better generated by those who understand the demands of
NICE’s decision-making responsibilities, or by individuals who are familiar with the potential of
research methodology to support decision-making.
The web-based survey to prioritize potential topics was also limited by time – it was available for
completion for a month. It is likely that this time constraint, and the extensive length of the
questionnaire which reflected the number of potential topics identified in earlier stages of the project,
limited the number of responses for analysis. There were also some technical problems with the
survey such as the possibility for respondents to choose more than three priority topics across areas
and themes despite being asked to select only three. Despite these limitations, the web comment
provides some indication of how important the suggested topics are judged by a broad group of
individuals with an interest in NICE and/or evaluation methods.
5.2 Issues of process
Little emerged from the focussed review of literature and key policy documents regarding how NICE
currently identifies and prioritises potential methodological research topics. Methodological topics
have been discussed with the MRP and, in a few cases, taken forward as vignettes and, in one case,
active commissioning has taken place (although the MRP Panel and its processes for taking forward
needs-led research have only been operating since April 2008). This indicates that some form of
process exists through which these topics were selected and progressed.
However, from the interviews and email survey, many commented on the lack of an Institute-wide
process. RDAC was widely understood to have a key role in the existing process, but the
specification of this role was thought to be poorly developed. Several commented on NICE's reactive
approach to methodological issues, with the changes to the methods guidance relating to 'End of Life'
technologies evidenced in this regard. There was a feeling that a more proactive approach would be
advantageous.
Overall, then, there was a feeling that the process of topic identification, communication and
prioritisation needs either changing or making more clear and explicit. A range of ideas emerged on
how this might be progressed. Issues to consider in any changes to the process include:
x How the full range of NICE’s activities are to be covered, recognising the variety of methods
issues that are likely to be seen as important across the centres and teams. Key to this is to
provide very clear communication about the aims, objectives and processes of identifying and
prioritising topics.
x Which team or as yet unspecified group of individuals within the Institute is to be the repository for
topic suggestions over time? It would seem sensible for RDAC to have overall responsibility for
this, or a sub-group which effectively acts as a ‘methodology committee’. The existing database
for potential research topics needs to be extended to include methodological topics, or a similar
database considered. There may be value in developing a web-based interface to that database,
to which NICE staff will have access and can make topic suggestions.
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x To what extent would this team/group be proactive in identifying topics or wait to be contacted by
others? It is likely that the centres responsible for generating guidance will have to take a lead in
identifying topics. Questions remain, however, about the extent to which a methodological
research culture exists in some parts of NICE. Therefore, there is likely to be a need for the
group responsible for methodology to reach out to all parts of the Institute and to understand their
needs.
x Whether additional specific discussion forums within NICE are organised at which methodological
issues are discussed with a view to identifying potential research topics. The Technical Forum
already exists and could be extended to cover the discussion of methodological research
priorities. There is a need to get methodology research routinely into the minds of decision-
making committees – for example, through specific agenda items being included in existing
meetings (e.g. centre or committee away days, committee meetings).
x What role would be played by those not formally employed by NICE, but closely related to its
activities, in the identification process? This would include assessment groups/evidence review
groups, NCCs, public health evidence groups, decision-making committees, REBIP and the NICE
Decision Support Unit. These groups include individuals who have expertise in methodology as
well as understanding the needs of NICE. They are surely essential in helping NICE staff to
identify issues where methodological research would be potentially beneficial.
x What role would be specified for external methodologists in the process? Would this group
extend any further than methodologists involved in NICE’s decision-making bodies and evidence
groups?
x What role could other external stakeholders play in the process (e.g. technology manufacturers)?
Relatively few comments emerged on the process of prioritisation of a long list of potential research
topics, although there was some discussion regarding whether an explicit scoring system would be a
useful part of the process. One feature of a more explicit process that may be of value (and has
been part of the web-based prioritisation reported here) is to ask those individuals and groups
forwarding topics to justify their suggestions by addressing some very key questions for each. These
might include: To which area of NICE’s activities does the research relate? What potential exists for
methodological research to increase the value or efficiency of NICE’s activities?
Little was discussed in the interview and survey about two particular issues. The first is how to
translate an area of methodological uncertainty, where it is felt that research might be potentially
helpful, into a researchable question. This is not a trivial stage in the process as it requires an
understanding of the range of methods available for a particular task (not just those currently used by
NICE), methodological research already undertaken and alternative approaches to methodological
research. The current process of developing topics for the MRC MRP involves some initial
specification of a question by NICE which is then further developed into a vignette, for consideration
by the MRC MRP, by a contracted researcher. Although this process serves more stakeholders than
just NICE, there is a need to consider whether these arrangements are appropriate for NICE’s needs
over the longer-term. It is likely that NICE will require considerably more capacity to be available to
develop researchable questions (when they exist) out of potential topics.
A second process issue that would need to be considered relates to the use of methodologists
external to NICE who might contribute to the process of identifying and prioritising research topics,
and then working them up into researchable questions. The advice of such externals is likely to be
important in the process, but the problem of their potential conflicts of interest are clear if they were
subsequently to bid for research in a topic on which they have advised. One way to address this is for
academic advisors to agree in advance that they will not apply for a grant relating to the specific
topics on which they are advising.
An alternative approach would be to work with the MRC to prepare quite general calls for methods
research applications – that is, to take topics which are not much more specifically defined than those
detailed here as coming out of the scoping project. This would put the onus on those seeking
research funding to define their proposed project and to justify its value to NICE’s decision-making
processes. One potential disadvantage of this is that it would potentially put a good deal of pressure
on the MRP Panel to assess the value of the proposals. NICE would also presumably need to be
involved in this process to ensure that proposed research is likely to satisfy their needs.
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5.3 Methodological research topics
A series of activities was undertaken to assemble a long list of methodological research topics of
potential value to NICE decision-making. These included interviews with key stakeholders, an email
survey with a broader set of stakeholders and methodologists, a workshop and a web-based survey.
A total of 125 topics were presented on the web survey, with a limited number of additional
suggestions coming from that part of the process. Figures 1 to 5 above show that, across the 5
areas into which topics were arranged, there appears to be a broad relevance across the range of
NICE’s decision-making activities.
One issue that was raised throughout the process, that needs to be considered as these topics are
developed further, is, what constitutes methodological research? A large proportion of suggested
topics would probably be considered clearly methodological in that they relate to the further
development and refinement of evaluative and analytical tools which have relevance beyond a single
application. Other topics may be considered less obviously methodological. An example relates to
the empirical estimation of NICE’s cost-effectiveness threshold where it might be argued that the
estimation per se may not be methodological, but that there are a number of methodological
questions that need to be addressed before such empirical work is undertaken. It may be that
research commissioners other than the MRP whose remit is specifically focussed on generalisable
methods development research, should be approached about funding some of the topics suggested
in this document.
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ABBREVIATIONS
ABPI Association of the British Pharmaceutical Industry
AHRQ Agency for Healthcare Research and Quality
CCP NICE Centre for Clinical Practice
CEA Cost-Effectiveness Analysis
CG NICE Clinical Guideline
CRD Centre for Reviews and Dissemination, University of York
CUA Cost Utility Analysis
EUnetHTA European Network for Health Technology Assessment
HTA Health Technology Assessment
ICER Incremental Cost-Effectiveness Ratio
InterTASC Technology Assessment Services Collaboration
IP NICE Interventional Procedures programme
ISPOR International Society for Pharmacoeconomics and Outcomes
Research
MHRA Medical and Healthcare products Regulatory Agency
MRC Medical Research Council
MRP MRC Methodology Research Programme
MTA Multiple Technology Appraisal programme
NCC National Collaborating Centre
NCCHTA NIHR Coordinating Centre for Health Technology Assessment
NETSCC NIHR Evaluation, Trials and Studies Coordinating Centre
NHS National Health Service
NHSEED National Health Service Economic Evaluation Database
NICE National Institute for Health and Clinical Excellence
NIHR National Institute for Health Research
OSCHR Office for Strategic Coordination of Health Research
PHIAC NICE Public Health Interventions Advisory Committee
QALY Quality Adjusted Life Year
RDAC The NICE Research and Development Advisory Committee
STA Single Technology Appraisal programme
TA NICE Technology Appraisal
TAG NICE Technology Assessment Group
KEY TECHNICAL TERMS1
Aggregated data: Data presented as the sum of all the resources and costs involved.
Assessment group: An independent assessment group commissioned by the NHS Research and
Development Health Technology Assessment (HTA) programme to produce an independent review of
the evidence for technologies being appraised within the multiple technology appraisal (MTA)
process.
Assessment report: A critical review of the clinical and cost-effectiveness of a health
technology/technologies being appraised within the multiple technology appraisal (MTA) process. It is
prepared by the Assessment Group. To prepare the report, the Assessment Group carries out a
review of the published literature and the submissions from manufacturers and sponsors.
Bias systematic: (as opposed to random) deviation of the results of a study from the ‘true’ results.
Case–control study: Comparative observational study in which the investigator selects people who
have experienced an event (for example, developed a disease) and others who have not (controls),
and then collects data to determine previous exposure to a possible cause.
1 Taken from the Glossary in the NICE Guide to the Methods of Tec
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Clinical effectiveness: The extent to which an intervention produces an overall health benefit, taking
into account beneficial and adverse effects, in routine clinical practice.
Cohort study: A retrospective or prospective follow-up study. People included in the study are
grouped on the basis of whether or not they have been exposed to a suspected risk factor or
intervention. A cohort study can be comparative, but the study investigator has no control over who is
exposed or not.
Co-morbidity: Coexistence of a disease, or more than one disease, in a person in addition to the
disease being studied or treated.
Comparator: The standard intervention against which the intervention under appraisal is compared.
The comparator can be no intervention, for example, best supportive care.
Cost-effectiveness analysis: An economic study design in which consequences of different
interventions are measured using a single outcome, usually in ‘natural’ units (for example, life-years
gained, deaths avoided, heart attacks avoided, or cases detected). Alternative interventions are then
compared in terms of cost per unit of effectiveness.
Cost-effectiveness model: An explicit mathematical framework, which is used to represent clinical
decision problems and incorporate evidence from a variety of sources to estimate costs and health
outcomes.
Data synthesis: Combining evidence from different sources.
Decision problem: A clear description of the interventions, patient populations, outcome measures
and perspective adopted in a health technology evaluation, which relates specifically to the
decision(s) that the evaluation is designed to inform.
Efficacy: The extent to which an intervention is active when studied under controlled research
conditions.
EQ-5D: An instrument for the measure and valuation of health developed by the EuroQol Group
Evidence: Information on which a decision or guidance is based. Evidence is obtained from a range of
sources, including randomised controlled trials, observational studies and expert opinion (of clinical
professionals and/or patients/carers).
Experimental study (analytic study): A study with an explicit control group that allows testing of a
hypothesis.
Extrapolation: In data analysis, predicting the value of a parameter outside the range of observed
values.
Health-related quality of life (HRQL): A combination of a person’s physical, mental and social
wellbeing; not merely the absence of disease.
Health technology: Any method used by those working in health services to promote health, prevent
and treat disease, and improve rehabilitation and long-term care. Technologies in this context are not
confined to new drugs or items of sophisticated equipment.
Heterogeneity: Used in meta-analyses and systematic reviews to describe when the results or
estimates of effects of a treatment from separate studies seem to be very different (for example, the
size of treatment effects may vary across studies, or some studies may indicate beneficial treatment
effects whereas others suggest adverse treatment effects). Such difference in results may occur by
chance, because of variation in study quality or because of variation in populations, interventions, or
methods of outcome measurement in the included studies.
Homogeneity: Used to describe when the results of studies included in a systematic review or meta-
analysis are similar and there is no more variation than would occur by chance alone. Results are
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usually regarded as homogeneous when any differences observed between studies could reasonably
be expected to occur by chance.
Incremental cost-effectiveness ratio (ICER): The ratio of the difference in the mean costs of a
technology compared with the next best alternative to the differences in the mean outcomes.
Indirect comparison: An analysis comparing interventions that have not been compared directly within
a head-to-head randomised trial.
Meta-analysis: A statistical technique for combining (pooling) the results of a number of studies that
address the same question and report on the same outcomes to produce a more precise summary
estimate of the effect on a particular outcome.
Mixed treatment comparison: An analysis that compares two or more interventions using a
combination of direct evidence (from head-to-head trials of the interventions of interest) and indirect
evidence (trials that do not compare the interventions of interest directly in head-to-head trials).
Multiple technology appraisal (MTA): The name given to the NICE process in which appraisals of
more than one technology, or a single technology for more than one indication, are conducted.
Opportunity cost: The opportunity cost of investing in a healthcare intervention is the other healthcare
programmes that are displaced by its introduction. This may be best measured by the health benefits
that could have been achieved had the money been spent on the next best alternative healthcare
intervention.
Outcome: The measure of the possible results that may stem from exposure to a preventive or
therapeutic intervention. Outcome measures can be either intermediate or final endpoints.
Parameter uncertainty: Uncertainty about the population mean values of parameters (for example,
health outcomes, utilities and resource use) included in the model.
Patient-level data: Information on the outcome and cost of treatment collected for individual patients.
Quality-adjusted life year (QALY): An index of survival that is adjusted to account for the patient’s
quality of life during this time. QALYs have the advantage of incorporating changes in both quantity
(longevity/mortality) and quality (morbidity, psychological, functional, social, and other factors) of life.
Used to measure benefits in cost–utility analysis.
Quality of life: See ‘Health-related quality of life’.
Randomisation: Allocation of participants in a research study to two or more alternative groups using
a chance procedure, such as computer-generated random numbers. This approach is used to attempt
to ensure there is an even distribution of participants with different characteristics between groups
and thus reduces bias and confounding.
Randomised controlled trial (RCT): A comparative study in which people are randomly allocated to
intervention and control groups and followed up to examine differences in outcomes between the
groups.
Reference case: When estimating clinical and cost-effectiveness, the reference case specifies the
methods considered by NICE to be the most appropriate for the Appraisal Committee’s purpose and
consistent with an NHS objective of maximising health gain from limited resources.
Single technology appraisal (STA): The name given to the NICE process in which appraisals of single
technologies for one indication are conducted.
Structural uncertainty: Uncertainty relating to the range of assumptions and judgements necessary in
constructing a model. This can include design features of the model (for example, the assumed
standard pathway of care) as well judgements about the relevance of evidence, assumptions about
appropriate distributions for parameters and alternative methods of estimation.
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Synthesis of evidence: A generic term to describe methods used for summarising (comparing and
contrasting) evidence into a clinically meaningful conclusion to answer a defined clinical question.
This can include systematic review (with or without meta-analysis), and qualitative and narrative
summaries.
Systematic review: Research that summarises the evidence on a clearly formulated question
according to a predefined protocol. Systematic and explicit methods to identify, select and appraise
relevant studies, and to extract, collate and report their findings are used. Statistical meta-analysis
may or may not be used.
Technology assessment: The process of evaluating the clinical, economic and other evidence relating
to use of a technology to formulate guidance on its most efficient use.
Time trade-off: A method used to measure utility (for example, health states). The utility value is
measured by finding the point at which the respondent cannot choose between two scenarios. For
chronic illness, the choice is between the illness for a period of time and perfect health for a shorter
time, both followed by death. For short-term illness, the choice is between the illness for a period of
time and a worse health state for a shorter time, both followed by the same specified outcome.
Utility: A measure of the strength of a person’s preference for a specific health state in relation to
alternative health states. The utility scale assigns numerical values on a scale from 0 (death) to 1
(optimal or ‘perfect’ health). Health states can be considered worse than death and thus have a
negative value.
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APPENDICES
Appendix A1: NICE ‘What’s new’ literature search strategies
Database: Medline (Ovid)
1. Guidelines as Topic/
2. Practice Guidelines as Topic/
3. Guideline Adherence/
4. exp *Epidemiologic Research Design/
5. Evidence-Based Medicine/
6. Technology Assessment, Biomedical/
7. exp Epidemiologic Research Design/mt, sn, st [Methods, Statistics and Numerical Data,
Standards]
8. Meta-Analysis as Topic/
9. exp Review Literature as Topic/
10. exp *Epidemiologic Study Characteristics as Topic/
11. exp Epidemiologic Study Characteristics as Topic/mt, sn, st [Methods, Statistics and Numerical
Data, Standards]
12. exp Controlled Clinical Trials as Topic/
13. exp *Statistics as Topic/
14. exp Statistics as Topic/mt, st [Methods, Standards]
15. Publication Bias/
16. Consensus/
17. ((grade$ or grading$) adj3 (evidence or recommendation$)).tw.
18. (consensus adj3 (develop$ or method$ or build$)).tw.
19. (indirect adj3 comparison$).tw.
20. or/1-19
21. limit 20 to (abstracts and english language)
22. Animals/ not Humans/
21 not 22
Database: Medline In-Process (Ovid)
1. guideline$.ti.
2. (meta-analy$ or metaanaly$).ti.
3. (systematic$ adj3 review$).ti.
4. ((randomi?ed or clinical) adj2 trial$).ti.
5. (diagnostic adj3 accuracy).ti.
6. ((diagnos$ or prognos$ or observational or qualitative) adj2 (stud$ or research)).ti
7. (publication adj3 bias$).ti
8. ((grade$ or grading$) adj3 (evidence or recommendation$)).ti.
9. (consensus adj3 (develop$ or method$ or build$)).ti.
10. (indirect adj3 comparison$).ti.
11. or/1-10
limit 11 to (abstracts and english language)
In addition the following journals and websites were specifically tracked for relevant papers.
BMC Health Services Research (alerts received every 7 days)
BMC Medical Research Methodology (alerts received every 7 days)
BMJ (published weekly – alert set up)
Emerging Themes in Epidemiology (BMC) (alerts received every 7 days)
Epidemiologic Perspectives & Innovations (BMC) (alerts received every 7 days)
International Journal of Technology Assessment in Health Care (published 4 times/year – alert set up)
Journal of Clinical Epidemiology (published 12 times/year – alert set up)
Journal of Health Services Research & Policy (published 4 times/year – alert set up)
Medical Decision-making (published 6 times/year – alert set up)
Quality & Safety in Health Care (published 4 times/year – alert set up)
Trials (BMC) (alerts received every 7 days)
NIHR HTA programme – alert set up for methodological reviews
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Appendix A2: List of face-to-face and telephone interviewees
Stakeholder Organisation
Ken Stein University of Exeter
Tony Whitehead ABPI
Matt Bradley GSK
Georgios Lyratzopoulos NICE
Catherine Law Public Health Interventions Advisory Committee
Kent Woods MHRA
Tom Walley HTA
Mike Kelly NICE
Steve Pilling National Collaborating Centre for Mental Health
Adrian Griffin ABHI
Peter Littlejohns NICE
David Barnett NICE
Andrew Stevens NICE
Fergus MacBeth NICE
Marcia Kelson NICE
Carol Longson NICE
Sarah Garner NICE
Tony Culyer NICE
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Appendix A3: Face-to-face and telephone interview schedule
Background
This semi-structured interview schedule is designed to act as a guide for the interviewer so that the
issues identified in the questions are addressed. The specific framing of the questions will be tailored
to the interviewee’s role and organisation where appropriate.
The sets of questions that interviewees will be asked will depend on whether they have been selected
to discuss one or more of the following issues (i) current processes for identifying and prioritising
methodological research (ii) potential future processes for identifying and prioritising methodological
research at NICE (iii) potential priority topics for method development.
Introduction
We have arranged this interview as part of a project designed to assist NICE and MRC in identifying
methodological research priorities. The purpose of this interview is to elicit details of the processes
currently employed by NICE to identify priority areas for methodological research, your views on
possible future processes for identifying topics and provide a proposed list of current priority areas for
methodological research [delete as appropriate].
The scope of the project is limited to methodological research relevant to NICE decision-making.
Therefore we are focussing on the development of methods, rather than the application of existing
methodologies to generate data for specific appraisals or diseases. In addition the focus is on priority
areas for development of methods that could directly enhance decision-making at NICE, rather than
other more general developments in HTA methods.
Current NICE process for identifying methodological research priorities
Audience: To be addressed to members of NICE secretariat and Committee Chairs.
Aim: to identify current formal and informal processes for how potentially important methods research
topics are identified and progressed through the NICE system.
Questions:
What processes are currently in place to identify areas where methods could be further developed to
facilitate the needs of decision-makers at NICE?
Are there specific individuals or teams within the institute who have the responsibility of identifying
potential areas for methodological research or development?
Are regular meetings held to discuss methodological research needs? If yes, what kind of meeting?
(Senior management team meetings? Meetings of directorates? Meetings of technical teams within
directorates? Across institute meetings (e.g. technical forum meetings)? Meetings of Chairs?)
Internal/external/mixed meetings? (e.g. Decision Support Unit? Intertasc (appraisals)? Guideline
Development Groups (guidelines)?
If no, are there ad hoc meetings, or ad hoc agenda items added to existing meetings as required?
Does anyone within your team or the Institute regularly review literature for developments in
methodology that may be potentially important to your work? (Who does this? What is reviewed? How
often? How is this fed back to the team and/or the Institute?)
Does the need for further methodological research (as opposed to specific application of existing
research methods to topic under consideration) arise during the production of a specific
appraisal/guideline/guidance/review?
How often? What type of methods research need? (Give examples) Who would usually identify this
need? (Technical analyst/advisor? Committee /Group member? External review team/ Consultee?)
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Would the need for further methodological research be discussed during the deliberations of the
Appraisal Committee/Guideline Group/Advisory Committee? How is this fed back to the Institute?
Provide examples where possible
Are there any ongoing or planned changes to the current process?
Have there been any reviews conducted to identify such methodological research needs within the
Institute/your team?
Who was involved?
What was reviewed (e.g. topic area)?
How was the review conducted?
Are such reviews conducted on an ad hoc basis or part of a regular review?
Have these led to formal processes being adopted? What problems were encountered?
Once a potential area of methods research has been identified who would this be referred to
internally?
How would you/the Institute prioritise a potential area for future methodological research alongside
other potential topics?
Are there formal mechanisms for this?
What are the criteria used?
Who decides?
How would the identified need for methods development be developed into a researchable question?
How would funding for the research be obtained?
Directly from NICE (centrally or via the directorate?)? Referral to another body (e.g. MRC)/ Conduct
research internally?
How does having the Methods Guide impact on identifying methods research priorities? E.g. are
methods research topics identified during the process of producing the guides? Does it negatively
impact on research development?
Current process for identifying methodological research priorities in other organisations
Audience: To be addressed to members of other research/HTA organisations
Aim: to identify current formal and informal processes for prioritisation in other organisations.
Questions:
Does your organisation currently identify areas where further methods development is required or
desired?
How does your organisation go about doing this?
Are there teams/individuals in the organisation who have a specific responsibility for identifying
potential topics for methodological research?
How do they identify potential topics?
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Are reviews of potential areas for methodological research conducted? If so, are they conducted
regularly or on an ad hoc basis? How are the reviews conducted (e.g. by reviewing literature?
Consultation with external collaborators/organisations?)
Does the need for further methodological research (as opposed to specific application of existing
research methods to topic under consideration) arise during the production of a specific review?
Is the process for identifying such topics published or documented?
Please give examples of where a need for further methodological research has been identified?
How are proposed areas for research prioritised?
Who would be involved in prioritising the topic area?
What criteria would be used to assess the priority of each topic?
If examples provided, were they prioritised? If so, how?
Once a potential area of methods research has been identified, how would it be progressed to a
potential study?
How would a researchable question be developed from the identified need for further research?
Would funding for the study be provided internally or would external organisations be contacted?
Which organisations?
Does your organisation have a documented Guide for HTA methods? If yes, has this impacted on the
identification of methods research priorities? If so, how? e.g. are methods research topics identified
during the process of producing the guides? Does it negatively impact on research
Potential future processes for identifying methodological research priorities
Audience: Members of NICE secretariat and Committee Chairs.
Aims: to elicit opinions from those internally at NICE about improved processes for identifying
research priorities
Questions:
How do you think the process for identifying potential methodological research needs could be
improved?
Who do you think should be involved in identifying such requirements (internally/externally)?
How do you think the process for prioritising methodological research topics could be improved?
Who should be responsible for this (internally/externally)?
Is there anyone else who should be involved?
What do you think should be the basis for prioritisation of proposed methodological research topics?
Potential methodological research priority topics
Audience: To be addressed to all interviewees involved in NICE.
Aim: to produce a list of potential methodological research topics relevant to decision-making at NICE
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Questions:
What do you think are the most important methodological research questions that need to be
addressed to enhance/facilitate the needs of decision-makers at NICE? [Up to five topic areas can be
provided]
Why do you think this is an important issue for NICE?
How will this research improve the decision-making process at NICE?
Can you give any examples of NICE work where improvements in this methodological area would
have been beneficial?
Does the research topic relate to any recent policy developments?
Are you aware of any ongoing or recent research addressing this issue?
Are you aware of any barriers to conducting this research/ why has it not been conducted in the past
(new methodological devt? New policy devt? Lack of funding? Not seen as priority?)
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Appendix A4: Email surveys
Figure A4a: Email survey version 1
Review of methodological research priorities for NICE/MRC
Introduction
We have contacted you as part of a short project, funded by the MRC, which is designed to assist
NICE in identifying priorities for methodological research to support its decision-making. The purpose
of this is to elicit details of the processes currently employed by NICE to identify priority areas for
methodological research, your views on possible future processes for identifying topics and provide a
proposed list of current priority areas for methodological research.
The scope of the project is limited to methodological research relevant to NICE decision-making.
Therefore we are focussing on the development of methods, rather than the application of existing
methodologies to generate data for specific appraisals or diseases. In addition, the focus is on priority
areas for development of methods that could directly enhance decision-making at NICE, rather than
other more general developments in HTA methods.
Please place your answers in the text boxes provided. If you have no response to a particular
question, please leave that box blank.
If you need additional space for your answers please continue in the space provided at the end of the
questionnaire.
THANK YOU FOR YOUR RESPONSE
1. Current NICE process for identifying methodological research priorities
This section aims to identify current formal and informal processes for how potentially important
methods research topics are identified and progressed through the NICE system.
1.1 How are potential areas of methodological research relevant to NICE decision-making
currently identified at NICE?
In your answer you may wish to consider the following:
x What formal processes are currently in place?
x Do specific individuals or teams within the Institute have the responsibility of identifying
potential areas for methodological research or development?
x Does anyone within your team or the Institute regularly review literature for developments
in methodology that may be potentially important to the work of NICE?
x Are regular meetings held to discuss methodological research needs?
x Are people external to the Institute involved in identifying methodological research needs
for NICE?
x Does the need for further methodological research arise during the production of a
specific appraisal/guideline/guidance/review?
1.2 Are there any ongoing or planned changes to the current process?
1.3 Have there been any reviews conducted to identify such methodological research needs
within the Institute/your team?
In your response you may wish to consider the following:
x Who was involved?
x What was reviewed (e.g. topic area)?
x How was the review conducted?
x Are such reviews conducted regularly or on an ad hoc basis?
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x Have these led to formal processes being adopted?
1.4 Once a potential area of methods research has been identified, how would it be prioritised
and developed into a research project?
In your response you may wish to consider the following:
x Who would the need for methodological development be referred to internally?
x How would you/the Institute prioritise a potential area for future methodological research
alongside other potential topics?
x Are there formal mechanisms for this?
x What are the criteria used to prioritise methodological research?
x How would the identified need for methods research be developed into a researchable
question?
x How would funding for the research be obtained (e.g. directly from NICE or an external
organisation?)?
How does having the Methods Guide impact on identifying methods research priorities?
E.g. are methods research topics identified during the process of producing the guides? Does it
negatively impact on research development?
2. Potential future processes for identifying methodological research priorities
This section aims to elicit your opinion about improved processes for identifying research priorities at
NICE.
2.1. How do you think the process for identifying potential methodological research at NICE
needs could be improved?
In your response you may wish to consider who should be involved in the process.
2.2. How do you think the process for prioritising methodological research topics could be
improved?
In your response you may wish to consider the following:
x Who should be responsible for this (internally/externally)?
x Is there anyone else who should be involved?
x What do you think should be the basis for prioritisation of proposed methodological
research topics?
3. Potential methodological research priority topics
This sections aims to produce a list of potential methodological research topics relevant to decision-
making at NICE.
3.1. What do you think are the four most important methodological research questions that need to be
addressed to enhance/facilitate the needs of decision-makers at NICE?
3.2. Why do you think these are important issues for NICE?
3.3. How will this research improve the decision-making process at NICE?
3.4. Can you give any examples of NICE work where improvements in this methodological area
would have been beneficial?
3.5. Does the research topic relate to any recent policy developments?
3.6. Are you aware of any ongoing or recent research addressing this issue?
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3.7. Are you aware of any barriers to conducting this research/ why has it not been conducted in the
past (new methodological development? New policy development? Lack of funding? Not seen as
priority?)
If you have any additional comments then please use the space below.
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Figure A4b: Email survey version 2
Review of methodological research priorities for NICE/MRC
Introduction
We have contacted you as part of a short project, funded by the MRC, which is designed to assist
NICE in identifying priorities for methodological research to support its decision-making. The purpose
of this is to elicit details of the processes currently employed by your organisation to identify priority
areas for methodological research, your views on possible future processes for identifying topics at
NICE and provide a proposed list of current priority areas for methodological research.
The scope of the project is limited to methodological research relevant to NICE decision-making.
Therefore we are focussing on the development of methods, rather than the application of existing
methodologies to generate data for specific appraisals or diseases. In addition, the focus is on priority
areas for development of methods that could directly enhance decision-making at NICE, rather than
other more general developments in HTA methods.
Please place your answers in the boxes provided. If you need additional space for your answers
please continue in the space provided at the end of the questionnaire.
THANK YOU FOR YOUR RESPONSE
1. Current process for identifying methodological research priorities
This section aims to identify current formal and informal processes for prioritisation in your
organisation.
1.1. Does your organisation currently identify areas where further methods development is
required or desired? (please ‘X’ yes or no – if no please go to Section 2)
Yes
No
1.2. How does your organisation identify areas where further methods development is required or
desired?
In your response you may wish to consider the following:
x Are there teams/individuals in the organisation who have a specific responsibility for
identifying potential topics for methodological research?
x How do they identify potential topics?
x Are reviews of potential areas for methodological research conducted? If so, are they
conducted regularly or on an ad hoc basis? How are the reviews conducted (e.g. by
reviewing literature? Consultation with external collaborators/organisations?)
x Does the need for further methodological research (as opposed to specific application of
existing research methods to topic under consideration) arise during the production of a
specific review?
x If possible, please give examples of where methodological research needs have been
identified.
Is the process for identifying such topics published or documented? (If yes, please provide details)
1.3. How are proposed areas for research prioritised?
In your response you may wish to consider the following:
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x Who would be involved in prioritising the topic area?
x What criteria would be used to assess the priority of each topic?
x If examples provided, were they prioritised? If so, how?
1.4. Once a potential area of methods research has been identified, how would it be progressed
to a potential study?
x How would a researchable question be developed from the identified need for further
research?
x Would funding for the study be provided internally or would external organisations be
contacted? Which organisations?
1.5. Does your organisation have a documented Guide for HTA methods?
x How has this impacted on the identification of methods research priorities?
x Does it negatively impact on research?
2. Potential future processes for identifying methodological research priorities
This section aims to elicit your opinion about improved processes for identifying research priorities at
NICE.
2.1 How do you think the process for identifying potential methodological research at NICE needs
could be improved?
In your response you may wish to consider who should be involved in the process.
2.2 How do you think the process for prioritising methodological research topics could be
improved?
In your response you may wish to consider the following:
x Who should be responsible for this (internally/externally)?
x Is there anyone else who should be involved?
x What do you think should be the basis for prioritisation of proposed methodological
research topics?
3 Potential methodological research priority topics
This sections aims to produce a list of potential methodological research topics relevant to decision-
making at NICE.
What do you think are the four most important methodological research questions that need
to be addressed to enhance/facilitate the needs of decision-makers at NICE?
3.1 Why do you think these are important issues for NICE?
3.2 How will this research improve the decision-making process at NICE?
3.3 Can you give any examples of NICE work where improvements in this methodological area
would have been beneficial?
3.4 Does the research topic relate to any recent policy developments?
3.5 Are you aware of any ongoing or recent research addressing this issue?
3.6 Are you aware of any barriers to conducting this research/ why has it not been conducted in
the past (new methodological development? New policy development? Lack of funding? Not seen as
priority?)
Space for additional comments
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Figure A4c: Email survey version 3
Review of methodological research priorities for NICE/MRC
Introduction
We have contacted you as part of a short project, funded by the MRC, which is designed to assist
NICE in identifying priorities for methodological research to support its decision-making. The purpose
of this is to elicit your views on possible future processes for identifying topics at NICE and provide a
proposed list of current priority areas for methodological research.
The scope of the project is limited to methodological research relevant to NICE decision-making.
Therefore we are focussing on the development of methods, rather than the application of existing
methodologies to generate data for specific appraisals or diseases. In addition, the focus is on priority
areas for development of methods that could directly enhance decision-making at NICE, rather than
other more general developments in HTA methods.
Please place your answers in the text boxes provided. If you have no response to a particular
question, please leave that box blank.
If you need additional space for your answers please continue in the space provided at the end of the
questionnaire.
THANK YOU FOR YOUR RESPONSE
1. Potential future processes for identifying methodological research priorities
This section aims to elicit your opinion about improved processes for identifying research priorities at
NICE.
1.1 How do you think the process for identifying potential methodological research at NICE needs
could be improved?
In your response you may wish to consider who should be involved in the process.
1.2 How do you think the process for prioritising methodological research topics could be improved?
In your response you may wish to consider the following:
x Who should be responsible for this (internally/externally)?
x Is there anyone else who should be involved?
x What do you think should be the basis for prioritisation of proposed methodological
research topics?
2. Potential methodological research priority topics
This sections aims to produce a list of potential methodological research topics relevant to decision-
making at NICE.
2.1 What do you think are the four most important methodological research questions that need to be
addressed to enhance/facilitate the needs of decision-makers at NICE?
2.2 Why do you think these are important issues for NICE?
2.3 How will this research improve the decision-making process at NICE?
2.4 Can you give any examples of NICE work where improvements in this methodological area would
have been beneficial?
2.5 Does the research topic relate to any recent policy developments?
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2.6 Are you aware of any ongoing or recent research addressing this issue?
2.7 Are you aware of any barriers to conducting this research/ why has it not been conducted in the
past (new methodological development? New policy development? Lack of funding? Not seen as
priority?)
Space for additional comments
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Figure A4d: Email survey version 4
Review of methodological research priorities for NICE/MRC
Introduction
We have contacted you as part of a short project, funded by the MRC, which is designed to assist
NICE in identifying priorities for methodological research to support its decision-making. The purpose
of this is to provide a proposed list of current priority areas for methodological research.
The scope of the project is limited to methodological research relevant to NICE decision-making.
Therefore we are focussing on the development of methods, rather than the application of existing
methodologies to generate data for specific appraisals or diseases. In addition, the focus is on priority
areas for development of methods that could directly enhance decision-making at NICE, rather than
other more general developments in HTA methods.
Please place your answers in the text boxes provided. If you have no response to a particular
question, please leave that box blank.
If you need additional space for your answers please continue in the space provided at the end of the
questionnaire.
THANK YOU FOR YOUR RESPONSE
1. Potential methodological research priority topics
This sections aims to produce a list of potential methodological research topics relevant to decision-
making at NICE.
1.1 What do you think are the five most important methodological research questions that need to be
addressed to enhance/facilitate the needs of decision-makers at NICE?
1.2 Why do you think these are important issues for NICE?
1.3 How will this research improve the decision-making process at NICE?
1.4 Can you give any examples of NICE work where improvements in this methodological area would
have been beneficial?
1.5 Does the research topic relate to any recent policy developments?
1.6 Are you aware of any ongoing or recent research addressing this issue?
1.7 Are you aware of any barriers to conducting this research/ why has it not been conducted in the
past (new methodological development? New policy development? Lack of funding? Not seen as
priority?)
Space for additional comments
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Table A4a. Email survey respondents
Name Organisation E-mail Survey type
Janet Robertson NICE 1
Alex Sutton Society for Research Synthesis
Methodology 4
Finn Borlum
Kristensen
European Network for Health
Technology Assessment (EUnetHTA) 2
Jean Slutsky Agency for Healthcare Research and
Quality 2
Norman Waugh University of Aberdeen 4
Adrian Bagust University of Liverpool 4
Matt Stevenson ScHARR - University of Sheffield 4
Maggie Westby NCC 4
Craig Whittington NCC 4
Beth Shaw NICE 4
Angela Melder NCC 4
Francis Ruiz NICE 1
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Appendix A5: List of workshop participants
Name Affiliation
Dr Bhash Naidoo NICE
Professor Catherine Law UCL Institute of Child Health
Dr Celia Brown University of Birmingham
Dr Chris Hyde University of Birmingham
Professor David Barnett University of Leicester
Professor David Hughes Swansea University
Professor David Jones University of Leicester
Dr Allan Wailoo University of Sheffield
Dr Fergus MacBeth NICE
Francis Ruiz NICE
Dr Georgios Lyratzopoulos NICE
Professor James Raftery University of Southampton
Janet Robertson NICE
Jim Chilcott University of Sheffield
Professor John Brazier University of Sheffield
Professor Jon Nicholl University of Sheffield
Jon Tosh University of Sheffield
Dr Julia Earnshaw GlaxoSmithKline
Professor Karl Claxton University of York
Professor Keith Abrams University of Leicester
Dr Laura Bojke University of York
Dr Louise Longworth University of Sheffield
Dr Marcia Kelson NICE
Professor Mark Sculpher University of York
Meindert Boysen NICE
Dr Nerys Woolacott University of York
Professor Peter Littlejohns NICE
Dr Ruth Garside University of Exeter
Dr Sarah Garner NICE
Simon Ellis NICE
Professor Susan Michie UCL
Professor Tim Peters University of Bristol
Professor Tom Treasure UCL
Professor Tony Ades University of Bristol
Dr Tony Whitehead sanofi-aventis
Professor Trevor Sheldon University of York
Dr Nichole Taske NICE
Professor Adrian Towse OHE
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Appendix A6: Workshop agenda
NICE Methodology Scoping Study
Agenda for Workshop 6th February 2009
9.15 – 9.45 Coffee
9.45 – 10.00 Welcome and introductions
- Aims and objectives of
the day
- The organisation of the
day
Facilitator: Trevor Sheldon
10.00 – 10.15 Overview of study Mark Sculpher
Plenary: overviews of key methodology themes
10.15 – 10.45 Analysis and design of
effectiveness studies and their
synthesis
Keith Abrams
10.45 – 11.15 Synthesis of evidence from
patients, the public and
stakeholders
Ruth Garside
11.15 – 11.30 Coffee
11.30 – 12.00 Measurement and valuation of
benefits
John Brazier
12.00 – 12.30 Economic analysis and
uncertainty
Karl Claxton
12.30 – 1.00 Decision-making and NICE Peter Littlejohns
1.00 – 1.45 Lunch
1.45 – 3.30 Small group discussion*
5 small groups. Three sessions lasting for 30 minutes each (i.e. each participant can joins
three groups
3.30 – 4.00
The MRC Methodology Research Programme (Angela Cooper)
Next steps (Mark Sculpher)
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Appendix A7: Policy documents and journal papers included in the literature review
Reference Comment on the current
processes?
Has the
publication made
any suggestions
for
methodological
research that
would be or
could be used by
NICE in making
decisions?
What are these? Have these
been worked
up into
researchable
questions?
Have the
authors
reported
suggestions
for the type of
research
needed to
answer these
questions?
JOURNAL PAPERS
Claxton et al
(2005)8
No No Not a direct suggestion for methodological research -
A continued “need to quantify the implications of the
imprecision in parameter estimates for decision
uncertainty”. This paper discusses the appropriateness
and methods of PSA, which is a method now
incorporated into NICE methods.
No. Paper is a
research piece
on PSA methods
and its
incorporation in
the NICE TA
process
No
Claxton et al
(2002)9
No No The appropriateness of EVPI and its implications for
NICE.
No, the paper is
a research piece
on EVPI, and
proposes that it
is used in NICEs
decision-making
framework.
No
Culyer et al
(2007)10
No Yes Identifying the optimal threshold implied by the prevailing
NHS budget
No No
Mauskopf
(2000)11
No Yes Extrapolation – how a new drug will impact on lifetime
treatment patterns.
No No
Sculpher et al
(2005)12
No Yes Quality and exchangeability or relevant of evidence.
Link between intermediate end points and health gain.
Extrapolation – duration of treatment effect beyond that
observed in trails
No No
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Report of
Methods
Review
Working
Party: Sub-
groups
No Yes - Further research on the relationship between baseline
event risks and treatment effect.
- Methods to combine individual patient-level data and
aggregate data and modelling baseline and treatment
effects without them interfering.
- Bayesian methods for subgroup analysis e.g. biological
plausibility of a subgroup in terms of a prior probability.
- Cost implications of not considering subgroups and
methods to do this.
- Equity issues of subgroups and impact on decision-
making.
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
question not
proposed.
No
Report of
Methods
Review
Working
Party: Costs
No No No No No
Report of
Methods
Review
Working
Party:
Evidence
synthesis
No Yes - Studies applying indirect and mixed treatment
frameworks from pre-defined protocols to empirical data.
- The impact of extending networks of evidence on
results.
- Empirical research into the consistency of using mixed
treatment comparisons with direct trial evidence for the
analysis of relative treatment effects.
- Feasibility of developing approved networks of
evidence for difference diseases.
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
question not
proposed.
Empirical
research for
area 3
suggested. No
suggestions
for other
areas.
Report of
Methods
Review
Working
Party:
Diagnostic
Technologies
No No No No No
Report of
Methods
Review
Working
Party:
Uncertainty
No Yes Feasibility of recommending a common set of models
relating to disease areas for which there are frequent
referrals.
- Methods of assessing the need for evidence and the
consequences of an uncertain decision
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
No
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question not
proposed.
Report of
Methods
Review
Working
Party: Utility
measurement
No Yes - Developing a repository for health state utilities.
- Methods for synthesising health-state utilities.
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
question not
proposed.
No
Brazier No Yes - Research into methods for the synthesis of health state
utility values, including the use of meta-regression using
published or patient-level data.
- How to use and adapt health state utility values
published in the literature for cost-effectiveness models
(for example, accounting for co-morbidities or socio-
demographic factors).
- How uncertainty in health state utility values should be
quantified and how that uncertainty should be
incorporated into economic analyses.
- Does the value of a QALY depend on when it arises
and who receives it (e.g. age, severity, social class,
responsibility)?
Noted the following current areas of promising early
research:
- Use of ranking and discrete choice experiments to
value health states.
- Ways of measuring experience values (valuation of
utility moment by moment) and incorporating values into
cost-effectiveness analysis.
- Deriving vignettes to describe health states using
cluster analysis.
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
question not
proposed.
N
Chalkidou
13
No Yes - Research to establish who should pay for the research
when recommended through OIR recommendations?
- How should NICE establish the value for money of
conducting further research (do the costs outweigh the
benefits?)
Some
suggestions for
particular focus
within areas (see
previous
N
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- How can NICE assess whether publicly funded
research will impact on current policy and practice? -
Perceptions of Only in Research recommendations and
ethical implications? (E.g. Are they coercive?).
column) but a
research
question not
proposed.
Claxton,
200814
No Yes - Recent reforms to NICE processes and UK health
research funding lead to the need for new ways of
prioritising and effectively communicating the importance
of additional evidence to those responsible for
commissioning research.
- For ‘coverage with evidence’ decisions, research
needed into how NICE should assess whether (i)
additional evidence is needed (ii) what type of evidence
is required (iii) the type of evidence
For model averaging:
- Who should be responsible for choosing the weights
- How can differing views be combined
- Which methods can be used to elicit probabilities
- How many scenarios can be used to represent the
possibilities
For elicitation:
- Who should provide judgements
- Which methods of elicitation should be used
- How should the quality of judgements be calibrated and
weighted
- Should more than one expert be used? If so how
should multiple judgements be combined
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
question not
proposed.
N
Claxton, 20058 No Yes - Develop criteria for selecting an appropriate structure
for a decision model given available evidence on
disease prognosis and the impact of alternative
interventions
N N
Koopmanschap15No No N0 No No
Martelli16 No No No No No
Miller17 No No No No No
Noorani18 No No No No No
Sculpher19 No Yes - Which types of sub-groups should be considered in
economic evaluation studies undertaken to inform the
decisions of the Institute? In particular, are there other
Some
suggestions for
particular focus
No
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sources of heterogeneity that are not described in this
paper?
- Is there any role for looking at any forms of preference
sub-groups which were not explcitly considered in the
2004 methods guidance.
within areas (see
previous
column) but a
research
question not
proposed.
Miners20 No Yes - How should costs be proportioned / attributed in cases
where the NHS / PSS is only partially responsible for a
cost, either for a specific individual or across different
population groups? An example of the latter could be if
the costs of residential care were dependent on
individuals levels of wealth, with the health care
purchaser covering a greater proportion of the costs of
care for relatively less wealthier individuals.
Some
suggestions for
particular focus
within areas (see
previous
column) but a
research
question not
proposed.
No
Sutton21 No Yes - Methods to incorporate information on the validity of
evidence into a synthesis model used in technology
appraisal
- Development of user friendly software to fit MTC
models
- When an intervention is a relevant comparator but not
connected to an evidence network, what are the
methods issues of linking that treatment in, for example
using observational evidence?
- Since the resources required for study identification
and data extraction will also increase with the size of the
network there may be a point after which it will not be
cost-effective to expand a network, although no formal
methods exist for indicating when this is.
- Since MTC methods are presently in their infancy; do
we know enough about the performance of such
methods to recommend them for routine practice?
- Slightly different model specifications exist in the
literature for conducting MTC analysis; is more
methodological research required before a specific
modelling approach can be recommended? If so, what?
- Development of more user-friendly software to fit MTC
models.
No No
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Turner, 200822 No Yes - Need for interactive elicitation software No No
Welton,
200823
No Yes - Explore values assigned to bias variance parameters
- Assumption that the mean bias in a new meta analysis
is exchangeable with the mean biases in the meta-
analyses included in previous empirical studies
- Issue of multiple sources of bias and confounding
- Using bias adjustment methods for observational
studies
No No
REPORTS/GUIDES
The
Pharmaceutic
al Price
Regulation
Scheme; An
OFT Market
Study. The
Office of Fair
Trading.
20073
No No Comments about the wider view of therapeutic value
should included others who are affected by a patients
condition, such as carers
No No
House of
Commons
Health
Committee:
National
Institute for
Health and
Clinical
Excellence.
House of
Commons
2007/081
The department praises the
open nature of the
(re)development of NICE
methods guides:
[p 29]
“The ongoing development
of NICE’s methods of
working and its open
discussion of them were
praised by the Department:
It [is] right that NICE’s
process and methodology is
the subject of continued
development and debate
and [the Department]
welcomes the open and
consultative
approach NICE takes to the
development of its work”
Yes Research is undertaken to follow up specific guidance to
see whether the predictions
of the cost-effectiveness analysis are borne out in
practice
Wider benefits and costs, such as costs borne by carers
and social care services, be
more fully incorporated into NICE’s assessment.
Recommend that more work
similar to that undertaken by Professor Smith and
colleagues at York University takes place on the
thresholds used by NICE.
No No
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Cooksey, D.
A Review of
UK Health
Research
Funding.
Treasury
20062
No Yes - biostatistics
- indirect comparisons between treatment options
- economic evaluation of public health
- appraisal of evidence derived from clinical trials
- disinvestment methods
- behavioural research
- the assessment of the impact of NICE guidance
pilot studies for new approaches by the NHS HTA
programme and NICE, involving earlier engagement in
assessing new drugs, perhaps involving those
pharmaceutical companies who are more open to such
an approach. This may well
need to be backed by more underpinning research into
HTA methodology and
health economic models;
Diagnostic Tests
“Investigate
improvements in
methodologies
for use in both
NICE appraisals
and
assessments of
the impact of
NICE guidance
on the NHS”
Recommends
the
establishment
of “Knowledge
Transfer
Champions –
under the joint
auspices of
the NHS SDO
programme
and the NHS
Connecting for
Health
‘National
Knowledge
Service’, this
small number
of full-time
‘KTCs’ would
disseminate
the findings of
health service
research and
facilitate the
early adoption
of those
findings into
routine
practice in the
NHS
Guide to the
methods of
technology
appraisal.
NICE. June
20087
Yes:
P4 – “The Institute regularly
reviews its processes and
methodology”
“The Institute would like to
encourage further
development of the
No No No
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methods of technology
appraisal.”
“The Institute sponsors
research into the methods
of technology appraisal and
welcomes suggestions to
the Director of the Centre
for Health Technology
Evaluation for both primary
and secondary research
that might lead to
improvements in methods
and make subsequent
editions of this document
more helpful.”
NICE
Research and
Development
Strategy. May
20045
Yes – Objective 2 No No No No
Darzi (2008)24 No Yes An introduction of a National Quality Board which will
offer advice on what priorities should be for clinical
standard setting by NICE. Formal introduction of this
input into the NICE decision-making process will
obviously be required
Faster appraisal process, within a few months of drug
launch. Improvements to topic selection process.
NICE will manage evidence synthesis and dissemination
through NHS Evidence.
Clearer standards from NICE on disinvesting
superseded treatments
No No
End of Life
consultation6
Not directly. This
supplementary piece of
guidance is a formal change
to the decision-making
criteria used by NICE, and
No Comments that “The advice will be subject to a
methodological evaluation. The Institute will design and
manage the methodological evaluation, which will be
published and used to make modifications to the
supplementary advice, if necessary.”
No No
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has not been developed
through one of the formal
reviews of NICE’s methods,
or the R&D process. The
ad hoc nature of its
development highlights the
importance of a formal
process of NICE Methods
research identification.
Guidelines
Manual -
200925
No No No No No
Interventional
Procedures
Programme –
Methods
Guide – June
200726
No No No No No
Methods for
the
development
of NICE public
health
guidance –
Draft for
consultation –
October
200827
No No No No No
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Appendix A8: Draft list of topics discussed at workshop
Area 1: Analysis and design of effectiveness studies and their synthesis
Systematic reviews
Topic 1.A.1: Establishing methods and rules for efficient systematic reviews (trade-off between
efficiency and quality)
Topic 1.A.2: Methods for keeping research synthesis up to date
Topic 1.A.3: Methods for identifying, appraising and synthesising ‘grey literature’
Topic 1.A.4: Methods for best conducting reviews of effectiveness, diagnostic test accuracy and
prognostic factors, and other observational studies that are of high quality, in a short timeframe
Meta-analysis (including indirect and mixed treatment comparisons)
Topic 1.B.1: Bias adjusted meta-analysis techniques (for example, values assigned to bias variance
parameters and issues of multiple sources of bias and confounding)
Topic 1.B.2: Methods to combine individual patient and aggregate data
Topic 1.B.3: Assessing the effect of extending networks of evidence for NICE guidance on the
reliability of results
Topic 1.B.4: Establishing the extent to which networks of evidence should be expanded for NICE
guidance in terms of conducting cost-effective research
Topic 1.B.5: Methods for linking treatments into networks of evidence where there is no direct
evidence link (for example using observational evidence)
Topic 1.B.6: Establishing the reliability of MTC results and consistency with direct trial data
Topic 1.B.7: Weighting of different comparators (for example, weighting of comparators less
frequently used in clinical practice)
Topic 1.B.8: How to assess the comparability of control arms when included in meta-analyses/MTC
Topic 1.B.9: Feasibility of developing approved networks of evidence for different diseases
Topic 1.B.10: Application of indirect and mixed treatment frameworks from pre-defined protocols to
empirical data
Topic 1.B.11: Methods to incorporate information on the validity of evidence into a synthesis
Topic 1.B.12: Software to carry out meta-analysis and MTC
Use of non-experimental data
Topic 1.C.1: Use of data from disease registers to estimate effectiveness
Topic 1.C.2: Establishing efficacy for an overall composite comparator
Topic 1.C.3: Research to produce better methods and solutions for accessing evidence from
observational research streams (including interventional procedures registers) in a valid and timely
fashion
Topic 1.C.4: The use of routine surveillance and monitoring data in developing NICE public health
recommendations
Topic 1.C.5: Using bias adjustment methods for observational studies
Interpretation and analysis of clinical trial data
Topic 1.D.1: Translating trial data from adults to children
Topic 1.D.2: Translating phase II research
Topic 1.D.3: Research to produce better methods to handle evidence uncertainty and validation of
these methods, particularly for rare events
Topic 1.D.4: Reflecting the quality and exchangeability of evidence in analyses
Topic 1.D.5: Appraisal of evidence derived from clinical trials
Topic 1.D.6: Use of surrogate or intermediate measures
Topic 1.D.7: The analysis of treatment sequences
Topic 1.D.8: How best to present data for NICE Committees
Topic 1.D.9: Development and validation of ways to synthesise evidence and illustrate 'risk' in the
context of new interventional procedures.
Topic 1.D.10: Methods to incorporate information on the validity of evidence into a synthesis model
used in technology appraisal
Clinical heterogeneity
Topic 1.E.1: Methods to assess the applicability of evidence to different populations
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Topic 1.E.2: Bayesian methods for subgroup analysis e.g. biological plausibility of a subgroup in
terms of a prior probability
Topic 1.E.3: Use of, and problems associated with, meta-regression based on summary data to
consider the relationship between baseline event risks and treatment effects
Topic 1.E.4: Methods to combine IPD and aggregate data
Diagnostics and medical devices
Topic 1.F.1: Ethical and practical challenges in using 'sham' procedures (or control arms) in a surgical
environment.
Topic 1.F.2: How should the product life-cycle and the procurement of devices in the NHS be factored
into the appraisal process
Topic 1.F.3: How best to evaluate diagnostic technologies
Topic 1.F.4: How does NICE best produce reviews of effectiveness, diagnostic test accuracy and
prognostic factors that are of high quality, but are carried out quickly?
Behavioural research
Topic 1.G.1: Methods for changing behaviour in the context of public health
Topic 1.G.2: Methods for establishing incentives to change behaviour
Area 2: Synthesis of evidence from patients, the public and stakeholders
Evidence from patients
Topic 2.A.1: Incorporating patients’ opinions into the decision-making process
Topic 2.A.2: Guidance on providing information to patients/carers on breaking bad news
Topic 2.A.3: How does NICE guidance address the needs of the ‘real patient’ (e.g. those with multiple
co-morbidities)
Topic 2.A.4: The appraisal and synthesis of ‘colloquial evidence’ (from policy, stakeholder
comments, expert opinion, committee expertise)
Evidence from the general public
Topic 2.B.1: Understanding how the public view characteristics of conditions and technologies used to
treat them
Topic 2.B.2: Evaluation of the existing, and development of new, methods for citizen participation into
HTA for NICE
Qualitative research
Topic 2.C.1: Synthesising qualitative and quantitative research
Topic 2.C.2: Methods for quality assessing qualitative research
Topic 2.C.3: Methods for identifying qualitative research
Topic 2.C.4: The appraisal and synthesis of descriptive data/process evaluations
Area 3: Economic analysis and uncertainty
Costing
Topic 3.A.1: What is the most appropriate source of cost data for NICE decision-making?
Topic 3.A.2: How should costs be apportioned where the NHS/PSS is only partially responsible (either
for a specific individual or across different population groups)?
Topic 3.A.3: Methods for estimating the opportunity cost of making recommendations for whole
populations rather than subgroups
Perspective for analysis
Topic 3.B.1: What is the appropriate perspective for the analysis of public health interventions?
Topic 3.B.2: Should a societal perspective be adopted in technology appraisals? How should this best
be done?
Time horizon for analysis
Topic 3.C.1: Including long-run effects of interventions in analyses (e.g. inclusion of treatment costs
unrelated to initial disease by extending morbidity)
Topic 3.C.2: Extrapolation of duration of treatment effects beyond those observed in trials
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Economic modelling
Topic 3.D.1: Establish standardised lists of parameter values that have been used in previous
technology appraisals
Topic 3.D.2: Establish checklists for establishing quality of economic models and input parameters
Topic 3.D.3: Research to assess whether the predictions of the cost-effectiveness analysis used to
inform specific pieces of guidance are borne out in practice
Topic 3.D.4: Methods related to the use of surrogate or intermediate measures
Topic 3.D.5: Assessment of the feasibility of recommending/producing a common set of models
relating to disease areas for which there are frequent referrals
Topic 3.D.6: Development of criteria for selecting an appropriate structure for a decision model given
available evidence on disease prognosis and the impact of alternative interventions
Topic 3.D.7: Better methods for estimating cost-effectiveness in subgroups
Topic 3.D.8: Assessing the cost-effectiveness of 'long' diagnostic/treatment pathways
Topic 3.D.9: The identification and use of prognostic data in economic models
Topic 3.D.10: The role of QALYs in NICE decision-making and establishing how best to go beyond
QALYs
Topic 3.D.11: Methods for determining the optimal complexity of economic models
Uncertainty
Topic 3.E.1: Methods for conducting probabilistic sensitivity analysis for more complex models
Topic 3.E.2: Developing methods for eliciting priors from people
Topic 3.E.3: Alternatives to probabilistic sensitivity analysis for handling uncertainty
Topic 3.E.4: Bayesian and frequentist models for analysis – what are the differences between the
approaches & which is most appropriate for NICE?
Topic 3.E.5: Methods of assessing the need for evidence and the consequences of an uncertain
decision
Topic 3.E.6: Model averaging for representing structural uncertainty (e.g. whose weights to use,
elicitation methods)
Topic 3.E.7: Quantifying the implications of imprecision in parameter estimates on decision
uncertainty
Other
Topic 3.F.1: What is the appropriate discount rate for health?
Topic 3.F.2: Methods for the economic evaluation of public health interventions
Topic 3.F.3: Methods for consolidating the range of costs and outcomes that decision makers are
presented with
Topic 3.F.4: Translation of research methods so that the process is understandable/transparent
Area 4: Measurement and valuation of benefits
Role of the QALY
Topic 4.A.1: Understanding the role of the QALY in the NICE decision-making process
Topic 4.A.2: Establishing what is/is not currently captured by the QALY
Topic 4.A.3: How to capture those things not included in the QALY
Topic 4.A.4: Consolidating patient reported outcomes with other measures of benefit (e.g. QALYs)
Topic 4.A.5: Establishing how much utility data drives the outcome of decision-making
Standardised measurement tools
Topic 4.B.1: Use of mapping techniques
Topic 4.B.2: Alternatives to the EQ-5D – deviations from the reference case
Topic 4.B.3: Appropriateness of EQ-5D (e.g. sensitivity of instrument)
Topic 4.B.4: Use of disease specific measures in decision-making
Topic 4.B.5: Evaluating health in less bounded ways (beyond questionnaires)
Topic 4.B.6: Measuring the impact of public health interventions
Topic 4.B.7: Methods for consolidating various measures of benefit
Valuation of health
Topic 4.C.1: Re-evaluation of the EQ-5D tariff
Topic 4.C.2: Comparison/re-evaluation of the methods of preference elicitation
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Topic 4.C.3: Establishing the trade-off between quantity and quality of health at different time points in
a person’s life including at the end of life)
Topic 4.C.4: Public versus patient valuations: why do they differ and whose values should be used?
Topic 4.C.5: Weighting QALYs for disease severity – should we and how?
Topic 4.C.6: Weighting QALYs for socio-demographic characteristics – should we and how?
Topic 4.C.7: How do patients view the burden of a condition (possibly outside of the HRQL
framework)?
Use of health state utility data in economic models
Topic 4.D.1: Developing a repository for health state utilities
Topic 4.D.2: Methods for synthesising health-state utilities (e.g. the use of meta-regression using
published or patient-level data)
Topic 4.D.3: How to use and adapt health state utility values published in the literature for cost-
effectiveness models (for example, accounting for co-morbidities or socio-demographic factors)
Topic 4.D.4: How uncertainty in health state utility values should be quantified and how that
uncertainty should be incorporated into economic analyses
Area 5: Decision-making at NICE
Threshold for cost-effectiveness
Topic 5.A.1: What is the current ICER of things that are being displaced by NICE guidance
(opportunity cost of NICE guidance?)?
Topic 5.A.2: Should the threshold change to reflect changes over time (e.g. inflation, changes to NHS
funding)?
Topic 5.A.3: Methodological challenges in estimating the opportunity cost of NICE guidance (i.e. the
threshold)
Influences on NICE decision-making
Topic 5.B.1: What other factors should be considered for decision-making for interventions for
children, including the use of medicines ‘off-license’?
Topic 5.B.2: How should equity and utility feed into NICE decision-making?
Topic 5.B.3: Should NICE decision-making be based on cost-effectiveness analysis (CEA) modified
by social value judgements, or should a range of social values be used of which CEA is one?
Topic 5.B.4: Defining and using multi-criteria decision analysis for NICE decision-making
Topic 5.B.5: Establishing the societal and professional 'belief system' about judging what is 'safe' and
what is 'efficacious’, and the influence of contextual factors
Topic 5.B.6: Which types of sub-groups should be considered in economic evaluation studies
undertaken to inform the decisions of the Institute (including consideration of equity issues)?
Handling uncertainty in decision-making
Topic 5.C.1: Establishing decision rules for incorporating estimates of uncertainty into decision-
making?
Topic 5.C.2: How can NICE predict whether guidance may lead to ‘only in research’ or ‘coverage with
evidence development’ recommendations
Topic 5.C.3: What criteria should be used for establishing only in research recommendations?
Topic 5.C.4: How should NICE establish the value for money of conducting further research (do the
costs outweigh the benefits)?
Topic 5.C.5: How can NICE assess whether publicly funded research will impact on current policy and
practice?
Topic 5.C.6: What are the ethical implications of ‘only in research’ recommendations?
Topic 5.C.7: How NICE should assess whether additional evidence is needed, what type of evidence
is required and the type of evidence for ‘coverage with evidence’ decisions
Topic 5.C.8: The use of expected value of perfect information (EVPI) methods to make both appraisal
recommendations and research recommendations
Process of decision-making
Topic 5.D.1: How do/should Committees and Guideline Development Groups operate?
Topic 5.D.2: Evaluation of the psychology of decision-making and the effect of contextual factors
(such as public presence or media campaigns)
Topic 5.D.3: Review existing analytical methods to ensure they add value for decision-making
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Topic 5.D.4: A comparison of the Appraisal Committee views on the two different processes for
conducting technology appraisals
Topic 5.D.5: A review of the quality of assessment reports that inform decision-making at NICE
Topic 5.D.6: What changes should be made to the development of NICE guidance so that electronic
decision support tools can be produced simultaneously?
Topic 5.D.7: What are the best methods for determining the most important clinical questions for a
given topic?
Topic 5.D.8: Methods for earlier engagement in assessing new drugs
Topic 5.D.9: An evaluation of the short guideline program compared to the standard process, and
possibilities for modification of the two processes
Topic 5.D.10: Methods for communicating to professionals and public (e.g. risk, results of economic
analysis)
Topic 5.D.11: Methods for scoping decision problems
Topic 5.D.12: An evaluation of the current appraisal programme in the context of the original intention
for the programme (e.g. focus on pharmaceuticals) and the reasons for differences (e.g. why other
interventions are harder to evaluate)
Developing the format/ type of NICE recommendations
Topic 5.E.1: Methods to assess the impact of NICE guidance on changing health states (or the
‘payback’ from NICE) and/or changing clinical practice
Topic 5.E.2: Development of methods to produce guidance to the NHS on the disinvestment of
existing interventions
Topic 5.E.3: Development of methods to consider value based pricing arrangements
Topic 5.E.4: Methodological issues in evaluation of patient access schemes
Topic 5.E.5: Evaluation of the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) process
Topic 5.E.6: How can NICE produce symptom-led guidance, rather than disease-based guidance?
Topic 5.E.7: Improved methods for the evaluation of diagnostic technologies
Topic 5.E.8: Improved methods for the evaluation of screening interventions/programmes
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Appendix A9: Topics highlighted as priorities for research at the workshop (topics
highlighted in bold were raised by multiple groups)
Area 1: Analysis and design of effectiveness studies and their synthesis
Topic 1.A.1: Establishing methods and rules for efficient systematic reviews of effectiveness,
diagnostic test accuracy and prognostic factors (i.e. tackling the trade-off between efficiency and
quality)
Topic 1.A.2: Methods for keeping research synthesis up to date; developing on-going and up
to date repositories of ‘approved’ networks of evidence in key diseases using mixed treatment
comparison
Topic 1.B.1: Methods to adjust for potential bias in meta-analysis (for example, issues of multiple
sources of bias and confounding)
Topic 1.B.12: Methods for jointly synthesising qualitative and quantitative research
Topic 1.C.1: Establishing optimal methods for analysis of disease registers and other sources of non-
experimental evidence (e.g. What methods to use? When should non-experimental data be used?
How are non-experimental data currently used at NICE?)
Topic 1.C.4: Using bias adjustment methods for observational studies, including adjustments for
indication bias in data from registers
Topic 1.D.4: Methods for the optimal use of surrogate or intermediate measures in assessing
effectiveness
Topic 1.D.5: Methods for the assessment of the effectiveness of treatment sequences
Topic1.D.8: Methods to attribute outcomes to specific components of care within complex
interventions (e.g. public health interventions)
Topic 1.E.1: Methods to assess the applicability of evidence from different countries to UK
populations
Topic 1.F.3: How best to evaluate diagnostic and screening technologies
Area 2: Synthesis of evidence from patients, the public and stakeholders
Topic 2.A.1: Methods to assess what types of patient evidence should be used at different
stages of NICE’s decision-making processes (e.g. when to undertake reviews of qualitative
evidence? What types of reviews should be conducted? When should colloquial evidence be
used?)
Area 3: Economic analysis and uncertainty
Topic 3.A.4: Should potential reductions in pharmaceutical prices over time be reflected in economic
analysis. If so, what methods should be used?
Topic 3.B.2: Methods to determine the appropriate costs and benefit perspective for the analysis of
health technologies?
Topic 3.C.2: Extrapolation of the duration of the costs and benefits of interventions beyond
those observed in trials, including the quantification of uncertainty
Topic 3.D.1: Methods to develop ‘standardised’ and ‘approved’ models in a given disease area,
including sets of parameter inputs
Topic 3.D.6: Better methods for estimating cost-effectiveness in subgroups
Topic 3.D.7: Assessing the cost-effectiveness of 'long' or complex diagnostic/treatment pathways
Topic 3.E.4: Methods of assessing the need for evidence and the consequences of uncertain
decisions to the NHS (e.g. in terms of sunk costs)
Topic 3.E.5: Averaging of model results to representing structural uncertainty (e.g. When should
averaging be used? What methods should be used?)
Topic 3.F.1: What is the appropriate discount rate for health and under what circumstances might it
vary?
Topic 3.F.4: Translation of research methods so that the process is understandable/transparent to
non-specialists
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Area 4: Measurement and valuation of benefits
Topic 4.A.2: Consolidating patient reported outcomes with other measures of benefit (e.g. QALYs)
Topic 4.B.3: Establishing what effects of interventions and programmes are/are not currently
captured by the EQ-5D
Topic 4.B.4.: Methods to establish when disease specific measures of health outcomes should be
used instead of, or as supplementary to, the EQ-5D
Topic 4.B.6: Methods for the measurement of changes in the health of children and people unable to
report the status of their own health
Topic 4.C.1: Methods for the re-evaluation of the EQ-5D preference set for the UK population
with consideration to (i) the use of patient valuations of health and/or more informed public
valuations and (ii) the appropriate valuation of health states considered to be worse than dead
Topic 4.C.3: Methods for valuing health at different time points in a person’s life (e.g. at the
end of life)
Topic 4.C.4: Methods to determine whether public or patient valuations of health should be
used
Area 5: Decision-making at NICE
Topic 5.A.1: What is the current ICER of things that are being displaced by NICE guidance (i.e.
opportunity cost of NICE guidance)?
Topic 5.A.2: Methods to estimate the opportunity cost of NICE guidance (i.e. the threshold) including
changes over time
Topic 5.A.3: Methods to communicate concept of a threshold and related issues to non-specialists
Topic 5.B.2: Methods to feed equity into NICE decision-making?
Topic 5.B.4: Methods for taking factors other than cost-effectiveness (e.g. societal costs/effects) into
account in NICE decision-making (e.g. using multi-criteria decision analysis)
Topic 5.B.7: How to take inequalities into account at different stages of NICE guidance production?
Topic 5.C.2: What criteria should be used for establishing Only in Research recommendations
(including a consideration of the ethical implications and whether publicly funded research will impact
on current policy and practice)?
Topic 5.D.1: How do/should Committees and Guideline Development Groups operate?
Topic 5.D.3: Methods to review existing analytical methods for systematic reviews and economic
analyses to ensure they add value for decision-making
Topic 5.D.4: Methods to evaluate the different processes within the technology appraisals programme
and within the clinical guidelines programme (including Appraisal Committee and stakeholder views
and the impact on recommendations)
Topic 5.D.8: Methods for scoping decision problems, including the potential use of qualitative
research
Topic 5.E.7: Methods for communicating guidance and supporting evidence to the general public
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Appendix A10: Web survey
NICE/MRC scoping study: Identifying NICE’s methodological research needs and priorities
Web feedback and opportunity to comment
Introduction
As part of the co-coordinated strategy for health research under OSCHR, MRC is the lead
organisation for methodology research. NICE is an important public stakeholder in this research area
and improving methods for undertaking health technology assessments, appraisals and evidence
synthesis was also highlighted as an area for further research in the 2007 Cooksey review
(http://www.hm-treasury.gov.uk/media/4/A/pbr06_cooksey_final_report_636.pdf).
To help identify priority methodology research topics to support NICE’s decision-making, MRC
commissioned a group of researchers at the Universities of York (Professor Mark Sculpher and Laura
Bojke) and Sheffield (Dr Louise Longworth and Jonathan Tosh) in September 2008 to undertake a
short scoping project. As part of the project the group has generated a list of possible future research
topics. These topics were identified via consultation with stakeholders, literature review and a
workshop involving people at NICE, the MRC and other representatives from academia and industry.
The final stage of this project is to rank the topics by level of importance. This web-based feedback
offers the wider research community, as well as those who have already contributed to the scoping
project, the opportunity to participate in this project by rating the level of importance of each topic.
Following this feedback survey, responses will be collated and the research team will provide a final
project report which will then be considered by the MRC/NIHR Methodology Research Programme
Panel, which oversees the MRC-led methodology work stream.
Details of how to complete the feedback survey are given below.
Completing the questionnaires
You are first asked to provide some information about yourself.
The questionnaire then splits into 5 broad areas, analysis and design of effectiveness studies and
their synthesis, synthesis of evidence from patients, the public and stakeholders, economic analysis
and uncertainty, measurement and valuation of benefits, decision-making at NICE.
Each area is divided into themes. Within each theme there are a number of specific topics. You are
asked to rate each topic by their level of importance as research areas. At the end of each theme you
are also asked to provide any suggestions for topics which you think may have been omitted. You can
comment on as many of these themes as you wish.
At the end of the questionnaire you are asked to provide your top three topics (across areas and
themes) along with some further detail on why these are important topics for NICE decision-making.
You can also suggest any areas and topics which you think may have been omitted. There is a free
text box at the end of the questionnaire for any additional comments. The questionnaire should take
approximately 30-45 minutes to complete.
Personnel information
What type of organisation do you work in?
University
Private consultancy
Pharmaceutical company
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NHS
NICE
Patient organisation
Other
What is your professional background?
Health economist
Public health specialist
Clinician
Statistician
Health services researcher
NHS manager
Other
Did you attend the workshop, held as part of this scoping study?
Attended
Invited but could not attend
Did not attend
Were you interviewed as part of this scoping study?
Interviewed
Not interviewed
What is your involvement with NICE?
Employed directly by NICE
Member of a NICE committee or guidelines development group
Academic reviewer or provider of evidence
Provider of submission on behalf of sponsor organisation
Other DESCRIBE
No involvement with NICE
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Area 1: Analysis and design of effectiveness studies and their synthesis
Theme A: Systematic reviews
Topic 1.A.1: Establishing methods and rules for efficient systematic reviews of effectiveness,
diagnostic test accuracy and prognostic factors (i.e. tackling the trade-off between efficiency and
quality)
Not important Somewhat important Important Very important
Topic 1.A.2: Methods for keeping research synthesis up to date; developing on-going and up to date
repositories of ‘approved’ networks of evidence in key diseases using mixed treatment comparison
Not important Somewhat important Important Very important
Topic 1.A.3: Methods for identifying, appraising and synthesising ‘grey literature’
Not important Somewhat important Important Very important
Topic 1.A.4: Development of a checklist or reporting rules for standardised reporting of public health
reviews including undertaking sensitivity analysis
Not important Somewhat important Important Very important
Topic 1.A.5: Methods for quality assessing qualitative research
Not important Somewhat important Important Very important
Topic 1.A.6: Methods for the timely identification and synthesis of qualitative research within the
context of NICE processes
Not important Somewhat important Important Very important
Topic 1.A.7: Methods for conducting systematic reviews of complex interventions (e.g. in public
health)
Not important Somewhat important Important Very important
Theme B: Meta-analysis (including indirect and mixed treatment comparisons)
Topic 1.B.1: Methods to adjust for potential bias in meta-analysis (for example, issues of multiple
sources of bias and confounding)
Not important Somewhat important Important Very important
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Topic 1.B.2: Methods to combine individual patient and aggregate data in evidence synthesis
Not important Somewhat important Important Very important
Topic 1.B.3: Assessing the implications of extending networks of evidence for NICE guidance on the
reliability of results
Not important Somewhat important Important Very important
Topic 1.B.4: Methods for linking treatments into networks of evidence where there is no direct
evidence link on the basis of randomised trials (for example using observational evidence)
Not important Somewhat important Important Very important
Topic 1.B.5: Establishing the reliability of mixed treatment comparisons and consistency with direct
trial data
Not important Somewhat important Important Very important
Topic 1.B.6: Methods to deal with treatments not routinely used in practice within evidence synthesis
Not important Somewhat important Important Very important
Topic 1.B.7: How to assess the comparability of control arms when included in evidence synthesis
Not important Somewhat important Important Very important
Topic 1.B.8: What needs to be defined in a protocol for a mixed treatment comparison?
Not important Somewhat important Important Very important
Topic 1.B.9: Methods to assess the quality of randomised studies and to incorporate this into a formal
quantitative synthesis
Not important Somewhat important Important Very important
Topic 1.B.10: A review of software to carry out meta-analysis and mixed treatment comparison
Not important Somewhat important Important Very important
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Topic 1.B.11: Methods to assess the exchangeability of studies and to reflect the in evidence
synthesis
Not important Somewhat important Important Very important
Topic 1.B.12: Methods for synthesising both qualitative and quantitative research
Not important Somewhat important Important Very important
Theme C: Use of non-experimental data
Topic 1.C.1: Establishing optimal methods for analysis of disease registers and other sources of non-
experimental evidence (e.g. What methods to use? When should non-experimental data be used?
How are non-experimental data currently used at NICE?)
Not important Somewhat important Important Very important
Topic 1.C.2: Methods to establish the efficacy of a ‘composite comparator’ (e.g. current practice)
Not important Somewhat important Important Very important
Topic 1.C.4: The use of routine surveillance and monitoring data in developing NICE public health
recommendations
Not important Somewhat important Important Very important
Topic 1.C.5: Using bias adjustment methods for observational studies, including adjustments for
indication bias in data from registers
Not important Somewhat important Important Very important
Topic 1.C.6: Methods to assess the sensitivity of observational study results to study design
Not important Somewhat important Important Very important
Theme D: Interpretation and analysis of clinical trial data
Topic 1.D.1: Methods for translating trial evidence from adults to children
Not important Somewhat important Important Very important
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Topic 1.D.2: Methods for translating phase II research for NICE decisions
Not important Somewhat important Important Very important
Topic 1.D.3: Methods to quantify the incidence of rare events from interventions
Not important Somewhat important Important Very important
Topic 1.D.4: Methods for the optimal use of surrogate or intermediate measures in assessing
effectiveness
Not important Somewhat important Important Very important
Topic 1.D.5: Methods for the assessment of the effectiveness of treatment sequences
Not important Somewhat important Important Very important
Topic 1.D.6: How best to present effectiveness data for NICE Committees including the likelihood of
anticipated and unanticipated events
Not important Somewhat important Important Very important
Topic 1.D.7: Methods to assess the effect of practitioner experience (and other potentially relevant
contextual factors) on effectiveness
Not important Somewhat important Important Very important
Topic1.D.8: Methods to attribute outcomes to specific components of care within complex
interventions (e.g. public health interventions)
Not important Somewhat important Important Very important
Theme E: Clinical heterogeneity
Topic 1.E.1: Methods to assess the applicability of evidence to different populations between
countries
Not important Somewhat important Important Very important
Topic 1.E.2: Bayesian methods for subgroup analysis (e.g. biological plausibility of a subgroup in
terms of a prior probability)
Not important Somewhat important Important Very important
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Topic 1.E.3: Use of, and problems associated with, meta-regression based on summary data to
consider the relationship between baseline event risks and treatment effects
Not important Somewhat important Important Very important
Theme F: Diagnostics and medical devices
Topic 1.F.1: Ethical and practical challenges in using 'sham' procedures (or control arms) in a surgical
environment
Not important Somewhat important Important Very important
Topic 1.F.2: How should the product life-cycle and the procurement of devices in the NHS be factored
into the appraisal process
Not important Somewhat important Important Very important
Topic 1.F.3: How best to evaluate diagnostic and screening technologies
Not important Somewhat important Important Very important
Theme G: Behavioural research
Topic 1.G.1: Methods to evaluate interventions to change behaviour in the context of public health
Not important Somewhat important Important Very important
Are there any topics, within this area that you think have been omitted? Please provide detail
in the box below.
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Area 2: Synthesis of evidence from patients, the public and stakeholders
Theme A: Evidence from patients
Topic 2.A.1: Methods to assess what types of patient evidence should be used at different stages of
NICE’s decision-making processes (e.g. when to undertake reviews of qualitative evidence? What
types of reviews should be conducted? When should colloquial evidence be used?)
Not important Somewhat important Important Very important
Topic 2.A.2: Guidance on providing information to patients/carers on breaking bad news
Not important Somewhat important Important Very important
Topic 2.A.3: Methods for using colloquial evidence to determine the effect of complex interventions
(e.g. in public health)
Not important Somewhat important Important Very important
Theme B: Evidence from the general public
Topic 2.B.1: Methods to understand how the public view characteristics of conditions and the
technologies used to treat them
Not important Somewhat important Important Very important
Theme C: Evidence from stakeholders
Topic 2.C.4: The appraisal and synthesis of ‘colloquial evidence’ (e.g. comments received from
stakeholders during consultation)
Not important Somewhat important Important Very important
Topic 2.C.2: Evaluation of the existing, and development of new, methods for participation of different
stakeholder groups at different stages of NICE’s decision-making processes (including
representatives of the general public, patients and practitioners)
Not important Somewhat important Important Very important
Are there any topics, within this area that you think have been omitted? Please provide detail
in the box below.
MRC-NICE Scoping Project 79
Area 3: Economic analysis and uncertainty
Theme A: Costing
Topic 3.A.1: What are the most appropriate sources of cost data for NICE decision-making?
Not important Somewhat important Important Very important
Topic 3.A.2: Methods to establish the amount of costs of resources should be included in analysis
where these fall only partially on the National Health Service/Personal Social Services (either for a
specific individual or across different population groups)?
Not important Somewhat important Important Very important
Topic 3.A.3: Methods for estimating the opportunity cost of recommending treatments for aggregate
populations rather than for subgroups
Not important Somewhat important Important Very important
Topic 3.A.4: Should potential reductions in pharmaceutical prices over time be reflected in economic
analysis. If so, what methods should be used?
Not important Somewhat important Important Very important
Theme B: Perspective for analysis
Topic 3.B.1: Methods to determine the appropriate costs and benefit perspective for the analysis of
public health interventions?
Not important Somewhat important Important Very important
Topic 3.B.2: Methods to determine the appropriate costs and benefit perspective for the analysis of
health technologies?
Not important Somewhat important Important Very important
Topic 3.B.3: Methods for the evaluation of interventions from a societal perspective
Not important Somewhat important Important Very important
80 CHE Research Paper 51
Theme C: Time horizon for analysis
Topic 3.C.1: Including long-run effects of interventions in analyses (e.g. inclusion of treatment costs
unrelated to initial disease by extending morbidity)
Not important Somewhat important Important Very important
Topic 3.C.2: Extrapolation of the duration of the costs and benefits of interventions beyond those
observed in trials, including the quantification of uncertainty
Not important Somewhat important Important Very important
Theme D: Economic modelling
Topic 3.D.1: Methods to develop ‘standardised’ and ‘approved’ models in a given disease area,
including parameter inputs
Not important Somewhat important Important Very important
Topic 3.D.2: Further develop checklists for establishing the quality of economic models including input
parameters and reporting standards
Not important Somewhat important Important Very important
Topic 3.D.3: Research to assess whether the predictions of economic models used to inform NICE
guidance are borne out in practice
Not important Somewhat important Important Very important
Topic 3.D.4: Methods for the use of surrogate or intermediate measures in models
Not important Somewhat important Important Very important
Topic 3.D.5: Development of criteria for selecting an appropriate structure for a decision model given
available evidence on disease prognosis and the impact of alternative interventions
Not important Somewhat important Important Very important
Topic 3.D.6: Better methods for estimating cost-effectiveness in subgroups
Not important Somewhat important Important Very important
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Topic 3.D.7: Assessing the cost-effectiveness of 'long' or complex diagnostic/treatment pathways
Not important Somewhat important Important Very important
Topic 3.D.8: The identification and use of prognostic data in economic models
Not important Somewhat important Important Very important
Topic 3.D.9: Methods for determining the optimal complexity of economic models (i.e. how complex
does a model need to be to be fit for purpose?)
Not important Somewhat important Important Very important
Topic 3.D.10: Methods for the incorporation of evidence on adherence in economic models
Not important Somewhat important Important Very important
Topic 3.D.11: Methods to identify and inform appropriate structure of economic models
Not important Somewhat important Important Very important
Topic 3.D.12: Methods for modelling complex social interventions
Not important Somewhat important Important Very important
Theme E: Uncertainty
Topic 3.E.1: Methods for quantifying the uncertainty in cost-effectiveness models, including for
complex models, and for showing the implications of uncertainty for decisions
Not important Somewhat important Important Very important
Topic 3.E.2: Developing methods for eliciting ‘prior’ parameter estimates from relevant experts
Not important Somewhat important Important Very important
Topic 3.E.3: Bayesian and Frequentist models for analysis – what are the differences between the
approaches & which is most appropriate for NICE?
Not important Somewhat important Important Very important
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Topic 3.E.4: Methods of assessing the need for evidence and the consequences of uncertain
decisions to the NHS (e.g. in terms of sunk costs)
Not important Somewhat important Important Very important
Topic 3.E.5: Averaging of model results to represent structural uncertainty (e.g. When should
averaging be used? What methods should be used?)
Not important Somewhat important Important Very important
Topic 3.E.6: Quantifying the implications of imprecision in parameter estimates on decision
uncertainty
Not important Somewhat important Important Very important
Theme F: Other
Topic 3.F.1: What is the appropriate discount rate for health and under what circumstances might it
vary?
Not important Somewhat important Important Very important
Topic 3.F.2: Methods for the economic evaluation of public health interventions
Not important Somewhat important Important Very important
Topic 3.F.3: Methods for consolidating the range of costs and outcomes that decision makers are
presented
Not important Somewhat important Important Very important
Topic 3.F.4: Translation of research methods so that the process is understandable/transparent to
non-specialists
Not important Somewhat important Important Very important
Topic 3.F.5: Methods to assess the cost-effectiveness of interventions which have costs and
(dis)benefits outside of the health care sector
Not important Somewhat important Important Very important
Topic 3.F.6: Methods to establish the type of economic model and appraisal process that should be
used to formulate guidance (When is it necessary to commission development of a new economic
model?)
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Not important Somewhat important Important Very important
Topic 3.F.7: Methods to implement cost-effectiveness analysis (and evidence synthesis) early into
the development of new technologies to inform future research and development decisions
Not important Somewhat important Important Very important
Topic 3.F.8: Methods to reflect the objective of reducing inequalities in cost-effectiveness analysis
Not important Somewhat important Important Very important
Topic 3.F.9: How should NICE establish the value for money of conducting further research (do the
costs outweigh the benefits)?
Not important Somewhat important Important Very important
Are there any topics, within this area that you think have been omitted? Please provide detail
in the box below.
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Area 4: Measurement and valuation of benefits
Theme A: Use of the QALY
Topic 4.A.1: Methods to capture a wider set of (dis)benefits that may not be included in the QALY
Not important Somewhat important Important Very important
Topic 4.A.2: Consolidating patient reported outcomes with other measures of benefit (e.g. QALYs)
Not important Somewhat important Important Very important
Theme B: Standardised measurement tools
Topic 4.B.1: Use of mapping techniques between clinical and patient-reported outcomes, and
preference-based instruments for use in QALYs
Not important Somewhat important Important Very important
Topic 4.B.2: Methods to derive quality of life weights (utilities) when no EQ-5D data are available or
the EQ-5D is inappropriate
Not important Somewhat important Important Very important
Topic 4.B.3: Methods to establish what effects of interventions and programmes are/are not currently
captured by the EQ-5D
Not important Somewhat important Important Very important
Topic 4.B.4.: Methods to establish when disease specific measures of health outcomes should be
used instead of, or as supplementary to, the EQ-5D
Not important Somewhat important Important Very important
Topic 4.B.5: Evaluating health in less bounded ways (beyond questionnaires)
Not important Somewhat important Important Very important
Topic 4.B.6: Methods for the measurement of changes in the health of children and people unable to
report the status of their own health
Not important Somewhat important Important Very important
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Theme C: Valuation of health
Topic 4.C.1: Methods for the re-evaluation of the EQ-5D preference set for the UK population with
consideration to (i) the use of patient valuations of health and/or more informed public valuations and
(ii) the appropriate valuation of health states considered to be worse than dead
Not important Somewhat important Important Very important
Topic 4.C.2: Comparison/re-evaluation of the methods of preference elicitation for QALYs
Not important Somewhat important Important Very important
Topic 4.C.3: Methods for valuing health at different time points in a person’s life (especially at the end
of life)
Not important Somewhat important Important Very important
Topic 4.C.4: Methods to determine whether public or patient valuations of health should be used
Not important Somewhat important Important Very important
Topic 4.C.5: Methods for weighting QALYs for characteristics of individuals (e.g. disease severity,
social demographic characteristics)
Not important Somewhat important Important Very important
Topic 4.C.6: Methods to determine how patients view the burden of a condition (possibly outside of
the HRQL framework)?
Not important Somewhat important Important Very important
Theme D: Use of health state utility data in economic models
Topic 4.D.1: Methods for synthesising health-state utilities (e.g. the use of meta-regression using
published or patient-level data)
Not important Somewhat important Important Very important
Topic 4.D.2: How to use and adapt health state utility values published in the literature for cost-
effectiveness models (for example, accounting for co-morbidities or socio-demographic factors)
Not important Somewhat important Important Very important
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Topic 4.D.3: How uncertainty in health state utility values should be quantified and how that
uncertainty should be incorporated into economic analyses
Not important Somewhat important Important Very important
Are there any topics, within this area that you think have been omitted? Please provide detail
in the box below.
Area 5: Decision-making at NICE
Theme A: Threshold for cost-effectiveness
Topic 5.A.1: What is the current ICER of things that are being displaced by NICE guidance
(opportunity cost of NICE guidance?)?
Not important Somewhat important Important Very important
Topic 5.A.2: Methods to estimate the opportunity cost of NICE guidance (i.e. the threshold) including
changes over time
Not important Somewhat important Important Very important
Topic 5.A.3: Methods to communicate concept of a threshold and related issues to non-specialists
Not important Somewhat important Important Very important
Theme B: Influences on NICE decision-making
Topic 5.B.1: What other factors should be considered for decision-making for interventions for
children, including the use of medicines ‘off-license’?
Not important Somewhat important Important Very important
Topic 5.B.2: Methods to feed equity and utility into NICE decision-making?
Not important Somewhat important Important Very important
Topic 5.B.3: Should NICE decision-making be based on cost-effectiveness analysis (CEA) modified
by social value judgements, or should a range of social values be used of which CEA is one?
Not important Somewhat important Important Very important
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Topic 5.B.4: Methods for taking factors other than cost-effectiveness (e.g. societal costs/effects) into
account in NICE decision-making (e.g. using multi-criteria decision analysis)
Not important Somewhat important Important Very important
Topic 5.B.5: Methods for establishing how contextual affect decisions about the safety and efficacy of
interventions (e.g. availability of alternatives, stage of life)
Not important Somewhat important Important Very important
Topic 5.B.6: Which types of sub-groups should be considered in economic evaluation studies
undertaken to inform the decisions of the Institute (including consideration of equity issues)?
Not important Somewhat important Important Very important
Topic 5.B.7: How to take inequalities into account at different stages of NICE guidance production?
Not important Somewhat important Important Very important
Theme C: Handling uncertainty in decision-making
Topic 5.C.1: Establishing decision rules for incorporating estimates of uncertainty into decision-
making
Not important Somewhat important Important Very important
Topic 5.C.2: What criteria should be used for establishing only in research recommendations
(including a consideration of the ethical implications and whether publicly funded research will impact
on current policy and practice)?
Not important Somewhat important Important Very important
Topic 5.C.3: How should NICE assess whether additional evidence is needed, what type of evidence
is required and the type of evidence for ‘coverage with evidence’ decisions
Not important Somewhat important Important Very important
Topic 5.C.4: The use of expected value of perfect information (EVPI) methods to make both appraisal
recommendations and research recommendations
Not important Somewhat important Important Very important
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Theme D: Process of decision-making
Topic 5.D.1: How do/should Committees and Guideline Development Groups operate?
Not important Somewhat important Important Very important
Topic 5.D.2: Evaluation of the psychology of decision-making and the effect of contextual factors
(such as public presence or media campaigns)
Not important Somewhat important Important Very important
Topic 5.D.3: Methods to review existing analytical methods for systematic reviews and economic
analyses to ensure they add value for decision-making
Not important Somewhat important Important Very important
Topic 5.D.4: Methods to evaluate the different processes within the technology appraisals programme
and within the clinical guidelines programme (including Appraisal Committee and stakeholder views
and the impact on recommendations)
Not important Somewhat important Important Very important
Topic 5.D.5: Methods to review the quality of assessment reports that inform decision-making at NICE
Not important Somewhat important Important Very important
Topic 5.D.6: What changes should be made to the development of NICE guidance so that electronic
decision support tools can be produced simultaneously?
Not important Somewhat important Important Very important
Topic 5.D.7: What are the best methods for determining the most important clinical questions for a
given topic?
Not important Somewhat important Important Very important
Topic 5.D.8: Methods for scoping decision problems, including the potential use of qualitative
research
Not important Somewhat important Important Very important
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Topic 5.D.9: An evaluation of the current appraisal programme in the context of the original intention
for the programme (e.g. focus on pharmaceuticals) and the reasons for differences (e.g. why other
interventions are harder to evaluate)
Not important Somewhat important Important Very important
Topic 5.D.10: How should potential future changes in health care be taken into account in decision-
making?
Not important Somewhat important Important Very important
Theme E: Developing the format/ type of NICE recommendations
Topic 5.E.1: Methods to assess the impact of NICE guidance on changing health states (or the
‘payback’ from NICE) and/or changing clinical practice
Not important Somewhat important Important Very important
Topic 5.E.2: Development of methods to produce guidance to the NHS on the disinvestment of
existing interventions
Not important Somewhat important Important Very important
Topic 5.E.3: Development of methods to consider value based pricing arrangements
Not important Somewhat important Important Very important
Topic 5.E.4: Methodological issues in evaluation of patient access schemes
Not important Somewhat important Important Very important
Topic 5.E.5: Evaluation of the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) process
Not important Somewhat important Important Very important
Topic 5.E.6: How can NICE produce symptom-led guidance, rather than disease-based guidance?
Not important Somewhat important Important Very important
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Topic 5.E.7: Methods for communicating guidance and supporting evidence to the general public
Not important Somewhat important Important Very important
Are there any topics, within this area that you think have been omitted? Please provide detail
in the box below.
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Rating topics across areas
Please can you indicate what you consider to be the three most important topics across areas and
themes. These should be on the basis of their importance as methodological research questions.
Please select three topics from the list below
Area 1: Theme A
Topic 1.A.1: Establishing methods and rules for efficient systematic reviews of effectiveness,
diagnostic test accuracy and prognostic factors (i.e. tackling the trade-off between efficiency and
quality)
Topic 1.A.2: Methods for keeping research synthesis up to date; developing on-going and up to date
repositories of ‘approved’ networks of evidence in key diseases using mixed treatment comparison
Topic 1.A.3: Methods for identifying, appraising and synthesising ‘grey literature’
Topic 1.A.4: Development of a checklist or reporting rules for standardised reporting of public health
reviews including undertaking sensitivity analysis
Topic 1.A.5: Methods for quality assessing qualitative research
Topic 1.A.6: Methods for the timely identification and synthesis of qualitative research within the
context of NICE processes
Topic 1.A.7: Methods for conducting systematic reviews of complex interventions (e.g. in public
health)
Area 1: Theme B
Topic 1.B.1: Methods to adjust for potential bias in meta-analysis (for example, issues of multiple
sources of bias and confounding)
Topic 1.B.2: Methods to combine individual patient and aggregate data in evidence synthesis
Topic 1.B.3: Assessing the implications of extending networks of evidence for NICE guidance on the
reliability of results
Topic 1.B.4: Methods for linking treatments into networks of evidence where there is no direct
evidence link on the basis of randomised trials (for example using observational evidence)
Topic 1.B.5: Establishing the reliability of mixed treatment comparisons and consistency with direct
trial data
Topic 1.B.6: Methods to deal with treatments not routinely used in practice within evidence synthesis
Topic 1.B.7: How to assess the comparability of control arms when included in evidence synthesis
Topic 1.B.8: What needs to be defined in a protocol for a mixed treatment comparison?
Topic 1.B.9: Methods to assess the quality of randomised studies and to incorporate this into a formal
quantitative synthesis
Topic 1.B.10: A review of software to carry out meta-analysis and mixed treatment comparison
Topic 1.B.11: Methods to assess the exchangeability of studies and to reflect this in evidence
synthesis
Topic 1.B.12: Methods for jointly synthesising qualitative and quantitative research
Area 1: Theme C
Topic 1.C.1: Establishing optimal methods for analysis of disease registers and other sources of non-
experimental evidence (e.g. What methods to use? When should non-experimental data be used?
How are non-experimental data currently used at NICE?)
Topic 1.C.2: Methods to establish the efficacy of a ‘composite comparator’ (e.g. current practice)
Topic 1.C.3: The use of routine surveillance and monitoring data in developing NICE public health
recommendations
Topic 1.C.4: Using bias adjustment methods for observational studies, including adjustments for
indication bias in data from registers
Topic 1.C.5: Methods to assess the sensitivity of observational study results to study design
Area 1: Theme D
Topic 1.D.1: Methods for translating trial evidence from adults to children
Topic 1.D.2: Methods for translating phase II research for NICE decisions
Topic 1.D.3: Methods to quantify the incidence of rare events from interventions
Topic 1.D.4: Methods for the optimal use of surrogate or intermediate measures in assessing
effectiveness
Topic 1.D.5: Methods for the assessment of the effectiveness of treatment sequences
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Topic 1.D.6: How best to present effectiveness data for NICE Committees including the likelihood of
anticipated and unanticipated events
Topic 1.D.7: Methods to assess the effect of practitioner experience (and other potentially relevant
contextual factors) on effectiveness
Topic 1.D.8: Methods to attribute outcomes to specific components of care within complex
interventions (e.g. public health interventions)
Area 1: Theme E
Topic 1.E.1: Methods to assess the applicability of evidence from different countries to UK
populations
Topic 1.E.2: Bayesian methods for subgroup analysis (e.g. biological plausibility of a subgroup in
terms of a prior probability)
Topic 1.E.3: Use of, and problems associated with, meta-regression based on summary data (e.g. to
consider the relationship between baseline event risks and treatment effects
Area 1: Theme F
Topic 1.F.1: Ethical and practical challenges in using 'sham' procedures (or control arms) in a surgical
environment
Topic 1.F.2: How should the product life-cycle and the procurement of devices in the NHS be factored
into the appraisal process
Topic 1.F.3: How best to evaluate diagnostic and screening technologies
Area 1: Theme G
Topic 1.G.1: Methods to evaluate interventions to change behaviour in the context of public health
Area 2: Theme A
Topic 2.A.1: Methods to assess what types of patient evidence should be used at different stages of
NICE’s decision-making processes (e.g. when to undertake reviews of qualitative evidence? What
types of reviews should be conducted? When should colloquial evidence be used?)
Topic 2.A.2: Guidance on providing information to patients/carers on breaking bad news Topic 2.A.3:
Methods for using colloquial evidence to determine the effect of complex interventions (e.g. in public
health)
Area 2: Theme B
Topic 2.B.1: Methods to understand how the public view characteristics of conditions and the
technologies used to treat them
Area 2: Theme C
Topic 2.C.1: The appraisal and synthesis of ‘colloquial evidence’ (e.g. comments received from
stakeholders during consultation)
Topic 2.C.2: Evaluation of the existing, and development of new, methods for participation of different
stakeholder groups at different stages of NICE’s decision-making processes (including
representatives of the general public, patients and practitioners)
Area 3: Theme A
Topic 3.A.1: What are the most appropriate sources of cost data for NICE decision-making? Topic
3.A.2: Methods to determine the proportion of costs that should be included in analyses where there
is variability in the amount paid by the National Health Service/Personal Social Services and by the
individual patient?
Topic 3.A.3: Methods for estimating the opportunity cost of recommending treatments for aggregate
populations rather than for subgroups
Topic 3.A.4: Should potential reductions in pharmaceutical prices over time be reflected in economic
analysis. If so, what methods should be used?
Area 3: Theme B
Topic 3.B.1: Methods to determine the appropriate costs and benefit perspective for the analysis of
public health interventions?
Topic 3.B.2: Methods to determine the appropriate costs and benefit perspective for the analysis of
health technologies?
Topic 3.B.3: Methods for the evaluation of interventions from a societal perspective
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Area 3: Theme C
Topic 3.C.1: Including long-run effects of interventions in analyses (e.g. inclusion of treatment costs
unrelated to initial disease by extending life)
Topic 3.C.2: Extrapolation of the duration of the costs and benefits of interventions beyond those
observed in trials, including the quantification of uncertainty
Area 3: Theme D
Topic 3.D.1: Methods to develop ‘standardised’ and ‘approved’ models in a given disease area,
including sets of parameter inputs
Topic 3.D.2: Further development of checklists for establishing the quality of economic models
including input parameters and reporting standards
Topic 3.D.3: Research to assess whether the predictions of economic models used to inform NICE
guidance are borne out in practice
Topic 3.D.4: Methods for the use of surrogate or intermediate measures in models
Topic 3.D.5: Development of criteria for selecting an appropriate structure for a decision model given
available evidence on disease prognosis and the impact of alternative interventions
Topic 3.D.6: Better methods for estimating cost-effectiveness in subgroups
Topic 3.D.7: Assessing the cost-effectiveness of 'long' or complex diagnostic/treatment pathways
Topic 3.D.8: The identification and use of prognostic data in economic models
Topic 3.D.9: Methods for determining the optimal complexity of economic models (i.e. how complex
does a model need to be to be fit for purpose?)
Topic 3.D.10: Methods for the incorporation of evidence on adherence in economic models
Topic 3.D.11: Methods for modelling complex social interventions
Area 3: Theme E
Topic 3.E.1: Methods for quantifying the uncertainty in cost-effectiveness models, including for
complex models, and for showing the implications of uncertainty for decisions
Topic 3.E.2: Developing methods for eliciting ‘prior’ parameter estimates from relevant experts
Topic 3.E.3: Bayesian and Frequentist models for analysis – what are the differences between the
approaches and which is most appropriate for NICE?
Topic 3.E.4: Methods of assessing the need for evidence and the consequences of uncertain
decisions to the NHS (e.g. in terms of sunk costs)
Topic 3.E.5: Averaging of model results to representing structural uncertainty (e.g. When should
averaging be used? What methods should be used?)
Topic 3.E.6: Quantifying the implications of imprecision in parameter estimates on decision
uncertainty
Area 3: Theme F
Topic 3.F.1: What is the appropriate discount rate for health and under what circumstances might it
vary?
Topic 3.F.2: Methods for the economic evaluation of public health interventions
Topic 3.F.3: Methods for consolidating the range of costs and outcomes that decision makers are
presented
Topic 3.F.4: Translation of research methods so that the process is understandable/transparent to
non-specialists
Topic 3.F.5: Methods to assess the cost-effectiveness of interventions which have costs and
(dis)benefits outside of the health care sector
Topic 3.F.6: Methods to establish the type of economic model and appraisal process that should be
used to formulate guidance (When is it necessary to commission development of a new economic
model?)
Topic 3.F.7: Methods to implement cost-effectiveness analysis (and evidence synthesis) early into the
development of new technologies to inform future research and development decisions
Topic 3.F.8: Methods to reflect the objective of reducing inequalities in cost-effectiveness analysis
Topic 3.F.9: How should NICE establish the value for money of conducting further research (do the
costs outweigh the benefits)?
Area 4: Theme A
Topic 4.A.1: Methods to capture a wider set of (dis)benefits that may not be included in the QALY
Topic 4.A.2: Consolidating patient reported outcomes with other measures of benefit (e.g. QALYs)
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Area 4: Theme B
Topic 4.B.1: Use of mapping techniques between clinical and patient-reported outcomes, and
preference-based instruments for use in QALYs
Topic 4.B.2: Methods to derive quality of life weights (utilities) when no EQ-5D data are available or
the EQ-5D is inappropriate (e.g. the use of condition-specific preference based measures or direct
valuation of health state descriptions)
Topic 4.B.3: Establishing what effects of interventions and programmes are/are not currently captured
by the EQ-5D
Topic 4.B.4: Methods to establish when disease specific measures of health outcomes should be
used instead of, or as supplementary to, the EQ-5D
Topic 4.B.5: Evaluating health in less bounded ways (beyond questionnaires)
Topic 4.B.6: Methods for the measurement of changes in the health of children and people unable to
report the status of their own health
Area 4: Theme C
Topic 4.C.1: Methods for the re-evaluation of the EQ-5D preference set for the UK population with
consideration to (i) the use of patient valuations of health and/or more informed public valuations and
(ii) the appropriate valuation of health states considered to be worse than dead
Topic 4.C.2: Comparison/re-evaluation of the methods of preference elicitation for QALYs
Topic 4.C.3: Methods for valuing health at different time points in a person’s life (e.g. at the end of life)
Topic 4.C.4: Methods to determine whether public or patient valuations of health should be used
Topic 4.C.5: Methods for weighting QALYs according to the characteristics of individuals (e.g. disease
severity, social demographic characteristics)
Topic 4.C.6: Methods to determine how patients view the burden of a condition (possibly outside of
the HRQL framework)?
Area 4: Theme D
Topic 4.D.1: Methods for synthesising health-state utilities (e.g. the use of meta-regression using
published or patient-level data)
Topic 4.D.2: How to use and adapt health state utility values published in the literature for cost-
effectiveness models (for example, accounting for co-morbidities or socio-demographic factors)
Topic 4.D.3: How uncertainty in health state utility values should be quantified and how that
uncertainty should be incorporated into economic analyses
Topic 4.D.4: Using EQ5D data routinely collected in Patient Reported Outcome Measures (PROMS)
in the NHS to provide standardised quality of life weights (utilities) for economic models for NICE
Area 5: Theme A
Topic 5.A.1: What is the current ICER of things that are being displaced by NICE guidance (i.e.
opportunity cost of NICE guidance)?
Topic 5.A.2: Methods to estimate the opportunity cost of NICE guidance (i.e. the threshold) including
changes over time
Topic 5.A.3: Methods to communicate concept of a threshold and related issues to non-specialists
Area 5: Theme B
Topic 5.B.1: What other factors should be considered for decision-making for interventions for
children, including the use of medicines ‘off-license’?
Topic 5.B.2: Methods to feed equity into NICE decision-making?
Topic 5.B.3: Should NICE decision-making be based on cost-effectiveness analysis (CEA) modified
by social value judgements, or should a range of social values be used of which CEA is one?
Topic 5.B.4: Methods for taking factors other than cost-effectiveness (e.g. societal costs/effects) into
account in NICE decision-making (e.g. using multi-criteria decision analysis)
Topic 5.B.5: Methods for establishing how contextual details affect decisions about the safety and
efficacy of interventions (e.g. availability of alternatives, stage of life
Topic 5.B.6: Which types of sub-groups should be considered in economic evaluation studies
undertaken to inform the decisions of the Institute (including consideration of equity issues)?
Topic 5.B.7: How to take inequalities into account at different stages of NICE guidance production?
Area 5: Theme C
Topic 5.C.1: Establishing decision rules for incorporating estimates of uncertainty into decision-
making
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Topic 5.C.2: What criteria should be used for establishing Only in Research recommendations
(including a consideration of the ethical implications and whether publicly funded research will impact
on current policy and practice)?
Topic 5.C.3: How should NICE assess whether additional evidence is needed, what type of evidence
is required and the type of evidence necessary for ‘coverage with evidence’ decisions
Topic 5.C.4: The use of expected value of perfect information (EVPI) methods to make both appraisal
recommendations and research recommendations
Area 5: Theme D
Topic 5.D.1: How do/should Committees and Guideline Development Groups operate?
Topic 5.D.2: Evaluation of the psychology of decision-making and the effect of contextual factors
(such as public presence or media campaigns)
Topic 5.D.3: Methods to review existing analytical methods for systematic reviews and economic
analyses to ensure they add value for decision-making
Topic 5.D.4: Methods to evaluate the different processes within the technology appraisals programme
and within the clinical guidelines programme (including Appraisal Committee and stakeholder views
and the impact on recommendations)
Topic 5.D.5: Methods to review the quality of assessment reports that inform decision-making at NICE
Topic 5.D.6: What changes should be made to the development of NICE guidance so that electronic
decision support tools can be produced simultaneously?
Topic 5.D.7: What are the best methods for determining the most important clinical questions for a
given topic?
Topic 5.D.8: Methods for scoping decision problems, including the potential use of qualitative
research
Topic 5.D.9: An evaluation of the current appraisal programme in the context of the original intention
for the programme (e.g. focus on pharmaceuticals) and the reasons for differences (e.g. why other
interventions are harder to evaluate)
Topic 5.D.10: How should potential future changes in health care be taken into account in decision-
making?
Area 5: Theme E
Topic 5.E.1: Methods to assess the impact of NICE guidance on changing health (or the ‘payback’
from NICE) and/or changing clinical practice
Topic 5.E.2: Development of methods to produce guidance to the NHS on disinvestment from existing
interventions
Topic 5.E.3: Development of methods to consider value-based pricing arrangements
Topic 5.E.4: Methodological issues in evaluation of patient access schemes
Topic 5.E.5: Evaluation of the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) process
Topic 5.E.6: How can NICE produce symptom-led guidance, rather than disease-based guidance?
Topic 5.E.7: Methods for communicating guidance and supporting evidence to the general public
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Further detail on chosen topics
Topic 1
To which area of NICEs work does it relate?
How will it inform the challenges faced by NICE?
Ideas for specific research questions
Ongoing and previous research
Possible characteristics of research
Topic 2
To which area of NICEs work does it relate?
How will it inform the challenges faced by NICE?
Ideas for specific research questions
Ongoing and previous research
Possible characteristics of research
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Topic 3
To which area of NICEs work does it relate?
How will it inform the challenges faced by NICE?
Ideas for specific research questions
Ongoing and previous research
Possible characteristics of research
Omitted areas
If you feel we have omitted any areas in this questionnaire please can you provide details along with
suggested topics within the omitted area.
Any other feedback or suggestions
This space is for any additional feedback or suggests you may have.
Thank you for completing the questionnaire
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Appendix A11: Additional topics suggested through the web survey
Area 1
Acceptability and feasibility of interventions for different groups. Identification and prioritisation
of treatment outcomes by patients. Identifying and exploring why some interventions work, and
others don't - i.e. the mechanisms (guilt, for example)
Econometric based analysis
Measurement and reliability of self-reported data on alcohol, diet and exercise; assessment
effects and their potential for bias; direct effects of screening on risk behaviours; effectiveness
of simple low-cost interventions with high potential for wide dissemination
Prevention Science is characterised by the use of complex statistical models, e.g. multi-level
growth mixture models and more work is required to examine the rigour of these models and to
understand the best way to communicate complex results to policy makers and public health
specialists
How to develop a reliable method of defining intervention components and use of meta-
regression in conjunction with such a method to identify effective components.
Problems of effectively diffusing 'good 'practice interventions that change professional practice
Similar issues surrounding evaluation of interventions to change behaviour in the context of
chronic disease self-management (i.e. not just in a preventative context)
Development and testing of measures of behaviour/behaviour change and associated factors,
particularly in the context of chronic disease self-management
Methods to evaluate inequalities in outcome of behavioural interventions (e.g. across socio-
economic groups, age groups, ethnic groups, sexes)
Methods to incorporate equity considerations or differential weighting of health benefits
dependent on the characteristics of the patient to whom they accrue.
Increasing numbers of behaviour change interventions are being delivered online - these offer
specific methodological challenges for evaluation, including the challenges of undertaking
online trials. Methodological work on maximising the internal validity of online trials (esp re
recruitment, retention, randomisation (and avoidance of re-registration by individual
participants), fidelity of the intervention and data quality.
Role of regulation and environment on behaviour relative to individual behavioural interventions
My main observation is to question why there are no health psychologists on this panel, given
that this is a/ the central discipline in developing health behaviour interventions, whereas there
are 3 sociologists
Methods to assess behavioural components of complex interventions
Structural uncertainty of decision analytic models;
Extrapolation of evidence and validation of results beyond the duration of trials
Ethical issues related to the use of interventions to change behaviour in the context of public
health
These topics are focused. What is needed is a coherent policy for synthesis across these
topics. I.e. when to use network meta-analysis, when to consider obs evidence, when to
consider qualitative + quant evidence & how such data should inform the decision models. This
is to ensure consistency in overall approach and thus fairness across all appraisals.
Area 2
NICE's new-found willingness to place differential values on health might be justified in terms of
stakeholder's interests (general public). Methods to determine conditions under which NICE will
weaken its own (rational) procedures should be made clearer.
Transparency over how stakeholders are recruited, and their interests. Lack of academic or
specialist methodological expertise within review groups. No consistent peer review of the
systematic reviews making up the guidelines.
2.C.2 needs to include specific reference to NHS commissioning organisations
I think that the questions in this section focus somewhat unhelpfully on process when the key
issues is what information about patient views and experiences does NICE need - the methods
for collecting it should then follow. So should be asking this question rather than evaluating
current methods for collecting information when we still arent clear what information is needed.
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Impact of stakeholder participation in appraisal committee meetings
Optimal nature and timing of stakeholder input to NICE processes
Area 3
Methods to openly peer-review the systematic reviews produced by collaborating centres.
methods to assess the way recommendations were reached from the conclusions of the
reviews.
Methods examining the validity of the cost-effectiveness threshold. The use of mathematical
programming approaches for examining the optimal allocation of resources for different
budgets over time
Methods to assess the trade offs between equity and efficiency in the delivery of interventions
(including clinical and public health, simple and complex) which are unequally successful
across population subgroups (e.g. socio-economic groups, ethnic groups, age groups, sexes)
Societal value of a QALY.
When should NICE withhold positive guidance due to uncertainty (OIR) and what methods
would help the assessment of the importance of sunk costs and value of evidence forgone
Area 4
Assumptions of the standard QALY model
In relation to 4.C.1 the biggest problem with the existing EQ5D is the statistical method used to
derive the weights, not the fact it comes from the general public.
Work around comparisons between alternative utility based measures e.g SF6D and HUI3 and
EQ5D-5L
How to collect utility values for children
Investigation of the relative value of alternative utility based measures eg SF-6D or HUI3
Re-estimating the EQ5D tarrif using existing data but better methods to account for states
worse than death.
Establishing whether the assumptions of additivity and constant proportional time trade off
matter, if so when they matter most and what alternative practical methods/adjustments would
be most appropriate
Area 5
It seems odd that the public's view of the threshold has not been included as an option to 'vote'
on. This would seem to be as important as trying to find a threshold through examination of
NHS commissioners' decisions.
Methods for ensuring quality in development of guidelines, assessing staff support of guideline
producers (e.g. research fellows)
The added value of developing a conceptual map (causal model) of the problem area in order
to focus and guide literature reviewing
Evaluation of the impact of the differences in decision-making criteria between NICE and local
level NHS
Assessment of how to include an assessment/measure of innovation within
appraisals/guidelines
for 5.a.1 Rather than look at the ICER of things displaced by NICE, the ICERs of the >80% of
health care not currently being assessed should be considered
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Appendix A12: Web Survey Prioritisation Results
Very
Important
Important Somewhat
Important
Not
Important
Area 1: Analysis and design of effectiveness studies and their synthesis
Theme A. Systematic reviews
Topic 1_A_1: Establishing methods and rules for efficient systematic reviews of effectiveness,
diagnostic test accuracy and prognostic factors (i.e. tackling the trade-off between efficiency and
quality)
34.7% 40.0% 21.3% 4.0%
Topic 1_A_2: Methods for keeping research synthesis up to date; developing on-going and up to
date repositories of ‘approved’ networks of evidence in key diseases using mixed treatment
comparison
26.7% 40.0% 28.0% 5.3%
Topic 1_A_3: Methods for identifying, appraising and synthesising ‘grey literature’ 8.0% 30.7% 49.3% 12.0%
Topic 1_A_4: Development of a checklist or reporting rules for standardised reporting of public
health reviews including undertaking sensitivity analysis
10.7% 32.0% 42.7% 14.7%
Topic 1_A_5: Methods for quality assessing qualitative research 17.3% 28.0% 37.3% 17.3%
Topic 1_A_6: Methods for the timely identification and synthesis of qualitative research within the
context of NICE processes
24.0% 37.3% 29.3% 9.3%
Topic 1_A_7: Methods for conducting systematic reviews of complex interventions (e.g. in public
health)
50.7% 25.3% 21.3% 2.7%
Theme B. Meta-analysis (including indirect and mixed treatment comparisons)
Topic 1_B_1: Methods to adjust for potential bias in meta-analysis (for example, issues of multiple
sources of bias and confounding)
30.6% 45.8% 20.8% 2.8%
Topic 1_B_2: Methods to combine individual patient and aggregate data in evidence synthesis 29.7% 41.9% 25.7% 2.7%
Topic 1_B_3: Assessing the implications of extending networks of evidence for NICE guidance on
the reliability of results
21.4% 34.3% 38.6% 5.7%
Topic 1_B_4: Methods for linking treatments into networks of evidence where there is no direct
evidence link on the basis of randomised trials (for example using observational evidence)
27.4% 41.1% 28.8% 2.7%
Topic 1_B_5: Establishing the reliability of mixed treatment comparisons and consistency with
direct trial data
38.4% 34.2% 24.7% 2.7%
Topic 1_B_6: Methods to deal with treatments not routinely used in practice within evidence
synthesis
6.8% 37.0% 41.1% 15.1%
Topic 1_B_7: How to assess the comparability of control arms when included in evidence synthesis 17.8% 45.2% 34.2% 2.7%
Topic 1_B_8: What needs to be defined in a protocol for a mixed treatment comparison? 20.5% 45.2% 26.0% 8.2%
Topic 1_B_9: Methods to assess the quality of randomised studies and to incorporate this into a
formal quantitative synthesis.
24.7% 20.5% 38.4% 16.4%
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Topic 1_B_10: A review of software to carry out meta-analysis and mixed treatment comparison 11.1% 19.4% 47.2% 22.2%
Topic 1_B_11: Methods to assess the exchangeability of studies and to reflect the in evidence
synthesis.
9.7% 34.7% 45.8% 9.7%
Topic 1_B_12: Methods for synthesising both qualitative and quantitative research 16.4% 32.9% 34.2% 16.4%
Theme C. Use of non-experimental data
Topic 1_C_1: Establishing optimal methods for analysis of disease registers and other sources of
non-experimental evidence (e.g. What methods to use? When should non-experimental data be
used? How are non-experimental data currently used at NICE?)
29.7% 47.3% 21.6% 1.4%
Topic 1_C_2: Methods to establish the efficacy of a ‘composite comparator’ (e.g. current practice). 12.2% 50.0% 31.1% 6.8%
Topic 1_C_3: The use of routine surveillance and monitoring data in developing NICE public
health recommendations
15.3% 38.9% 41.7% 4.2%
Topic 1_C_4: Using bias adjustment methods for observational studies, including adjustments for
indication bias in data from registers
21.9% 43.8% 28.8% 5.5%
Topic 1_C_5: Methods to assess the sensitivity of observational study results to study design 13.5% 44.6% 39.2% 2.7%
Theme D. Interpretation and analysis of clinical trial data
Topic 1_D_1: Methods for translating trial evidence from adults to children 19.4% 27.8% 41.7% 11.1%
Topic 1_D_2: Methods for translating phase II research for NICE decisions 11.3% 29.6% 43.7% 15.5%
Topic 1_D_3: Methods to quantify the incidence of rare events from interventions 13.9% 30.6% 43.1% 12.5%
Topic 1_D_4: Methods for the optimal use of surrogate or intermediate measures in assessing
effectiveness
26.4% 38.9% 30.6% 4.2%
Topic 1_D_5: Methods for the assessment of the effectiveness of treatment sequences 25.4% 47.9% 22.5% 4.2%
Topic 1_D_6: How best to present effectiveness data for NICE Committees including the likelihood
of anticipated and unanticipated events.
17.8% 34.2% 32.9% 15.1%
Topic 1_D_7: Methods to assess the effect of practitioner experience (and other potentially relevant
contextual factors) on effectiveness
23.3% 23.3% 43.8% 9.6%
Topic1_D_8: Methods to attribute outcomes to specific components of care within complex
interventions (e.g. public health interventions)
27.0% 36.5% 31.1% 5.4%
Theme E. Clinical heterogeneity
Topic 1_E_1: Methods to assess the applicability of evidence to different populations between
countries
12.7% 35.2% 39.4% 12.7%
Topic 1_E_2: Bayesian methods for subgroup analysis (e.g. biological plausibility of a subgroup in
terms of a prior probability)
17.1% 37.1% 37.1% 8.6%
Topic 1_E_3: Use of, and problems associated with, meta-regression based on summary data to
consider the relationship between baseline event risks and treatment effects
14.7% 45.6% 30.9% 8.8%
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Theme F. Diagnostics and medical devices
Topic 1_F_1: Ethical and practical challenges in using 'sham' procedures (or control arms) in a
surgical environment.
11.3% 29.6% 43.7% 15.5%
Topic 1_F_2: How should the product life-cycle and the procurement of devices in the NHS be
factored into the appraisal process
12.9% 27.1% 40.0% 20.0%
Topic 1_F_3: How best to evaluate diagnostic and screening technologies 37.5% 37.5% 18.1% 6.9%
Theme G. Behavioural research
Topic 1e.g.1: Methods to evaluate interventions to change behaviour in the context of public health 37.8% 27.0% 27.0% 8.1%
Area 2: Synthesis of evidence from patients, the public and stakeholders
Theme A. Evidence from patients
Topic 2_A_1: Methods to assess what types of patient evidence should be used at different stages
of NICE’s decision-making processes (e.g. when to undertake reviews of qualitative evidence?
What types of reviews should be conducted? When should colloquial evidence be used?)
24.3% 41.9% 23.0% 10.8%
Topic 2_A_2: Guidance on providing information to patients/carers on breaking bad news 8.1% 8.1% 44.6% 39.2%
Topic 2_A_3: Methods for using colloquial evidence to determine the effect of complex
interventions (e.g. in public health)
11.0% 20.5% 41.1% 27.4%
Theme B. Evidence from the general public
Topic 2_B_1: Methods to understand how the public view characteristics of conditions and the
technologies used to treat them
17.3% 29.3% 38.7% 14.7%
Theme C. Evidence from stakeholders
Topic 2_C_1: The appraisal and synthesis of ‘colloquial evidence’ (e.g. comments received from
stakeholders during consultation)
13.7% 30.1% 37.0% 19.2%
Topic 2_C_2: Evaluation of the existing, and development of new, methods for participation of
different stakeholder groups at different stages of NICE’s decision-making processes (including
representatives of the general public, patients and practitioners).
19.4% 22.2% 44.4% 13.9%
Area 3: Economic analysis and uncertainty
Theme A. Costing
Topic 3_A_1: What are the most appropriate sources of cost data for NICE decision-making? 20.0% 45.7% 28.6% 5.7%
Topic 3_A_2: Methods to establish the amount of costs of resources should be included in analysis
where these fall only partially on the National Health Service/Personal Social Services (either for a
specific individual or across different population groups)?
14.3% 40.0% 31.4% 14.3%
Topic 3_A_3: Methods for estimating the opportunity cost of recommending treatments for
aggregate populations rather than for subgroups
19.7% 40.8% 29.6% 9.9%
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Topic 3_A_4: Should potential reductions in pharmaceutical prices over time be reflected in
economic analysis. If so, what methods should be used?
24.6% 30.4% 33.3% 11.6%
Theme B. Perspective for analysis
Topic 3_B_1: Methods to determine the appropriate costs and benefit perspective for the analysis
of public health interventions?
28.8% 38.4% 24.7% 8.2%
Topic 3_B_2: Methods to determine the appropriate costs and benefit perspective for the analysis
of health technologies?
22.2% 40.3% 29.2% 8.3%
Topic 3_B_3: Methods for the evaluation of interventions from a societal perspective 33.8% 31.1% 25.7% 9.5%
Theme C. Time horizon for analysis
Topic 3_C_1: Including long-run effects of interventions in analyses (e.g. inclusion of treatment
costs unrelated to initial disease by extending morbidity)
17.1% 41.4% 31.4% 10.0%
Topic 3_C_2: Extrapolation of the duration of the costs and benefits of interventions beyond those
observed in trials, including the quantification of uncertainty
47.9% 33.8% 16.9% 1.4%
Theme D. Economic modelling
Topic 3_D_1: Methods to develop ‘standardised’ and ‘approved’ models in a given disease area,
including parameter inputs
20.3% 39.1% 29.7% 10.9%
Topic 3_D_2: Further develop checklists for establishing the quality of economic models including
input parameters and reporting standards
10.6% 36.4% 28.8% 24.2%
Topic 3_D_3: Research to assess whether the predictions of economic models used to inform
NICE guidance are borne out in practice
41.8% 32.8% 20.9% 4.5%
Topic 3_D_4: Methods for the use of surrogate or intermediate measures in models 20.0% 49.2% 24.6% 6.2%
Topic 3_D_5: Development of criteria for selecting an appropriate structure for a decision model
given available evidence on disease prognosis and the impact of alternative interventions
14.3% 49.2% 31.7% 4.8%
Topic 3_D_6: Better methods for estimating cost-effectiveness in subgroups 15.2% 34.8% 43.9% 6.1%
Topic 3_D_7: Assessing the cost-effectiveness of 'long' or complex diagnostic/treatment pathways 24.2% 39.4% 30.3% 6.1%
Topic 3_D_8: The identification and use of prognostic data in economic models 12.3% 44.6% 38.5% 4.6%
Topic 3_D_9: Methods for determining the optimal complexity of economic models (i.e. how
complex does a model need to be to be fit for purpose?)
22.4% 47.8% 23.9% 6.0%
Topic 3_D_10: Methods for the incorporation of evidence on adherence in economic models 16.7% 37.9% 40.9% 4.5%
Topic 3_D_11: Methods to identify and inform appropriate structure of economic models 26.9% 34.3% 28.4% 10.4%
Theme E. Uncertainty
Topic 3_E_1: Methods for quantifying the uncertainty in cost-effectiveness models, including for
complex models, and for showing the implications of uncertainty for decisions
25.4% 38.8% 28.4% 7.5%
Topic 3_E_2: Developing methods for eliciting ‘prior’ parameter estimates from relevant experts 13.6% 33.3% 37.9% 15.2%
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Topic 3_E_3: Bayesian and Frequentist models for analysis – what are the differences between the
approaches & which is most appropriate for NICE?
15.2% 33.3% 36.4% 15.2%
Topic 3_E_4: Methods of assessing the need for evidence and the consequences of uncertain
decisions to the NHS (e.g. in terms of sunk costs)
22.7% 28.8% 36.4% 12.1%
Topic 3_E_5: Averaging of model results to representing structural uncertainty (e.g. When should
averaging be used? What methods should be used?)
12.1% 39.4% 34.8% 13.6%
Topic 3_E_6: Quantifying the implications of imprecision in parameter estimates on decision
uncertainty
13.6% 42.4% 33.3% 10.6%
Theme F. Other 11.6% 29.0% 40.6% 18.8%
Topic 3_F_1: What is the appropriate discount rate for health and under what circumstances might
it vary?
Topic 3_F_2: Methods for the economic evaluation of public health interventions 38.6% 30.0% 20.0% 11.4%
Topic 3_F_3: Methods for consolidating the range of costs and outcomes that decision makers are
presented
10.6% 36.4% 42.4% 10.6%
Topic 3_F_4: Translation of research methods so that the process is understandable/transparent to
non-specialists
43.7% 23.9% 21.1% 11.3%
Topic 3_F_5: Methods to assess the cost-effectiveness of interventions which have costs and
(dis)benefits outside of the health care sector
30.4% 43.5% 21.7% 4.3%
Topic 3_F_6: Methods to establish the type of economic model and appraisal process that should
be used to formulate guidance (When is it necessary to commission development of a new
economic model?)
13.2% 52.9% 22.1% 11.8%
Topic 3_F_7: Methods to implement cost-effectiveness analysis (and evidence synthesis) early
into the development of new technologies to inform future research and development decisions
26.9% 37.3% 23.9% 11.9%
Topic 3_F_8: Methods to reflect the objective of reducing inequalities in cost-effectiveness analysis 24.6% 30.4% 36.2% 8.7%
Topic 3_F_9: How should NICE establish the value for money of conducting further research (do
the costs outweigh the benefits)?
22.5% 45.1% 21.1% 11.3%
Area 4: Measurement and valuation of benefits
Theme A. Use of the QALY
Topic 4_A_1: Methods to capture a wider set of (dis)benefits that may not be included in the QALY 41.7% 36.1% 18.1% 4.2%
Topic 4_A_2: Consolidating patient reported outcomes with other measures of benefit (e.g. QALYs) 40.0% 30.0% 21.4% 8.6%
Theme B. Standardised measurement tools
Topic 4_B_1: Use of mapping techniques between clinical and patient-reported outcomes, and
preference-based instruments for use in QALYs
16.4% 46.3% 26.9% 10.4%
Topic 4_B_2: Methods to derive quality of life weights (utilities) when no EQ-5D data are available
or the EQ-5D is inappropriate.
27.9% 33.8% 30.9% 7.4%
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Topic 4_B_3: Methods to establish what effects of interventions and programmes are/are not
currently captured by the EQ-5D
35.8% 31.3% 26.9% 6.0%
Topic 4_B_4.: Methods to establish when disease specific measures of health outcomes should be
used instead of, or as supplementary to, the EQ-5D
33.8% 29.4% 25.0% 11.8%
Topic 4_B_5: Evaluating health in less bounded ways (beyond questionnaires) 15.7% 27.1% 28.6% 28.6%
Topic 4_B_6: Methods for the measurement of changes in the health of children and people unable
to report the status of their own health
24.6% 46.4% 24.6% 4.3%
Theme C. Valuation of health
Topic 4_C_1: Methods for the re-evaluation of the EQ-5D preference set for the UK population with
consideration to (i) the use of patient valuations of health and/or more informed public valuations
and (ii) the appropriate valuation of health states considered to be worse than dead
22.1% 45.6% 20.6% 11.8%
Topic 4_C_2: Comparison/re-evaluation of the methods of preference elicitation for QALYs 14.7% 36.8% 27.9% 20.6%
Topic 4_C_3: Methods for valuing health at different time points in a person’s life (especially at the
end of life)
33.8% 33.8% 21.1% 11.3%
Topic 4_C_4: Methods to determine whether public or patient valuations of health should be used 33.8% 33.8% 23.9% 8.5%
Topic 4_C_5: Methods for weighting QALYs for characteristics of individuals (e.g. disease severity,
social demographic characteristics)
14.3% 42.9% 25.7% 17.1%
Topic 4_C_6: Methods to determine how patients view the burden of a condition (possibly outside
of the HRQL framework)?
20.0% 40.0% 18.6% 21.4%
Theme D. Use of health state utility data in economic models
Topic 4_D_1: Methods for synthesising health-state utilities (e.g. the use of meta-regression using
published or patient-level data)
10.9% 32.8% 42.2% 14.1%
Topic 4_D_2: How to use and adapt health state utility values published in the literature for cost-
effectiveness models (for example, accounting for co-morbidities or socio-demographic factors).
7.6% 43.9% 37.9% 10.6%
Topic 4_D_3: How uncertainty in health state utility values should be quantified and how that
uncertainty should be incorporated into economic analyses.
13.8% 36.9% 41.5% 7.7%
Topic 4_D_4: Using EQ5D data routinely collected in Patient Reported Outcome Measures
(PROMS) in the NHS to provide standardised quality of life weights (utilities) for economic models
for NICE
9.1% 34.8% 42.4% 13.6%
Area 5: Decision-making at NICE
Theme A. Threshold for Cost-effectiveness
Topic 5_A_1: What is the current ICER of things that are being displaced by NICE guidance
(opportunity cost of NICE guidance?)?
41.2% 32.4% 20.6% 5.9%
Topic 5_A_2: Methods to estimate the opportunity cost of NICE guidance (i.e. the threshold)
including changes over time
41.2% 32.4% 20.6% 5.9%
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Topic 5_A_3: Methods to communicate concept of a threshold and related issues to non-specialists 27.9% 27.9% 26.5% 17.6%
Theme B. Influences on NICE decision-making
Topic 5_B_1: What other factors should be considered for decision-making for interventions for
children, including the use of medicines ‘off-license’?
16.4% 31.3% 38.8% 13.4%
Topic 5_B_2: Methods to feed equity and utility into NICE decision-making? 26.1% 29.0% 31.9% 13.0%
Topic 5_B_3: Should NICE decision-making be based on cost-effectiveness analysis (CEA)
modified by social value judgements, or should a range of social values be used of which CEA is
one?
21.4% 37.1% 24.3% 17.1%
Topic 5_B_4: Methods for taking factors other than cost-effectiveness (e.g. societal costs/effects)
into account in NICE decision-making (e.g. using multi-criteria decision analysis)
27.9% 38.2% 25.0% 8.8%
Topic 5_B_5: Methods for establishing how contextual affect decisions about the safety and
efficacy of interventions (e.g. availability of alternatives, stage of life)
17.9% 34.3% 31.3% 16.4%
Topic 5_B_6: Which types of sub-groups should be considered in economic evaluation studies
undertaken to inform the decisions of the Institute (including consideration of equity issues)?
16.2% 39.7% 29.4% 14.7%
Topic 5_B_7: How to take inequalities into account at different stages of NICE guidance
production?
18.6% 27.1% 37.1% 17.1%
Theme C. Handling uncertainty in decision-making
Topic 5_C_1: Establishing decision rules for incorporating estimates of uncertainty into decision-
making
25.0% 32.8% 28.1% 14.1%
Topic 5_C_2: What criteria should be used for establishing only in research recommendations
(including a consideration of the ethical implications and whether publicly funded research will
impact on current policy and practice)?
29.9% 32.8% 29.9% 7.5%
Topic 5_C_3: How should NICE assess whether additional evidence is needed, what type of
evidence is required and the type of evidence for ‘coverage with evidence’ decisions.
38.2% 39.7% 14.7% 7.4%
Topic 5_C_4: The use of expected value of perfect information (EVPI) methods to make both
appraisal recommendations and research recommendations.
20.3% 20.3% 35.9% 23.4%
Theme D. Process of decision-making
Topic 5_D_1: How do/should Committees and Guideline Development Groups operate? 23.6% 22.2% 36.1% 18.1%
Topic 5_D_2: Evaluation of the psychology of decision-making and the effect of contextual factors
(such as public presence or media campaigns).
25.0% 25.0% 30.6% 19.4%
Topic 5_D_3: Methods to review existing analytical methods for systematic reviews and economic
analyses to ensure they add value for decision-making
15.9% 33.3% 29.0% 21.7%
Topic 5_D_4: Methods to evaluate the different processes within the technology appraisals
programme and within the clinical guidelines programme (including Appraisal Committee and
stakeholder views and the impact on recommendations)
10.6% 34.8% 30.3% 24.2%
Topic 5_D_5: Methods to review the quality of assessment reports that inform decision-making at 18.3% 33.8% 36.6% 11.3%
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Topic 5_D_6: What changes should be made to the development of NICE guidance so that
electronic decision support tools can be produced simultaneously?
7.5% 22.4% 40.3% 29.9%
Topic 5_D_7: What are the best methods for determining the most important clinical questions for a
given topic?
24.2% 25.8% 34.8% 15.2%
Topic 5_D_8: Methods for scoping decision problems, including the potential use of qualitative
research
17.6% 27.9% 33.8% 20.6%
Topic 5_D_9: An evaluation of the current appraisal programme in the context of the original
intention for the programme (e.g. focus on pharmaceuticals) and the reasons for differences (e.g.
why other interventions are harder to evaluate)
17.9% 28.4% 29.9% 23.9%
Topic 5_D_10: How should potential future changes in health care be taken into account in
decision-making?
7.4% 33.8% 38.2% 20.6%
Theme E. Developing the format/ type of NICE recommendations
Topic 5_E_1: Methods to assess the impact of NICE guidance on changing health states (or the
‘payback’ from NICE) and/or changing clinical practice
25.0% 39.7% 29.4% 5.9%
Topic 5_E_2: Development of methods to produce guidance to the NHS on the disinvestment of
existing interventions
44.1% 33.8% 17.6% 4.4%
Topic 5_E_3: Development of methods to consider value based pricing arrangements 20.9% 35.8% 32.8% 10.4%
Topic 5_E_4: Methodological issues in evaluation of patient access schemes 19.7% 37.9% 27.3% 15.2%
Topic 5_E_5: Evaluation of the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) process
10.9% 18.8% 42.2% 28.1%
Topic 5_E_6: How can NICE produce symptom-led guidance, rather than disease-based guidance? 7.5% 22.4% 38.8% 31.3%
Topic 5_E_7: Methods for communicating guidance and supporting evidence to the general public 25.4% 29.9% 29.9% 14.9%
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Comments on the most highly rated topics (n=55)
Topic To which area of
NICE’s work does
it relate?
How will it inform the
challenges faced by
NICE?
Ideas for specific research
questions
Ongoing and previous
research
Possible characteristics
of research
1_G_1: Methods to
evaluate interventions
to change behaviour in
the context of public
health
NICE faces more and more
complexity in the
interventions being
considered.
Appraisal of public
health interventions
Many public health
interventions focus on
changing behaviours, and
then the change in
behaviour must then be
linked to changes in health
outcomes. The challenge
for NICE is assessing the
benefits from these
interventions in an
exchangeable way with the
benefits from
pharmaceutical
interventions.
How to gather evidence to
link change in behaviour
with change in outcome.
Evidence on the long-term
behaviour change induced
by such interventions.
1_A_7: Methods for
conducting systematic
reviews of complex
interventions (e.g. in
public health)
CPHE How should searches for
complex interventions
progress? e.g. methods for
iterative searching/ methods
of intervention led
searching.
How should non RCT
evidence be treated?
How to synthesis evidence
from multiple study designs.
How might theory led review
approaches help in CPHE
reviews? (What does
"systematic" mean in the
context of reviews of
complex interventions)
Realist review (Pawson et
al) but not in this policy
context.
Case studies to assess the
merit and utility of different
approaches.
Empirical comparisons of
the costs and benefits of
different types of search
strategy.
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1_A_1 Technology
appraisal
increasing diagnostics will
need to be evaluated
not just the systematic
review of diagnostics but
also the integration of this
evidence within a decision
model
work at Birmingham &
Leicester
review of methods used to
date; implications of using
different methods to case
studies
Appraisal and
guidelines
Michael Rawlins' Harveian
Oration suggested that
evidence from studies in
which selection bias had
been addressed using
random allocation was often
insufficient for NICE's
purposes, and that other
kinds of evidence should
used. However, he was not
explicit about the
circumstances in which non-
randomised evidence
should be used, or what
empirical evidence should
be used to guide such
judgements.
In which circumstances
does evidence from non-
randomised studies provide
a sufficiently robust basis for
guiding practice?
Vist GE, Hagen KB,
Devereaux PJ, Bryant D,
Kristoffersen DT, Oxman
AD (2007). Outcomes of
patients who participate in
randomised controlled trials
compared to similar patients
receiving similar
interventions who do not
participate. Cochrane
Database of Methodology
Reviews 2004, Issue 4. Art.
No.: MR000009. DOI:
10.1002/14651858.MR0000
09.pub3.
Glasziou P, Chalmers I,
Rawlins M, McCulloch P.
When are randomised trials
unnecessary? Picking signal
from noise. BMJ 2007;334:
349-351.
Replications of the above
two studies, addressing
Rawlins' concerns.
Guidelines
production
the trade-off between time
pressures and quality is an
important one. The bar
needs to be set high. Staff
are being squeezed and
quality is at risk.
Document current staffing
and change staffing (e.g.
put 2-3 Rfs on a guideline
not one) and conduct
interviews
All NICE has to use the best
evidence, but collecting that
evidence is very resource
intensive. It needs to be
done efficiently, but also
consistently across all NICE
All aspects of systematic
reviewing across all types of
technologies, questions, is
required
Significant amount already
on efficient searching of
literature.
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stream: this is not the
situation currently
All More transparent decisions
based on reliable methods
technology
appraisal
Diagnostic procedures are
being used increasingly
within the NHS, yet it is
unclear how their
effectiveness should be
measured and rated against
other types of treatment
Can a standardised
methodology be developed
for the allow appraisal of
this type of procedure?
I am aware that Jon Deek's
group in Birmingham are
researching some of the
issues
Comparison of different
approaches and
investigation of the impact
of these approaches on
decision-making
